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GENERAL INTRODUCTION
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Up to 70 % of drugs administered to children in the pediatric intensive care unit (PICU) are 
used unlicensed or off-label (1, 2). This means, without regulatory review of information 
about safety and efficacy and without appropriate dosages or formulations (3). As many 
drugs administered to children have not been systematically studied in the pediatric 
population, the dosing is often derived from adult dosing (4). This practice is not without 
risk, however, as children cannot be considered “small adults”. The absorption, distribu-
tion, metabolism and elimination of drugs as well as the drug response are maturing 
with age, and therefore the ontogeny of pharmacokinetic (PK) and pharmacodynamic 
(PD) processes needs to be taken into account to rationalize dosing in children (5–8). 
The relative lack of knowledge on drug disposition and effect in children can lead to 
treatment failure (9) and adverse events as serious as fatalities (10, 11). In the PICU, the 
effect of critical illness on PK and PD added to the effect of age further complicates 
the rational choice of drug and dosing. Therefore, research on drugs in the PICU is of 
paramount importance.
Drug studies in the pediatric ICU: pharmacokinetic, pharmacodynamic and 
ethical aspects
PK/PD
Critical illness has a major impact on all pharmacokinetic processes and on pharmaco-
dynamics (12), and one of the processes altered by critical illness is the oral absorption 
(13, 14). The volume of distribution is influenced by patient-related factors like change 
in albumin or total body water. Liver and kidney failure, which are prevalent among 
critically ill patients, alter drug clearance (15, 16). Inflammation may also affect clearance 
by down- or upregulating drug metabolizing enzymes and transporters (17,18). Acute 
illness involves specific treatments such as continuous venous-venous hemofiltration 
(19), extracorporeal membrane oxygenation (ECMO) (20) and hypothermia (21–24), 
which also affect PK and PD.
ETHICS
To rationalize choice of drug, route of administration and dosing, research on drugs 
used in the PICU is of paramount importance but is hampered by practical, ethical, and 
scientific challenges. Classic pharmacokinetic studies are not ethically feasible as they 
imply administration of a non-therapeutic drug followed by extensive blood sampling. 
Therefore alternative study designs have been developed, such as opportunistic PK 
studies that use concentrations of a drug administered per standard of care, thus doing 
away with the administration of a study drug (25, 26). These studies are FDA approved 
(27). Other studies measure drug concentrations in blood collected during routine blood 
sampling or in leftover samples from routine analysis, thereby eliminating the burden 
of blood sampling for research purposes (26). These sparse sampling data, obtained at 
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any moment during treatment, necessitate the use of a versatile method for the analysis, 
such as population pharmacokinetics (28, 29). Population pharmacokinetics also allows 
determining the influence of patient characteristics on PK and PD, permitting to design 
dosing guidelines tailored to the individual patient’s characteristics. This method is 
proven useful to study particular populations including critically ill and to investigate 
the influence of the interplay between age, disease severity and ECMO.
Moreover, alternative forms of the consent-seeking process have been developed tak-
ing into account the acute and unpredictable reality of the PICU where time constraints 
and parental stress are barriers to this process.
PK and PD of analgosedation in the PICu
Analgesics and sedatives are among the most commonly used drugs in the PICU (3). They 
are administered to alleviate any pain and stress related to the child’s disease and treat-
ment. Ideally, the child should be asleep but easily arousable (30). Reaching this ideal 
level of sedation implies a good knowledge of PK and PD of analgosedatives in a variety 
of different situations. Research on analgesics and sedatives in the PICU is improving 
but there is still a long way to go before the choice of the best agent and dose can be 
tailored to individual demographic, clinical and concomitant treatment characteristics.
Pharmacokinetics of analgosedation in the PICu
As pointed out above, the PK can be affected by several factors including interventions 
such as ECMO and hypothermia, but also, for example, altered oral absorption due to 
the critical illness. Thus, the existing PK data of analgosedatives may not always be 
applicable to each individual critically ill child, and each specific situation also merits 
further study.
Extracorporeal membrane oxygenation
Extracorporeal membrane oxygenation (ECMO) is one of the situations in which clini-
cians are challenged to determine optimal drug dosing. Patients on ECMO require 
optimal analgosedation but the optimal dosing is hard to establish because the PK of 
medications may be altered by the ECMO system (20). Many drugs have never been 
studied in patients on ECMO, and one of these medications is clonidine, a central α-2-
agonist with both sedative and analgesic properties (31, 32). As ex vivo studies on ECMO 
have shown that the speed and extent of drug adsorption correlate with lipophilicity 
(33) and amount of protein bound (34), the moderate lipophilicity (log P = 1.6) (35) and 
slight protein binding (20–40 %) (36) of clonidine suggest the potential of significant 
adsorption.
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Oral bioavailability
Although in general drugs to critically ill children are administered intravenously, oral 
administration is not uncommon in the PICU, and this has been documented in 15 % 
of ventilated and 27 % of non-ventilated patients (37). Still very little is known about 
oral drug absorption in critically ill children, who are likely to have altered gastro-
intestinal function and thereby altered oral drug absorption. The oral bioavailability of 
paracetamol, for example, has not been studied in paediatrics in general, let alone in 
critically ill children– and yet it is one of the most commonly used drugs in the PICU (3).
Oral bioavailability is best estimated by oral and intravenous administrations in the 
same patient. While this is traditionally done with crossover studies, in pediatrics these 
studies are advised against for ethical and practical reasons (38). Moreover, measure-
ments at different time points – days apart – do not provide an accurate estimation 
of bioavailability in critically ill children, whose clearance, volume of distribution and 
bioavailability keep changing during the course of disease (39–41). Microtracer stud-
ies can overcome these limitations as oral and intravenous doses of the same drug are 
given simultaneously and can be distinguished from one another by labelling one of 
the doses.
Pharmacodynamics of analgosedation in the Picu
The main goal of analgosedative therapy is to optimize comfort while minimizing ad-
verse events. The intended level of sedation may vary according to the goal, e.g. light 
sedation to keep the child comfortable and reduce the risk of as unintended removal 
of tubes and lines, or deeper sedation to guarantee hemodynamic stability, e.g. post 
cardiac surgery or in pulmonary hypertension. Interestingly, the effects of deep sedation 
on these outcomes have not received much attention in clinical trials. Additionally, apart 
from neuropsychological outcomes, adverse events are also understudied.
Depth of sedation after heart surgery
After heart surgery, patients may develop low cardiac output syndrome as a result 
of the decrease in cardiac output (43, 44). Sedation in this situation was traditionally 
aimed at lowering the metabolic demand and ensuring hemodynamic stability (45). 
But accumulating data suggest that profound sedation may be detrimental. It has been 
associated with longer durations of mechanical ventilation and ICU stay (46), extubation 
failure (47), increased risk of tolerance and withdrawal (48, 49), delayed recovery (50, 51) 
and detrimental neurodevelopment outcome on the longer term (52). Therefore there is 
much to be said for limiting sedative use after heart surgery, although the effect of this 
strategy on hemodynamic stability needs to be studied.
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Hemodynamic consequences of clonidine use in the Picu
The use of clonidine, which has both analgesic and sedative properties, is increasing in 
the PICU (31,32, 53, 54). Enthusiasm for this agent is driven by concerns about the neu-
rotoxic effects of benzodiazepines (55, 56) and by the absence of clinically significant 
respiratory depression with α2- agonists (57). On the other side, its potential adverse 
hemodynamic effects discourage its use, particularly in case of hemodynamic instability 
(32). Indeed, clonidine can induce hypotension and bradycardia mainly by inhibiting 
cardiac and vascular sympathetic activities (57) this may negatively affect cardiac out-
put. Compared to dexmedetomidine, another α2-agonists with similar safety profile, 
studies on clonidine’s hemodynamic effect in the PICU are few, preventing its use in the 
critically ill child.
In summary, a rational choice of drugs, dosing and route of administration of sedatives 
and analgesics for the critically ill child is so far hindered by the absence of data ac-
counting for the diversity of the clinical situations encountered in the PICU. Innovative 
approaches including population and microdosing PK studies, alternative informed 
consent methods, and attention to the interplay between critical illness and pharmaco-
dynamics outcomes are highly needed.
AIMS AND OULINE OF THIS THESIS
1) To review existing knowledge on PK, PD and ethical challenges in critically ill chil-
dren, with a focus on analgosedatives.
2) To study complex PICU pharmacokinetics using as examples:
 a) The pharmacokinetics of clonidine in ECMO patients
 b) Oral bioavailability of paracetamol in critically ill patients
3) To study hemodynamic efficacy and safety outcomes of analgosedatives
 a)  Is hemodynamic stability similar in tailored sedation versus pre-emptive seda-
tion after heart surgery in young infants?
 b)  What is the impact of clonidine on hemodynamic stability in neonates after 
heart surgery and in a general mixed PICU population?
Chapter 1
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Part II   Chapter 2 delineates the impact of critical illness and its treatment modalities 
on drug pharmacokinetics and pharmacodynamics. Chapters 3 and 4 review 
the ethical challenges of drug research in critically ill children. The recent pro-
gresses in sampling methods, data analysis and outcome measurement tools 
are described that minimize risk and burden for the children. Furthermore, 
alternative forms of consent that may be suited to the reality of the PICU are 
suggested. Chapter 5 describes the current knowledge on PK and PD of anal-
gosedatives in the critically ill.
Part III   Chapter 6 describes the first population PK study of clonidine on ECMO and 
proposes new dosing guidelines for children on ECMO. Chapter 7 presents the 
first determination of paracetamol bioavailability in a PICU population in an 
innovative microtracer bioavailability population pharmacokinetic study.
Part IV  Chapter 8 presents a study in infants after major heart surgery comparing the 
effect on hemodynamic stability of pre-emptive sedation with that of sedation 
tailored to the patient’s clinical condition. Chapter 9 describes the hemody-
namic effect of clonidine in a neonatal population after heart surgery. Chapter 
10 presents a study on the hemodynamic effect of clonidine and the conse-
quences of bradycardia and its risk factors in a large mixed PICU population.
Part V  Summarizes and discusses the main findings and conclusions of this thesis and 
gives recommendations for future research.
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PART II
DRUG STUDIES IN THE PICU:
PK, PD AND GENERAL ASPECTS
“Les médecins administrent des médicaments dont ils savent très peu, à des malades 
dont ils savent moins, pour guérir des maladies dont ils ne savent rien.” 
Voltaire
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INTRODUCTION
Drug dosing in the critically ill child is a real challenge. In addition to the age-related 
variation in volume of distribution, drug metabolism and renal excretion, we must take 
into account the effect of acute illness and its treatment modalities, which can impact 
on every step of drug pharmacokinetics (PK) and pharmacodynamics (PD). Our current 
knowledge does not allow for setting dosing guidelines accounting for the diversity of 
situations typically found in the intensive care unit (ICU). The aim of this chapter is to 
reduce the risk of improper dosing by delineating general principles governing PK-PD in 
the critically ill child and describing the main continuous medications used.
PK-PD IN THE CRITICALLY ILL CHILD
PK-PD changes in critically ill children can be due to either intrinsic factors related to the 
patient’s condition or treatment modalities (e.g. ECMO, hypothermia, CVVH). They are 
summarised in figure 1.
Intrinsic factors related to the patient
Intrinsic factors related to the patient’s condition can alter pharmacology in numerous 
ways:
Absorption
intestinal absorption
Is dependent on the drug’s chemical properties, gastric and intestinal motility and 
amount of blood flow to the gastro-intestinal tract.
Many conditions can impact on absorption:
•	 Ileus	or	decreased	 intestinal	motility	often	present	with	 shock,	 sepsis	 and	various	
gastro-intestinal conditions and may result in delayed absorption and thereby de-
layed effect (1).
•	 Malabsorption	and	gastroenteritis	may	increase	or	decrease	the	extent	of	absorption	
and thereby systemic concentrations
•	 Low	cardiac	output:	blood	flow	to	 the	gut	decreases	and	gut	oedema	 impairs	ab-
sorption (2) resulting in lower systemic concentrations of the parent drug.
•	 Inflammation:	 through	 regulation	 in	 drug	 metabolism	 and	 transporter	 activity,	
which influences gut absorption of drugs (3-5).
Therefore, in the unstable patient and in situations where there is doubt about the qual-
ity of absorption, IV formulations should be favoured (6).
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First-pass metabolism
In patients with cirrhosis, when the liver is bypassed by extensive porto-systemic shunts, 
the drugs that undergo extensive fi rst pass metabolism may have signifi cantly increased 
oral bioavailability leading to a risk of overdose (e.g. propranolol, morphine) (1, 7).
Distribution
The main factors aff ecting distribution in the critically ill are:
Albumin
A decrease in the amount of unbound albumin leads to:
•	 An	increase	in	the	free	concentration	of	the	drug:	if	the	drug	is	active	its	eff	ect	can	be	
enhanced because more free drug is available for receptor binding (e.g. phenytoin)
           
 
Figure 1: Illustration of the eff ect of critical illness on drugs pharmacokinetics. Changes in absorption are 
illustrated by the eff ect of illness on gut absorption (lower right) and fi rst by-pass metabolism (lower left). 
Volume of distribution (Vd) is aff ected by albumin bound (upper right) and features of illness and treatment 
modalities (listed in the square representing peripheral compartment). The liver is the main organ of drug 
metabolism; and kidneys (upper left) are the main excretory organ. Changes are represented by an arrow 
(↑: increase : ↓ decrease) and a graphical representation of drug concentration over time with a dashed line 
representing PK in a healthy patient and the solid line representing the change induced by critical illness.
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•	 An	increased	apparent	volume	of	distribution	(Vd):	the	drugs	usually	bound	to	albu-
min disperse into the tissue and decrease the relative concentration in blood for the 
same total amount.
This situation is typically found in the following situations:
(1)  Renal failure, where organic acids compete with the liaison of albumin with drugs 
(8).
(2) Hypoalbuminemia, which often is seen in critical illness or liver failure (6, 7).
(3) Polypharmacy, as drugs may compete for albumin binding sites.
change in total body water
Oedema and ascites were found to increase the Vd of hydrophilic drugs (e.g.: aminogly-
cosides), which distribute in the total body water (1, 8, 9).
change in blood fl ow
Normally, it takes around 30 seconds for the blood to fl ow from a peripheral vein to 
the arterial circulation. When heart function is severely impaired, cardiovascular stabil-
ity is fragile and distribution in the circulatory system can be signifi cantly delayed. This 
warrants careful titration of cardiodepressant drugs (i.e. virtually all analgesic sedative 
drugs) as sudden collapse may occur if insuffi  cient time is allowed for distribution.
metabolism
The liver is the main organ of drug metabolism. Drug metabolites are generally inac-
tive but can also be as active or sometimes even more potent than the parent drug 
(midazolam, morphine).
The mechanism by which liver disease impacts on drug clearance is determined by 
the extraction ratio (fraction of drug extracted by the liver):
•	 High	 clearance	“fl	ow	 limited”drugs:	 For	 the	 drugs	 that	 are	 almost	 completely	 ex-
tracted (extraction ratio around 1) (e.g. propofol), a decrease in liver blood fl ow leads 
to a decrease in metabolism.
•	 Low	clearance	“capacity	limited”	drugs:	For	drugs	only	partially	extracted	(extraction	
ration << 1) a decrease in liver metabolic capacity is the main determinant of the 
amount of drug metabolised.
The impact of acute liver failure on drug metabolism is diffi  cult to predict because it 
does not correlate with the measured indices of liver function (transaminases, bilirubin, 
albumin) (7).
Systemic infl ammation also impacts on liver metabolism (5, 10). Proinfl ammatory cy-
tokines induce downregulation of the expression of most CYP450 enzymes resulting in a 
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decreased clearance and increased plasma levels of their substrates with risk of adverse 
effects (e.g: midazolam, theophylline).
Excretion
Glomerular filtration is the main pathway of drug elimination by the kidneys. This ex-
plains why creatinine clearance (CrCl) is currently used to guide dosage of drugs that 
are renally excreted. In the absence of a practical marker of tubular function, glomerular 
filtration rate (GFR), which may serve as marker of tubular damage, is also used to guide 
dosing of drugs dependent on renal tubular function (morphine, cephalosporins)(8). 
Usually, doses need to be modified when GFR is < 30–40ml/min/1.73m2.
CrCl measurement in patients with low muscle mass warrants caution. As creatinine 
production is proportional to the muscle mass the measurement may overestimate 
GFR(11). Some drugs metabolized by the liver have active metabolites that accumu-
late in renal failure (e.g. one of morphine’s metabolites, M-6-G, is more potent than 
morphine). In patients with decreased GFR, maintenance dosage can be adjusted by 
increasing the dosing interval or by decreasing the dose. Dosing guidelines are available 
(e.g http://www.kdp-baptist.louisville.edu/renalbook/) and seeking advise from clinical 
pharmacists is recommended.
In contrast, augmented renal clearance (supranormal GFR) is an increasingly recog-
nised condition in PICU patients (12–14) which leads to increase drug clearance with risk 
of underdosing renally excreted drugs. Subtherapeutic levels of, for example, antimicro-
bial treatment may potentially have devastating consequences (15–17).
Extrinsic factors related to the treatment of the patient
A number of external treatment modalities, discussed below, can also affect PKPD in ICU.
ECmo
Distribution
For most drugs Vd increases (volume added and adsorption to the circuit). Lipophilic 
drugs (midazolam, fentanyl) are more adsorbed by the circuit than the more hydrophilic 
drugs (morphine, gentamicin, cefotaxime) and therefore their blood levels may be lower. 
Hence, at initiation of ECMO, an increase in drug requirement is expected. Thereafter, 
steady state levels are mainly affected by clearance and dose rate(18).
Change in PK depends also on the type of ECMO circuit and composition of the prim-
ing solution (19).
clearance
In general, clearance in ECMO-patients is lower than in non-ECMO patients (0–50 % 
decrease). Sedatives and analgesics are titrated to effect and require generally higher 
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doses (mostly at initiation of ECMO). Antibiotics are affected. Cautious dosing and close 
monitoring of highly toxic agents such as gentamcin is advised, but dose adjustments 
are not necessary for beta-lactams such as cefotaxime (20).
To date, there are no recommended dosing guidelines for medications on ECMO.
Hypothermia
Absorption
Hypothermia decreases the rate of absorption. This therapy is often used in patients 
with decreased intestinal motility (secondary to a cardiac arrest or asphyxia), adding 
to the unpredictability of oral absorption (21). Therefore, intravenous administration is 
more reliable in hypothermic patients.
Distribution
The volume of distribution changes due to redistribution of blood flow, and changes 
in blood pH and physicochemical properties of the drugs with hypothermia (change in 
protein binding). Vd can increase or decrease depending on the drug properties, with 
risk of under- and overdosing, respectively (22–24).
Metabolism
Decreased enzymatic rate at low temperature decreases clearance of drugs eliminated 
via hepatic metabolism (e.g.: morphine accumulation in neonates even with same infu-
sion rates (25)). There will be a delay of action for pro-drugs (slowed transformation into 
active compounds) while active drugs may accumulate.
Excretion
Decreased liver metabolism and renal clearance leads to a risk of accumulation. Main-
tenance doses need to be decreased especially for non-clinically titrable drugs and low 
therapeutic index medications.
Pharmacodynamics
The EC50 can increase or decrease with cooling, depending on the drug. For example 
morphine’s EC50 increases, which implies that higher drug levels will be needed for 
the same effect. The opposite happens for inotropic drugs, the effects of which may be 
increased. Consequently the changes in PK could match PD in particular situations (e.g.: 
a drug has increased levels, but these higher levels are actually needed to produce the 
same effect) (22).
During the rewarming phase following hypothermia, the PK-PD parameters should 
normalize and care must be taken to adapt medication dosing accordingly.
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Cardio-pulmonary bypass (CPb) and combined effect of ECmo and hypothermia
CPB is used to preserve perfusion during heart surgery. It combines the use of an extra-
corporeal circuit – similar to ECMO – and hypothermia (which preserves organ function) 
but it is applied for a shorter period and rewarming is initiated within a few hours.
ECMO combined with hypothermia is mainly used for neuroprotection after cardiac arrest. 
In the absence of any adult/paediatric data, the changes can only be speculated on based 
on the CPB literature and the available knowledge on each modality separately (24, 26).
Distribution
When either bypass or ECMO is combined with hypothermia, we have to account for op-
posite effects on Vd. Initiation of bypass or ECMO causes Vd to increase (notably in the case 
of lipophilic drugs), due to the added circuit and adsorption by the circuit. Hypothermia 
decreases Vd, but only to a limited degree compared to the increase secondary to ECMO.
Metabolism and excretion
In both cases, bypass combined with hypothermia, and ECMO combined with hypother-
mia, drug clearance will be lower.
Haemofiltration, which is commonly used on ECMO or bypass, affects elimination: the 
smaller size (< 500Da), hydrosoluble and poorly protein bound drugs will be significantly 
eliminated while the drugs that are not filtered will be concentrated (24, 27).
Continuous renal replacement therapy (CrrT)
Continuous haemofiltration is based on the principle of hydrostatic pressure to drive 
fluid through a filter. The filtered plasma is called ultrafiltrate. Continuous hemodialysis 
uses passive diffusion through a membrane for substrate removal. The dialysed plasma 
is called dialysate. Haemodiafiltration uses both principles.
CRRT has a major impact on drug clearance (28). Current dosing guidelines in paediat-
ric patients on CRRT are mostly derived from adult studies(29).
An easy way to get an idea about the expected amount of drug that will be removed 
by CRRT (28, 30) is to evaluate:
Volume of Distribution
The higher the Vd the less likely a drug will be cleared by CRRT because it is mainly con-
centrated in extravascular compartments unavailable for RRT. Drugs with a Vd exceed-
ing 0.7L/kg that are more lipophilic and concentrated in adipose tissues are less likely to 
be cleared. For example, CRRT is not effective for e.g. digoxin (Vd of 7.3L/kg) poisoning.
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Sieving coefficient (Sc)
This coefficient represents the degree to which a particular membrane allows the pas-
sage of a solute. It is measured by the ratio of solute concentration in the ultrafiltrate 
to the solute concentration in the plasma (Sc = 1 means that 100 % of solute will be 
removed; Sc = 0 means that the solute is not removed at all).
 The major determinants of the Sc of a drug are:
-  Degree of protein binding:
 Sc can be estimated by: Sc = 1-protein binding. It gives a quick estimate of the ex-
pected amount of drug removal.
- Drug-membrane interactions: The passage through the membrane is determined by:
•	 size	of	the	membrane	pores:	these	allow	molecules	up	to	a	certain	size	to	pass	
through (usually 20 kDa)
•	 charge	of	the	molecule
Amount of ultrafiltrate or dialysate
This is prescribed by the clinician and is the principal determinant of drug removal.
General principles
Despite recent advances in the understanding of PKPD in the PICU, our knowledge is 
not sufficient to allow adequate titration of drugs. Dosing guidelines that incorporate 
the complexity of critical illness are unlikely to be achieved in the near future. In the 
meantime, the above principles should help the PICU clinician to develop a critical view 
when prescribing.
Between these areas of uncertainty, some general principles apply:
1) Drugs that can be titrated to effect (e.g. sedatives and inotropes) can be dosed clini-
cally.
 Knowledge of their properties in a particular situation guides the choice of the right 
agent (for example morphine is less adsorbed than fentanyl in children on ECMO and 
therefore should be favoured) or the timely titration of the dose (decrease sedation 
in hypothermia).
2) Especially in critical illness with organ involvement, care must be taken to avoid 
every unnecessary medication. Favouring medication that is not inactivated by the 
liver or just metabolised through a single step decreases the potential for adverse 
reactions.
3) Frequent monitoring of serum levels of medication with a narrow therapeutic index 
(aminophylline, anticonvulsants, cardiac glycosides…) or medication with poten-
tially severe consequences of underdosing (aminoglycosides,…) is recommended 
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when the clinical condition changes or after use of particular treatment modalities 
(ECMO, hypothermia,…)
4) Favour IV formulation if there is uncertainty about absorption.
CONTINUOUS MEDICATION USED IN PICU
Continuous medication allows easy titration and stable plasma levels. It takes 3–5 half-
lives for a drug to reach steady-state, and for it to be largely cleared from the body. 
Hence, when the half-life is short, quick titration to the effective concentration is reached 
(inotropes, some antihypertensives). When the half-life is long a loading dose may 
be needed to reach therapeutic plasma level more quickly (e.g. milrinone, morphine, 
midazolam).
Cardio- and vasoactive drugs
Cardio- and vasoactive drugs are commonly used in the PICU for treatment of low cardiac 
output syndrome (LCOS) from sepsis, cardiogenic shock or its prevention after cardiac 
surgery. Conventional inotropic agents (adrenaline, noradrenaline, dopamine and do-
butamine) stimulate different adrenergic receptors and therefore differ in their positive 
inotropic effect (β1 receptor effect of increased contractility), peripheral vasoconstrictive 
(α receptor effect) or vasodilatory properties (β2 receptor). Newer agents include milri-
none, an inhibitor of phosphodiesterase type 3, and levosimendan, a calcium sensitizer 
agent that increases troponin C sensitivity to calcium (31, 32).The choice of medication 
is dictated by the patient’s haemodynamics and physician’s individual preferences. For 
example, in warm septic shock, vasodilation will be countered by noradrenaline while 
in cold shock adrenaline or dopamine will be preferred (33). Table  1 summarizes ef-
fects of cardio- and vasoactive drugs derived from adult studies. Milrinone has been 
shown to decrease the occurrence of LCOS diagnosed clinically (34). The lack of studies 
comparing the effectiveness of different agent for preventing of LCOS leads to a large 
difference in practice (35, 36). For prevention and treatment of LCOS, vasodilating agent 
are frequently added to cardioactive drugs to reduce afterload on the myocardium once 
BP has been restored toward normal range. Arteriolar and venodilator agents lacking 
inotropic negative effect are recommended (e.g. SNP, phentolamine).
Antihypertensive agents with inotropic negative properties (e.g. nicardipine and es-
molol) are used for the treatment of hypertension with preserved heart function (37, 38).
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Sedatives and analgesics
Analgesics are targeted to relieve pain while sedatives serve to calm the patient in the stress-
ful environment of the PICU and allow care (mechanical ventilation, usual nursing care,…).
Pain relief is most commonly achieved with continuous infusion of opiates (fentanyl or 
morphine); sedation with benzodiazepines (midazolam, lorazepam). Both agents induce 
respiratory depression. Alpha-agonists (clonidine and dexmedetomidine) have both 
sedative and analgesic properties and induce bradycardia instead of respiratory depres-
sion. Propofol has sedative and hypnotic properties, and a strong cardio-depressant 
effect hampering its use in the hemodynamically unstable child. It has a very short re-
covery time on discontinuation and facilitates weaning of long acting sedatives around 
the time of extubation. Its use is contraindicated in the official drug label for children 
<  16y due the risk of lethal propofol infusion syndrome. Despite these warnings, its 
Table 1: Effects of cardio- and vasoactive drugs derived from adult studies. The doses of dopamine and 
adrenaline inducing more vasoconstriction are approximate and should be correlated to the overall clinical 
picture.
 
 
 
Table 1: Effects of cardio- and vasoactive drugs derived from adult studies. The doses of dopamine 
and adrenaline inducing more vasoconstriction are approximate and should be correlated to the 
overall clinical picture. 
Abbreviations: BP: blood pressure; CO: cardiac output; HR: heart rate; SVR: systemic vascular 
resistance
Abbreviations: BP: blood pressure; CO: cardiac output; HR: heart rate; SVR: systemic vascular resistance 
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unique properties motivates some clinicians to use it even in small children and adverse 
effects may not be as common as feared (39).
The optimum level of sedation leading to better clinical outcomes is yet to be deter-
mined. Oversedation increases the risk of tolerance, withdrawal and delirium and pro-
longs duration of intubation (37). Despite this evidence, achieving the goal of optimal 
sedation remains a challenge and a tendency toward oversedation has been described 
in the PICU setting (40). A way of avoiding oversedation is to proceed to daily sedation 
interruption (41). Another way of decreasing medications that depress ventilation is to 
use alternative medications like paracetamol (42), clonidine (43) or dexmedetomidine. 
Virtually all available sedatives and analgesic medications are neurotoxic in animal 
models. Human studies are still scarce (44) and conflicing. Morphine administration in 
neonates has been reported to be without adverse long-term effects in a cohort of pre-
term newborns followed up at 8–9 years of age (45), while it has been shown to predict 
adverse neuropsychological outcome in meningococcal septic shock survivors (46). 
Improvement of neurological outcome is a significant concern in PICU, and analgesics 
and sedatives certainly play a significant role which requires further research.
CONCLUSION
Understanding of pediatric pharmacology in critical illness has grown enormously over 
recent years. This chapter has given an overview of this complex field. However, our 
current insight is still insufficient to allow targeted PK-PD optimization with simultane-
ous minimization of adverse effects in the critically ill. Population approaches of PK/
PD modeling are promising (47). PKPD models taking into account the complexity and 
rapidly evolving critical disease states and treatment modalities are the ultimate goal, to 
facilitate dose individualization and optimizing clinical outcomes.
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List of the most commonly used continuous drugs in the PICU
Mechanism of action
/ site of action
Relevant pharmacokinetic 
characteristics
Contraindications / Toxicity ( 
(48, 49)and TDM if relevant)
Important/common drug 
interactions
Morphine μ receptor agonist Liver metabolism into M3G and 
M6G (the latter is more potent 
than morphine) they are excreted 
by kidneys => may accumulate 
with renal failure.
Morphine clearance decreased 
with postnatal age < 10 days(48, 
49).
Not ideal for painful procedures: 
peak of action 20 minutes.
Can cause respiratory 
depression
Fentanyl μ receptor agonist
Synthetic opioid, 100 
times more potent than 
morphine
Anaesthetic agent
Metabolized by the liver by 
CYP450 3A4 into inactive 
metabolites. Compared to 
morphine: easier titration in renal 
failure (no active metabolite).
Quick peak of action: ideal for 
short painful procedures.
Context sensitive half-life: the 
longer the infusion, the
longer the time taken to clear.
Can cause respiratory 
depression
Can cause chest wall rigidity 
+/- associated laryngospasm 
inducing ineffective 
ventilation, desaturation 
(treatment options: naloxone, 
neuromuscular blocking agent, 
intubation)
Remifentanyl μ receptor agonist
Compared to fentanyl: 
equipotent, quicker 
onset of action
Anaesthetic agent
Metabolized by plasma esterases.
Elimination is independent of 
hepatic metabolism or renal 
excretion.
Short offset even after long 
infusion.
Can cause respiratory 
depression
Midazolam GABA receptor agonist
Anxiolytic and amnesic 
agent
Extensive hepatic metabolism 
by CYP 3A=> primary metabolite 
1-OH midazolam is equipotent to 
midazolam The 1-OH midazolam-
glucuronide (weak sedative effect) 
accumulates with renal failure.
Large Vd and low Sc therefore, no 
dosing adjustment is expected 
on CRRT.
Can cause respiratory 
depression
Avoid bolus of midazolam 
in hemodynamically 
compromised patient 
(hypotension)
Many interactions with CYP3A4 
inducing or inhibiting agents: 
careful titration to effect
Clonidine α-adrenergic receptor
sedative and analgesic 
properties
specificity for α-2
receptors: α-2:α-
1 = 200:1
Increased half-life with renal 
failure
Half-life: Neonates:18h (50) /
Children: 9h (51) / Healthy adult: 
12–26h / Adult with renal disease: 
41h
Bradyaryhtmia
No clinically significant 
respiratory depression (52)
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List of the most commonly used continuous drugs in the PICU (continued)
Mechanism of action
/ site of action
Relevant pharmacokinetic 
characteristics
Contraindications / Toxicity ( 
(48, 49)and TDM if relevant)
Important/common drug 
interactions
Dexmedetomidin e α-adrenergic receptor
sedative and analgesic 
properties
more specific than 
clonidine for α-2 
receptors (α-2: α-
1 = 1600:1)
Liver metabolism
Neonatal clearance: 40 % of adult 
value, At 1 year: 85 %
of adult clearance
½ life: 2,4 h (children) (53)
Bradyarythmia
No clinically significant 
respiratory depression (52)
Propofol Alkylphenol with 
sedative and hypnotic 
properties, not well 
defined mechanism of 
action
Rapid onset and short duration 
of sedation on discontinuation 
and facilitates weaning of long 
acting sedative around the time 
of extubation and neurologic 
evaluation of patient with 
traumatic brain injury.
Unaffected by renal and hepatic 
dysfunction.
FDA recommends maximum rate 
of 4mg/kg/h for max urs
Contraindicated in 
hemodynamically unstable 
child: can cause profound 
hypotension and collapse.
Risk of propofol infusion 
syndrome (PRIS) (clinical and 
biological signs: metabolic 
acidosis, increased liver, 
lipemia, rhabdomyolysis,…) 
that can be fatal. Any suspicion 
of PRIS should lead to an 
immediate interruption of 
propofol infusion but despite 
discontinuation, death can 
ensue (54).
Sodium nitroprusside Nitric oxide liberation 
during rapid metabolic 
breakdown => 
peripheral vasodilator
No negative inotropic 
effect: safe with 
decreased heart 
function or after cardiac 
surgery
Very easy titration: abrupt 
discontinuation or downward 
titration if hypotension with very 
quick response on BP
1. Converted into cyanide in blood 
and tissues
2. Liver: cyanide converted to 
thiocyanate (risk of cyanide 
accumulation in liver failure)
3. Thiocyanate renally excreted 
(risk of accumulation in renal 
failure)
Signs of cyanite toxicity: cellular 
dysoxia from mitochondrial 
dysfunction: lactic acidosis with 
high mixed venous saturation, 
hypotension, tachycardia, 
shock,
coma, death. Measure cyanide 
level if liver dysfunction.
Signs of thiocyanate toxicity: 
confusion, psychosis, coma, 
death. Level are advised if 
infusion > 3days or renal 
impairement.(38).
Esmolol β- blocker with β1 
selectivity / site of 
action: AV, SA node
Very quick onset of action
Easy titration (38)
Higher rate of clearance in 
neonates compared to older 
children
No accumulation with liver or 
renal failure (metabolised in blood 
by esterase)(55)
Some formulations contain 
ethanol and propylene glycol
Contraindication: Sinus 
bradycardia, heart block, 
uncompensated heart failure 
(negative inotropic effect)
Caution: reactive airway disease
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List of the most commonly used continuous drugs in the PICU (continued)
Mechanism of action
/ site of action
Relevant pharmacokinetic 
characteristics
Contraindications / Toxicity ( 
(48, 49)and TDM if relevant)
Important/common drug 
interactions
Nicardipine Slow Calcium channel 
blocker => decreased 
myocardial and vascular 
smooth muscle cell 
Calcium concentration 
=> less Calcium 
available for contractility 
=> vasodilation => 
decreased BP
Extensive hepatic metabolism by 
CYP 450 isoenzyme (CYP 3A4) => 
Many interactions (with CYP3A 
inducers or inhibitors)
If cardiac failure, be aware of 
negative inotropic effect.
Contraindicated if significant 
obstruction of systemic 
circulation (e.g: coarctation of 
the aorta)(55)
Labetalol Antagonist of α1 and
β-adrenergic Receptor
Long half-life (3–3h) Titration 
should be slow.
Metabolised by hepatic 
glucuronidation(55).
Contraindicated in cardiac 
failure due to negative inotropic 
effect
Risk of bronchospasm in 
asthmatic patient
Hydralazine Direct arteriolar 
vasodilator with 
unknown precise 
mechanism.
Combined positive 
inotropic and 
chronotropic 
stimulation of the heart 
=> increased cardiac 
output
Particularly useful in 
children with underlying 
hypertension on 
multiple medication
Extensive first pass effect with oral 
administration: 10-
30 % of oral bioavailability 
depending on acetylator status.
Onset of action: 10 minutes
Contraindication: dissecting 
aortic aneurysms, mitral valve 
rheumatic disease (increase 
of stroke volume can worsen 
dissection or regurgitation), 
significant coronary artery 
disease
(risk of ischemia).
Adverse effect with long term 
use: Drug-induced lupus like 
syndrome.
Concomitant use of MAO 
inhibitors may cause profound 
hypotension.
Phenoxybenzamine, 
Phentolamine
Systemic vasodilators by 
α -adrenergic blockade. 
Used in catecholamine- 
induced hypertension
(e.g 
pheochromocytoma) or 
for afterload
reduction after cardiac 
surgery.
Phentolamine: 
competitive reversible 
antagonist
Phenoxybenzamine:
irreversible
Once α –blockade is achieved, if 
needed β-blockade can be done 
to counteract tachycardia(37).
Suspect overdosage if signs 
of sympathic nervous system 
blockade: vomiting, marked 
tachycardia, hypotension shock.
Treatment of overdose:
Noradrenaline. NB: Adrenaline 
contraindicated (because 
α-receptors are blocked and 
adrenaline will cause selective 
β-adrenergic stimulation 
and will further increase 
hypotension)(55).
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List of the most commonly used continuous drugs in the PICU (continued)
Mechanism of action
/ site of action
Relevant pharmacokinetic 
characteristics
Contraindications / Toxicity ( 
(48, 49)and TDM if relevant)
Important/common drug 
interactions
Dopamine α1, α2, β1 >β2 
adrenergic receptors 
agonist, dopaminergic 
receptors increased 
contractility, increased 
BP.
Precursor of 
noradrenaline
Precursor of noradrenaline
Very easy titration
Short half life
At high doses may lower 
cardiac output by marked 
vasoconstriction
Dobutamine β1 > β2, α1 adrenergic 
receptors agonist 
leading to increased 
contractility, HR, 
vasodilation
Very easy titration
Short half life
Tachycardia not uncommon.
Can decrease BP by vasodilation 
(56)
Adrenaline α1, β1, β2 adrenergic 
receptors agonist
Multiple indications:
In bolus: cardiac 
arrest, extremely low 
BP or symptomatic 
bradycardia, 
anaphylactic reaction.
Infusion: shock, 
bronchospasm (if no 
more selective β2 
agonist available)
Very easy titration
Short half life
At high doses may lower 
cardiac output by marked 
vasoconstriction
Can increase lactates at high 
dose (can be misinterpreted as 
anaerobic metabolism due to 
shock) (56)
Noradrenaline α >> β1 adrenergic 
receptors agonist
Ideal drug for warm 
shock
Very easy titration
Short half life
Vasoconstriction can increase 
BP without affecting cardiac 
output or decrease CO (31)
Milrinone Phosphodiesterase 
inhibitor class 3
Lusitropic properties: 
improvement in 
diastolic function (and 
properties listed in 
table 1)
Excreted unchanged: 
accumulation with renal failure.
Relatively long half-life (slow 
titration and bolus dose may be 
needed to quickly reach steady 
state)(55)
Can cause hypotension by 
decrease in vascular resistance. 
Do not give if borderline BP(56)
Levosimendan Calcium sensitizing 
drug: interacts with 
troponin C and 
increases its sensitivity 
to calcium =>
increased efficiency of 
contractile apparatus of 
myocytes
Hepatic metabolism(8)
Infusion given over several hours. 
Loading can be given at the 
beginning of infusion but can lead 
to significant vasodilation and 
hypotension.
Effect last for many days
Can cause hypotension by 
decrease in vascular resistance. 
Do not give if borderline BP (31)
Abbreviations: AV: atrio-ventricular; BP: blood pressure; CO: cardiac output; CRRT: continuous renal replace-
ment therapy M3G morphine-3-glucuronide; HR: heart rate; M6G: morphine-6-glucuronide; SA node: sinus 
node; TDM: therapeutic drug monitoring
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AbSTRACT
Critical illness and treatment modalities change pharmacokinetics and pharmacody-
namics of medications used in critically ill children, in addition to age-related changes in 
drug disposition and effect. Hence, to ensure effective and safe drug therapy, research 
in this population is urgently needed. However, conducting research in the vulnerable 
population of the pediatric intensive care unit (PICU) presents with ethical challenges. 
This article addresses the main ethical issues specific to drug research in these critically 
ill children and proposes several solutions.
The extraordinary environment of the PICU raises specific challenges to the design 
and conduct of research with the ability to generate useful results. The need of proxy-
consent of parents (or legal guardians) and the stress-inducing physical environment 
may threaten informed consent. The informed consent process is challenging because 
emergency research reduces or even eliminates the time to seek consent. Moreover, 
parental anxiety may impede adequate understanding and generate misconceptions. 
Alternative forms of consent have been developed taking into account the unpredict-
able reality of the acute critical care environment
As with any research in children, the burden and risk should be minimized. Recent 
developments in sample collection and analysis as well pharmacokinetic analysis should 
be considered in the design of studies.
Despite the difficulties inherent to drug research in critically ill children, methods are 
available to conduct ethically sound research resulting in relevant and generalizable 
data. This should motivate the PICU community to commit to drug research to ultimately 
provide the right drug at the right dose for every individual child.
Key points
•	 Drug	research	in	the	pediatric	intensive	care	unit	is	highly	important	for	the	advance-
ment of pediatric medicine, but is a precarious enterprise due to the vulnerability of 
the research population.
•	 The	informed	consent	process	for	research	in	the	pediatric	intensive	care	unit	comes	
with ethical and practical challenges due to the stress-inducing environment, time 
constraints, lack of capacity of minors to decide about trial participation, and the role 
of parental (or other proxies’) consent.
•	 Innovative	 research	 methods	 might	 help	 minimize	 burden	 and	 risk	 for	 children	
participating in drug research in the intensive care unit.
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1. INTRODUCTION
1.1 Protection of minors vs. advancement of knowledge
Drug research in children balances between the advancement of knowledge – and 
consequently improvement in clinical care – and protection of this vulnerable popula-
tion susceptible to harm and exploitation. Children are relatively incapable of protecting 
their own interests and therefore need additional protection as recognized in many 
international ethical and legal documents concerning research with humans [1–4]. Spe-
cific provisions for minors, for example relating to the informed consent process and the 
acceptability of burden and risks have recently been reviewed by our group [5]. These 
provisions pose challenges to research in children. Failing to conduct clinical trials in 
minors turns children into « therapeutic orphans » because the level of protection is not 
balanced with the need of generating knowledge to improve care [6].
1.2 The need for drug research in children
We need to be aware that every medication used in clinical practice that has not been 
studied in clinical trials can be considered an experiment. Clinical drug trials in children 
are essential because data on effectiveness and safety often cannot reliably be derived 
from data in adults. Major changes in pharmacokinetics (PK) and pharmacodynamics 
(PD) occur with increasing age due to changes in body composition, ontogeny of drug 
metabolism and transport and renal function [7]. The relative lack of knowledge on drug 
disposition can lead to treatment failure [8, 9] and adverse events as serious as fatalities 
[10, 11]. It is known that extrapolation from adult data has caused harm in the past. 
For example, a lack of knowledge on ontogeny of enzymes responsible for conjugation 
caused grey baby syndrome in neonates treated with doses of chloramphenicol derived 
from adult studies [12, 13]. Similarly, drug choice and dosing for patients in the pediatric 
intensive care unit (PICU) cannot always be derived from research in the general pediat-
ric population because PK/PD is influenced by critical illness [e.g. inflammation [14], liver 
and renal failure [15–17]) and its treatment modalities (e.g. extra corporeal membrane 
oxygenation (ECMO) [18], hypothermia [19], continuous renal replacement therapy [20].
Some drugs (such as vasoactive and sedative drugs) are almost exclusively used in criti-
cally ill children, and therefore can only be researched in these patients. However, a large 
proportion of drugs used in pediatric practice has not been systematically tested in the 
pediatric population. To stimulate pediatric drug research the Best Pharmaceuticals for 
Children Act [21] and a similar directive in Europe [22] offered incentives to pharmaceuti-
cal companies to generate data in children. Regrettably, fewer than 50 % of these studies 
and 26 % of those focusing on safety were published in peer-reviewed journals. Moreover, 
studies on safe and efficient drugs were more likely to be published than studies resulting 
in negative labelling change [23], putting children at risk of inefficient or unsafe prescrip-
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tions. Although these stimulating measures generated some useful safety and prescribing 
information in children, they did not result in the expected reduction of off-label use [24, 
25]. Estimates of off-label use in the pediatric population still range from 10–65 % [26]. In 
the PICU, even up to 70 % of drugs are unlicensed or off-label [27, 28], which reflects the 
lack of knowledge on drug efficacy and safety in the PICU population [29].
1.3 Challenges of drug research in the PICU
The previous section has made clear that drug research in the PICU is essential. But 
research in this population of critically ill children is precarious and raises specific 
ethical challenges. These challenges may be specific to culture and legislation of each 
individual country; this article focuses mainly on research in high income countries. The 
ethical dilemma of conducting research in the PICU is recognized by pediatric intensiv-
ists themselves; in a survey of 415 pediatric intensivists, over 95 % found randomized 
controlled trials (RCTs) on potentially life-saving therapies ethically acceptable, but at 
the same time almost all were in ethical conflict with these studies [30]. The specific 
challenges faced by researchers in the PICU are, first, the extraordinary physical environ-
ment of the PICU that presents challenges to the design and conduct of research and its 
ability to generate useful results. Second, the children themselves may be too young to 
consent or incapable of it due to acute illness and sedation. Then, parents or surrogates 
are responsible for the decision to involve their child in research, with consequences for 
the informed consent process, notably under the stressful conditions of the admission. 
Last, patients in the PICU already undergo many painful and invasive procedures as part 
of clinical care. Therefore, additional burden must be minimized.
Improving care of the critically ill child implies generating reliable knowledge with 
research widely endorsed by caregivers and families. This article addresses the main 
ethical issues specific to drug research in the PICU and proposes several solutions.
2. OPTIMAL STUDY DESIGN AND CONDUCT
2.1 Introduction
Research subjects included in research of poor quality are exposed to risk and burden with-
out benefit, neither for themselves nor for others. Therefore only methodologically sound re-
search that can generate new results should be proposed to possible research subjects. This 
requirement was already laid down in the Nuremberg Code in 1949[2], and consequently in 
all other important ethical and legal documents concerned with research with humans (for 
example [1, 3, 4]). The specific study population, recruitment method, outcomes measures, 
use of rescue medication and protocol adherence can influence the validity of research in the 
critically ill child and consequently influence the usefulness of the generated results (Table 1).
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2.2 Study population
Children in the PICU represent a wide age range and a broad case mix of underlying 
diseases and ICU diagnoses. Moreover, the acutely ill child receives many drugs simul-
taneously and combinations differ between centers. Therefore, while studying a single 
drug, the interactions with co-medications and type of underlying diagnosis and care 
may interfere with outcomes. More than 80 % of randomized controlled trials (RCT) 
are single-centered [31]. This reduces generalizability of the results from these trials. 
Data sharing and collaboration in larger international PICU research networks could 
overcome this limitation. Examples of pediatric critical care networks are the Canadian 
Critical Care Trials Group (Pediatric Interest Group) and the NICHD Collaborative Pediat-
ric Critical Care Research Network. Europe and the other continents are lagging behind: 
to our knowledge international PICU networks are non-existent to date.
2.3 Recruitment
An underestimated limitation to the generalizability of PICU trial outcomes could be 
the difficulty with recruitment. One third of RCTs in the PICU is terminated before the 
needed sample size is achieved, often due to recruitment problems [31]. One of the 
reasons for recruitment problems could be reluctance to approach potential research 
subjects, also known as ‘gate-keeping’, which attitude may be due to the clinicians’ fear 
of excessive patient burden [32]. This usually means that the sickest patients are less 
likely to be included in research. To our knowledge, the study by Menon et. al. is the only 
addressing barriers to the recruitment process in the PICU. This was an observational 
trial implying an ACTH stimulation test, blood sampling on an existing line and recruit-
ment within 26 hours of admission. Almost 50 % of 1707 eligible research subjects were 
Table 1. Challenges to quality of clinical drug studies in critically ill children
 Theme Challenge Impact on results of trial
Study population Heterogeneous, small patient populations 
and relative lack of multi-center research 
networks
Risk of inconclusive trials due to 
limited sample size
Recruitment Risk of selective recruitment: the sickest 
patient may not be enrolled
Risk of bias and reduced 
generalizability
Outcome measure Selection of clinical relevant outcome 
measures may be jeopardized by small 
sample sizes
Outcome may be clinically irrelevant
Rescue medication Allowing rescue medication with the 
study drug in placebo arm, as not doing 
so may be perceived as unethical
True efficacy of study drug cannot 
be determined
Protocol adherence Protocol violations due to ethical conflicts 
e.g. when a child’s condition deteriorates 
and physician is biased towards the, 
potential life-saving, study intervention
May severely impact the validity of 
study results
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not approached due to unavailability of legal guardians, language issues, lack of agree-
ment of treating physician and prior enrolment in another study [33]. Thus, we need to 
be aware of possible selection bias and its effects on generalizability of research results 
in the PICU. One solution to recruitment issues could be co-enrolment of patients in 
multiple studies [34]. Research shows that participation rates do not decline when par-
ents are asked to have their child participate in two studies simultaneously. This is only 
possible, however, if it does neither effect study outcome (e.g. simultaneous inclusion 
in two RCTs with potential influence on outcome of the studies) nor increases patient 
burden and risk to unacceptable levels (e.g. additive blood sampling volume increases 
above safety margins).
2.4 Outcome measures
Appropriate outcome measures in PICU research are another challenge. It is difficult to 
identify good outcome measures due to the combination of low prevalence of major 
adverse events (e.g. severe morbidity, mortality) and small sample size of many studies 
(median of 49 patients) [31]. While the majority of trials report laboratory or physiologi-
cal primary outcomes, mortality was the primary outcome measure in 2 % of trials [31]. 
Data from a recent feasibility trial of clonidine for sedation suggest that at least 190 
patients are needed to show a 1.5 day difference in days of ventilation and many more 
to show relevant differences for other outcomes such as length of PICU and hospital 
stay [35]. Laboratory or physiological outcomes should be clinically relevant, otherwise 
the research cannot result in improvement of patient outcome [36]. Relevant outcome 
measures and validated assessment tools are therefore essential. The latter is not always 
the case. For example, Vet et al. showed that two thirds of the many different sedation 
scores used in studies on ventilated children receiving a continuous infusion of seda-
tives were not validated for PICU patients [37]. Regarding the effect of a medication, it 
must be kept in mind that adverse effects may not become apparent until years after 
PICU stay. A major concern in this regard is the possible effect of sedative and analgesic 
medication on longer-term neurological outcome [38]. Enrolling former PICU patient in 
follow-up programs can broaden our knowledge on long-term outcomes. This should be 
encouraged, as currently very few units provide care and research beyond the ICU stay.
2.5 Rescue medication
The use of rescue medication in a randomized trial for a potential life-saving interven-
tion with a placebo group presents additional ethical and scientific challenges [39]. 
Full equipoise regarding the efficacy of the study drug contrasts with the clinician’s 
perceived need to administer the study drug as a rescue therapy despite the inclusion of 
the patient in the placebo group. When rescue therapy is allowed, only ‘early’ versus ‘late’ 
effects can be determined when analyzing data on an intention to treat basis. More chil-
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dren are needed to show a beneficial effect of the drug. As a consequence, overall more 
children will receive placebo and be at risk for a negative outcome, including death, 
provided the study drug is really effective. Holubkov et al. [39] present an interesting 
hypothetical study, i.e. steroids for pediatric septic shock, and use sample size simula-
tions to illustrate this challenge. A solution to avoid misuse of rescue medication is to 
educate physicians, nurses and other staff involved in the care of research participants 
on the rationale and clinical equipoise in research.
2.6 Protocol adherence
Protocol adherence may be jeopardized if the treating physician is biased towards the 
study drug and may decide to violate the study protocol when a patient’s situation is de-
teriorating. In the survey of Morris et al., discussed above, a large majority of physicians 
admitted that they may be biased toward the study arm on the basis of published data 
from uncontrolled studies [30]. Moreover, two thirds indicated that they do not fully 
adhere to the study protocol when the patient’s condition deteriorates and parents ask 
for the study drug. There was a strong correlation between the occurrence of an ethical 
conflict and the likelihood of protocol violations, compassionate use of the study drug 
or alterations to the protocol. These violations are an important risk factor for bias in 
these studies and consequently may affect the validity of the findings. A way of avoiding 
protocol violation is to inform everyone involved in the care of the research subjects 
about the rationale for the study, the existing equipoise motivating its conduct and the 
potential benefits of the study.
3. INFORMED CONSENT PROCESS IN THE PICU
3.1 Informed consent in research
Informed consent is one of the ethical cornerstones of performing research with human 
subjects. It represents the implementation of the ethical principle of respect for persons. 
Respect means that persons are treated as autonomous agents, and that persons with 
diminished autonomy have a right to protection [3]. Informed consent has been incor-
porated in all ethical and legal guidelines concerned with research with humans (for 
example [1–4, 40, 41]). Five elements are distinguished, which are all essential for a valid 
consent: transmission of information; understanding of this information; no coercion by 
others; competence; and actual consent [42]. These requirements cannot always be met 
for children in the PICU as they may be too young, to ill or too heavily sedated. In these 
cases their parents (or legal guardian) need to consent for them, which process is known 
as proxy-consent [43].
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3.2 Factors influencing informed (proxy) consent in the PICU
A qualitatively good consent process prepares future research subjects for the trial, is 
free and informed. In the PICU, quality of consent is threatened by several factors.
Anxiety
The stressful PICU environment has great impact on parents and children. Many parents 
of acutely ill children suffer from acute and post-traumatic stress disorder and this often 
lasts for months after discharge [44, 45]. Practitioners asking consent for trials in emer-
gency situations reported that some parents are unable to focus on anything else than 
the health of their child and will not be able to take any decision about research, whereas 
others will still be receptive [46]. The most important reason for refusal to consent as 
spontaneously provided by parents in the PICU is anxiety or ‘being overwhelmed’ [33, 
47]. In contrast, in a study by Thomas et al. parents mentioned being anxious, but said 
that this did not influence their decision regarding research participation [48]. These 
parents provided useful suggestions. For example, tell parents about ongoing trials prior 
to PICU admission if possible (e.g. in the case of planned surgery) and do not approach 
parents when their child is in the operating room, but before or after surgery [48].
burden of research
In a large study by Hulst et al., 421 parents who declined informed consent to a nutri-
tional assessment study implying additional procedures were asked for the reason. Two-
thirds wanted to avoid additional burden to their child [49]. In two multicenter studies, 
Menon et. al. analyzed parents’ reasons to decline informed consent. The one study was 
an observational study involving blood sampling, the other concerned different kinds 
of PICU research. In both studies, the burden of blood sampling was a major reason 
for declining participation [47, 33]. A small qualitative interview study was conducted 
by Thomas et al. among parents who accepted or declined consent in an undefined 
PICU trial. The interviews identified added pain, discomfort and additional diagnostic 
testing as factors discouraging participation [48]. Overall, it would seem that limiting 
the burden of research procedures is essential to increase participation. This is further 
elaborated on in section 4.
Illness severity
Interestingly, severity of illness does not seem to influence consent rates in the PICU. 
Two studies done in the PICU could not identify a difference in severity of illness be-
tween children of consenting and non-consenting parents [49, 33]. Still it should be 
borne in mind that the life-threatening nature of illness in the ICU can make parents 
more susceptible to the idea that the trial might convey a therapeutic benefit, when this 
is very unlikely [50].
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understanding
Parents reach a good understanding of their child’s health condition within 24 hours 
after admission in PICU [51] but this need not be true for research participation. Studies 
in the neonatal intensive care unit (NICU) suggest that the conditions for a valid consent 
are often unmet [52, 53]. Understanding and recalling of information is difficult for 
parents in the hospital situation [54] and they also overestimate their understanding 
[55]. Written information and posters are identified by parents in the PICU as useful 
information tools in the informed consent process [48, 56].
3.3 Alternative forms of informed consent
The life-threatening and acute nature of illness in the PICU puts great pressure on the 
validity and process of informed consent. It is not always possible to achieve written in-
formed consent before start of the study in emergency settings. Alternative consent pro-
cesses should balance the respect for the decision of future research participants and the 
benefit trial participation might bring them. Two different alternative consent processes 
are available to deal with these time constraints: a waiver of consent or deferred consent.
Waiver of consent
A waiver of consent, also known as exemption from informed consent, means that no 
consent is required for inclusion of research participants in research. It is sometimes 
allowed for studies in life-threatening conditions for which available treatments are 
unproven or unsatisfactory and the study intervention needs to be applied urgently 
to be effective. The conditions under which a waiver (or) is acceptable vary between 
countries. For example in the USA, additional requirements are community consultation 
and public disclosure [57]. They favor dialogue with the community, which is informed 
about the project beforehand and its results afterwards [58]. Raymond et al. describe 
an efficient way of in-hospital community consultation for a trial of vasopressin added 
to adrenaline in cardiac arrest in the PICU. All parents were informed about the trial 
through posters, written information, a website and the research team, and were offered 
the possibility to opt-out of the study. 80 % of parents were aware of the trial and knew 
how to opt out. The authors suggested this approach could increase recruitment while 
preserving freedom of choice [56].
Deferred consent
Another way of dealing with the acute nature of decisions in emergency research, but 
still taking into consideration parental decision, is the use of deferred consent. This form 
of consent implies that patients are recruited without consent and that after enrollment 
consent is asked for use of already collected information and ongoing participation. 
Just like a waiver of consent, deferred consent is an alternative in emergency situations 
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where obtaining prior informed consent is not possible and postponing the interven-
tion would potentially harm the child. The conditions under which deferred consent is 
acceptable vary between countries, too. An example of conditions can be found in the 
upcoming new EU regulation on clinical trials [40].
Research suggests that parents favour deferred consent over waived consent and con-
sider it an acceptable alternative to informed consent for emergency situations [59, 60]. 
In a study by Woolfall et al. parents suggested it would be advisable for the researchers to 
seek advice from the bedside nurse to establish the moment when the child’s condition 
was stable and then ask consent [60]. Practitioners with experience in asking deferred 
consent were generally positive about parental acceptance of this method of consent. 
They highlighted the importance of explaining the purpose of its use [46]. A systematic 
review on waiver of informed consent in pediatric resuscitation trials concluded there 
is a general endorsement of research in life-threatening situations, but that parental 
preferences for waiving of consent or deferred consent vary depending on the approach 
and population [61]. Opinions of children about being enrolled in studies with a waiver 
of consent or deferred consent have not yet been addressed in research.
Interpretation of approval of alternative forms of consent by researchers and Institu-
tional Review Board (IRB) members may differ. It has been shown that IRB members may 
be less prone to accept alternative forms of consent than are researchers [62]. This may 
be a barrier to conduct trials with alternative forms of consent. Documenting parental 
acceptance of deferred consent process could provide insight into its acceptability.
Questions still remain on how to handle consent when a child dies before deferred 
consent from parents or proxies is asked. Problems arise with use and storage of the 
collected data. Excluding data from deceased patients (for whom no deferred consent 
was obtained) may impair validity of the results [63, 64]. Still, although seeking deferred 
proxy-consent for a deceased child can burden parents, the majority of parents wishes 
to be informed [59]. Bereaved parents said it was important to adapt to their needs on a 
case-by-case basis and to allow time after the child’s death [60].
Combined forms of consent
The waiver of consent and deferred consent methods are justified only in life-threatening 
situations where postponing trial inclusion would harm to the research subject.
If the required conditions should not be met, full informed consent needs to be given 
prior to inclusion. Practitioners have suggested that an approach taking the reality of 
parents into account would be ideal [46]. Combining different forms of consent could be 
a useful way of adapting to the unpredictability of acute care environment. The FEAST 
trial, which studied the effect of fluid resuscitation on mortality, is an example of such a 
combination [65]. Informed consent was asked only if the child was stable enough and 
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the parents not too distressed. Otherwise, verbal assent was sought prior to inclusion 
and full written consent after child’s stabilization.
3.4 Improvements to the informed consent process
It would be worthwhile to study alternative consent approaches in pediatric intensive 
care, taking into account that approaches in different situations cannot be uniform. Al-
though we should be wary about adding burden to parents (which an informed consent 
conversation and decision can be), parents must be given the opportunity to make a 
decision. The approaches to obtaining informed consent in different situations cannot 
be uniform. The solutions to practical problems may never be a permit for exploitation 
and harm of the vulnerable population at the PICU.
Getting informed consent is not a one time achievement: informed consent is a 
continuous process, especially in the PICU. After improvements in health or decrease 
of sedation, children can regain the capacity to consent or assent; and they are entitled 
to do so after reaching legal age of consent. They should then be informed about the 
study they were involved in and their assent or consent should be sought when feasible 
– usually when the acute phase of the disease is over or after transfer to the ward. It is 
advisable to consider this re-consent process in the design of the study because the 
research team needs to plan for the resources needed to allow this important follow-up. 
There are no studies on this re-consent process in critically ill children.
To our knowledge the amount of empirical research on preferences and motivations of 
parents and children to participate in drug research in the PICU is small. These preferences 
have been assessed more extensively in other pediatric populations, but data from the 
PICU are lacking.It would be relevant to study factors that shape the decision to consent 
or dissent to drug research in the PICU– for example with a focus on altruism, hope and 
loyalty. Having this information would enable us to better tailor the process of recruit-
ment and informed consent to the needs of the parents (or legal guardians) and children.
4. bURDEN AND RISK OF DRUG RESEARCH
4.1 burden and risk in pediatric research
According to the principle of proportionality, risk and burden of research participation 
should be balanced against the possible benefit of the trial. The principle of subsidiarity 
entails that research can only take place if there are no other less burdensome and less 
risky methods of generating the same results. In other words: burden and risk for the 
research participant need to be minimized, irrespective of the possible benefits of the 
trial for the individual or society. These principles of proportionality and subsidiarity 
underlie important ethical guidelines concerning research with humans [1–4] Children 
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are vulnerable and therefore need additional protection against the risks and burdens 
of research participation. Recent progress in drug research can decrease burden and 
risk for children participating in research in the PICU. Some of these new techniques are 
illustrated in the following section.
4.2 METHODS TO DECREASE bURDEN AND RISK bY USE OF NEw 
TECHNIqUES
PK studies traditionally implied collecting many 1–2ml blood samples from a patient 
at scheduled intervals upto 12 times in 24 hours, which means a considerable burden 
to research subjects. Recent progress in sampling methods, data analysis and outcome 
measurement tools can decrease this burden while rational evidence-based drug 
regimens can still be derived. As an example, a solution to oversedation with morphine, 
which is often observed in neonates was found using a three-step approach. First, PK 
data were collected during two RCTs [66, 67]. Second, the data were analyzed with 
population PK, and it was found that same dosing guidelines of morphine resulted in 
much higher plasma concentrations in neonates than older infants [68]. Third, a new 
dosing guideline was created on the basis of this finding, and validated [69]. The fol-
lowing section details how limited blood sampling schedules, novel drug concentration 
assays and data analysis methods can decrease burden and risk. 
opportunistic or sparse blood sampling methods
PICU patients usually have an arterial or venous central line from which blood can be 
drawn. To avoid accessing lines just for research purposes, sampling for research pur-
poses can be combined with regular blood work. In the absence of a line, samples can by 
collected during routine heel pricks [70]. Opportunistic studies determine levels of the 
drug received as part of the patient’s treatment and no study drug is given [71]. Another 
strategy is to measure drug concentration in blood left over from routine analysis [70, 
71].Population pharmacokinetics make use of randomly collected and limited blood 
samples per patient. Maximum allowed amounts of blood for research purposes vary 
between hospitals and countries, but generally the maximum is set at 3–5 % of total 
blood volume within 24 hours and 5–10 % of total blood volume over 8 weeks [72].
Low Volume Drug Assays
High performance liquid (LC-MS) or gas (GC-MS) chromatography allows simultane-
ous analyses of many low concentration substances in small plasma volumes (10–100 
µL) or left-overs [70, 73]. This is of particular interest for studies in neonates and small 
children, whose total blood volume is small [71]. New emerging technologies such as 
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digital microfluidics will further decrease the sample volume needed [74, 75] [76] and 
may represent the future of PK studies. If combined with sampling using micro needles 
sharp enough to minimize nerve contact [77] these technologies will further decrease 
the burden and risk of clinical drug trials in children.
Dried matrix Spots
Dried matrix spot analysis requires no more than a minimal volume (5–30μL) of biologi-
cal fluids (urine, plasma, blood) on blotting paper, allowing for easy and cost-effective 
sample processing, storage and shipping [71, 78]. These samples can be used in PK 
studies [79, 78, 80] and pharmacogenetic tests [81, 82]. Dried blood spots obtained 
during routine newborn screening can be for genetic (DNA) [82] and epigenetic (DNA 
methylation) [83] analysis until 30 years later if stored at -20°C, as is routinely done in 
some countries.
PK-PD modelling tools
Population PK-PD analysis using non-linear mixed effect models allows using samples 
derived from different dosing regimens with random timing and only few samples per 
patient to estimate PK parameters and the PK-PD relationship and to optimize dosing 
recommendations [84]. Sparse sampling is a strategy by which just 2–3 samples per in-
dividual allow deriving PK parameters from a group of 25–100 infants [85]. This enables 
studies in which the patient already receives the drug for clinical reasons and even the 
use of left-over material from regular blood work. Population PK calculates both the 
inter- and intra-individual variability. The effects of different covariates like age and 
weight are tested by delineating their effects on inter-individual variability. Particularly 
relevant to PICU patients, the effect of disease and its treatment can be taken into ac-
count (e.g. renal function, inflammation, ECMO) [86]. PK-PD parameters in particular 
populations, such as patients on ECMO [87], can be estimated . A next step is to validate 
the obtained PK data and the dosing guidelines derived from these data in a prospective 
trial performing the same sample analysis. In an efficient new dosing regimen, inter-
individual variability should be greatly reduced and dose-effect relationships should 
remain unchanged or improve. Regrettably, this validation is rarely performed [71, 85].
microdosing studies
Microdosing is an elegant new method to minimize burden and risk in PK-studies in chil-
dren [88]. It uses a sub therapeutic, extremely low dose of drug, known as a microdose 
(e.g. 1/100th of therapeutic dose) [89, 90].
Microdosing is ideal for non-therapeutic pharmacokinetic studies in critically ill chil-
dren because therapeutic or adverse effects will not occur. Microdosing also enables 
knowledge gain on drug metabolism or excretion, using probe drugs for these specific 
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pathways. Radioactive labeling allows detection of the extremely low dose [91] and 
carries very minimal risk, because the level of radioactivity is well below international 
cut-offs for radiation safety. It cannot be excluded, however, that parents and health care 
providers perceive this differently, and it is recommended therefore to underline in the 
informed consent process the minimal risks of microdosing.
5. CONCLUSION
Drug research in the PICU is essential because there is a great need of evidence-based 
dosing guidelines. Conducting drug research in critically ill children is a precarious 
enterprise because of the vulnerability of the research population and the specific 
circumstances in the PICU – which present specific ethical challenges. Examples of these 
challenges are presented in table 2.
 
Characteristics of the specific study population, recruitment issues, challenging out-
come measures, use of rescue medication and sub-optimal protocol adherence stand in 
the way of obtaining useful results. Gatekeeping does not only limit recruitment but is 
Table 2 Examples of ethical challenges of clinical drug trials in critically ill children
Example of drug trial* Ethical challenge**
RCT with daily sedation interruption [92] Risk of ‘’gate-keeping’ during recruitment and 
non-adherence to protocol during study for fear of 
accidental extubation or line removal
RCT with corticosteroids for pediatric septic shock [39] Potential life-saving medication: rescue medication in 
placebo arm may reduce validity of trial
RCT with vasopressin add-on for cardiopulmonary 
resuscitation [93]
Emergency treatment leaves no time for informed 
consent: when are deferred consent or waiver for 
consent acceptable?
Pharmacokinetic study with drug already prescribed to 
patient [70]
No potential benefit to patient. Multiple catheter 
accesses may increase risk of infection. Blood sample 
volume may compromise health, especially in small 
children
Dose-finding study for new drug, e.g. imatinib for 
pulmonary arterial hypertension
Risk of off-label prescription without any trial, ethical 
barriers may be perceived too high to perform a ‘non-
therapeutic trial’
Microdosing pharmacokinetic study with radio-active 
labeled drug [94]
No potential benefit to patient despite safe radiation 
dose: ‘gate-keeping’ by physicians and/or nursing staff 
out of fear for radiation-related negative outcomes. 
And possible misunderstanding of minimal risks by 
parents.
* Examples are illustrative and based on trials and experiences of researchers in the PICU.
** Ethical challenges are examples that researchers could face when performing these kind of studies, but 
are of course not limited to these examples.
Chapter 3
59
also an underestimated source of bias especially with acutely ill children. Collaboration 
of intensive care units is bound to improve quality of research and to increase the likeli-
hood of producing generalizable data.
Informed consent for research in the PICU implies almost invariably proxy-consent by 
the parents or legal guardians. Documenting informed consent does not imply, however, 
that parents know what they signed for. Indirect evidence shows that informed consent 
may not be achieved in the stressful situation of the PICU due to parental anxiety and 
misunderstanding. The informed consent process does not stop when the consent is 
signed, but is rather a continuous process. Continuous dialogue between researchers 
and parents is the only way to do justice to the unpredictable and changing reality of 
the PICU. «One size fits all» is not always possible for structuring informed consent in the 
PICU therefore alternative approaches to consent need to be developed and evaluated.
Drug research carries burdens and risks for the subjects and it is only logical that 
we should prevent or minimize these, especially in the vulnerable population in the 
PICU. New technics allow us to generate evidencewith decreased burden and risk to 
the research subject and deserve to be widely used and systematically evaluated. The 
different types of studies (e.g. dose-finding studies, PK studies, RCTs) each present spe-
cific challenges. Dealing effectively with these challenges is an essential step towards 
evidence for dosing and drug choice in pediatric intensive care practice.
60
6. REFERENCES
 1. Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guide-
lines for Biomedical Research Involving Human Subjects. Geneva2002.
 2. Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10. 
Wachington D.C: U.S. Government Printing Office; 1949. p. 181-2.
 3. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research. The Belmont Report Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research. Wachington D.C.: U.S. Government Printing Office; 1978.
 4. Declaration of Helsinki. Ethical principles for medical research involving human subjects (8th 
revision; original: 1964), (2013).
 5. Bos W, Tromp K, Tibboel D, Pinxten W. Ethical aspects of clinical research with minors. Eur J Pediatr. 
2013; 172(7): 859-66. doi: 10.1007/s00431-012-1856-8.
 6. Shirkey H. Therapeutic orphans. The Journal of pediatrics. 1968; 72(1): 119-20.
 7. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental 
pharmacology—drug disposition, action, and therapy in infants and children. The New England 
journal of medicine. 2003; 349(12): 1157-67. doi: 10.1056/NEJMra035092.
 8. Shann F, Chiletti R. Neonatal herpes virus infection: duration of extracorporeal support and the 
dose of acyclovir. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine 
and the World Federation of Pediatric Intensive and Critical Care Societies. 2011; 12(5): 605; author 
reply -6. doi: 10.1097/PCC.0b013e3182191780.
 9. Prodhan P, Okhuysen-Cawley R, Imamura M. Central extracorporeal membrane oxygenation 
for refractory pediatric septic shock. Pediatric critical care medicine : a journal of the Society of 
Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 
2011; 12(5): 606; author reply -7. doi: 10.1097/PCC.0b013e31821917cc.
 10. Conroy S. Association between licence status and medication errors. Archives of disease in child-
hood. 2011; 96(3): 305-6. doi: 10.1136/adc.2010.191940.
 11. Turner S, Gill A, Nunn T, Hewitt B, Choonara I. Use of “off-label” and unlicensed drugs in paediatric 
intensive care unit. Lancet. 1996; 347(9000): 549-50.
 12. Sutherland JM. Fatal cardiovascular collapse of infants receiving large amounts of chlorampheni-
col. AMA journal of diseases of children. 1959; 97(6): 761-7.
 13. Johnson TN. The development of drug metabolising enzymes and their influence on the suscep-
tibility to adverse drug reactions in children. Toxicology. 2003; 192(1): 37-48.
 14. Vet NJ, de Hoog M, Tibboel D, de Wildt SN. The effect of inflammation on drug metabolism: a focus 
on pediatrics. Drug discovery today. 2011; 16(9-10): 435-42. doi: 10.1016/j.drudis.2011.02.014.
 15. Daschner M. Drug dosage in children with reduced renal function. Pediatric nephrology. 2005; 
20(12): 1675-86. doi: 10.1007/s00467-005-1922-9.
 16. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eu-
ropean journal of clinical pharmacology. 2008; 64(12): 1147-61. doi: 10.1007/s00228-008-0553-z.
 17. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal 
dysfunction. European journal of clinical pharmacology. 2009; 65(8): 757-73. doi: 10.1007/s00228-
009-0678-8.
 18. Wildschut ED, Ahsman MJ, Houmes RJ, Pokorna P, de Wildt SN, Mathot RA et al. Pharmacotherapy 
in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). Current drug metabo-
lism. 2012; 13(6): 767-77. doi: 10.2174/138920012800840383.
Chapter 3
61
 19. van den Broek MP, Groenendaal F, Egberts AC, Rademaker CM. Effects of hypothermia on pharma-
cokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clinical 
pharmacokinetics. 2010; 49(5): 277-94. doi: 10.2165/11319360-000000000-00000.
 20. Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit 
Care. 2007; 13(6): 645-51. doi: 10.1097/MCC.0b013e3282f0a3d3.
 21. Best Pharmaceuticals for Children Act, US Public Law 107-109 (2002).
 22. European Parliament and the Council of the Europan Union. Regulation (EC) No. 1901/2006 of the 
European Parliament and of the Council of 12 December 2006 on medicinal products for paediat-
ric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC 
and Regulation (EC) No. 726/2004. Official Journal of the European Union. 2006; 49(L 378): 1-19.
 23. Benjamin DK, Jr., Smith PB, Murphy MD, Roberts R, Mathis L, Avant D et al. Peer-reviewed pub-
lication of clinical trials completed for pediatric exclusivity. JAMA : the journal of the American 
Medical Association. 2006; 296(10): 1266-73. doi: 10.1001/jama.296.10.1266.
 24. Wimmer S, Rascher W, McCarthy S, Neubert A. The EU Paediatric Regulation: Still a Large Discrep-
ancy Between Therapeutic Needs and Approved Paediatric Investigation Plans. Paediatr Drugs. 
2014. doi: 10.1007/s40272-014-0082-4.
 25. Davies EH, Ollivier CM, Saint Raymond A. Paediatric investigation plans for pain: painfully slow! 
European journal of clinical pharmacology. 2010; 66(11): 1091-7. doi: 10.1007/s00228-010-0886-2.
 26. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012; 91(5): 
796-801. doi: 10.1038/clpt.2012.26.
 27. Yang CP, Veltri MA, Anton B, Yaster M, Berkowitz ID. Food and Drug Administration approval for 
medications used in the pediatric intensive care unit: a continuing conundrum. Pediatric critical 
care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pedi-
atric Intensive and Critical Care Societies. 2011; 12(5): e195-9. doi: 10.1097/PCC.0b013e3181fe25b9.
 28. Doherty DR, Pascuet E, Ni A, Stewart P, Splinter W, Vaillancourt R. Off-label drug use in pediatric 
anesthesia and intensive care according to official and pediatric reference formularies. Cana-
dian journal of anaesthesia = Journal canadien d’anesthesie. 2010; 57(12): 1078-88. doi: 10.1007/
s12630-010-9395-0.
 29. Ceelie I, van der Starre C, Tibboel D, Stol K, Koren G, de Wildt SN. Evaluation of drug formularies for 
pediatric intensive care. Pediatric critical care medicine : a journal of the Society of Critical Care 
Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2011; 12(1): 
e14-9. doi: 10.1097/PCC.0b013e3181d90228.
 30. Morris AD, Zaritsky AL, LeFever G. Evaluation of ethical conflicts associated with random-
ized, controlled trials in critically ill children. Critical care medicine. 2000; 28(4): 1152-6. doi: 
10.1097/00003246-199801001-00173.
 31. Duffett M, Choong K, Hartling L, Menon K, Thabane L, Cook DJ. Randomized controlled trials in 
pediatric critical care: a scoping review. Critical care. 2013; 17(5): R256. doi: 10.1186/cc13083.
 32. Sharkey K, Savulescu J, Aranda S, Schofield P. Clinician gate-keeping in clinical research is not 
ethically defensible: an analysis. Journal of medical ethics. 2010; 36(6): 363-6. doi: 10.1136/
jme.2009.031716.
 33. Menon K, Ward R, Canadian Critical Care Trials G. A study of consent for participation in a non-
therapeutic study in the pediatric intensive care population. Journal of medical ethics. 2014; 
40(2): 123-6. doi: 10.1136/medethics-2012-101075.
 34. Harron K, Lee T, Ball T, Mok Q, Gamble C, Macrae D et al. Making co-enrolment feasible for ran-
domised controlled trials in paediatric intensive care. PloS one. 2012; 7(8): e41791. doi: 10.1371/
journal.pone.0041791.
62
 35. Duffett M, Choong K, Foster J, Cheng J, Meade MO, Menon K et al. Clonidine in the sedation 
of mechanically ventilated children: A pilot randomized trial. Journal of critical care. 2014; 29(5): 
758-63. doi: 10.1016/j.jcrc.2014.05.029.
 36. Rabe H. The need for noninvasive biomarkers for drug safety in neonatal circulation. Biomarkers 
in medicine. 2010; 4(5): 771-6.
 37. Vet NJ, Ista E, de Wildt SN, van Dijk M, Tibboel D, de Hoog M. Optimal sedation in pediatric inten-
sive care patients: a systematic review. Intensive care medicine. 2013; 39(9): 1524-34. doi: 10.1007/
s00134-013-2971-3.
 38. de Graaf J, van Lingen RA, Valkenburg AJ, Weisglas-Kuperus N, Groot Jebbink L, Wijnberg-Williams 
B et al. Does neonatal morphine use affect neuropsychological outcomes at 8 to 9 years of age? 
Pain. 2013; 154(3): 449-58. doi: 10.1016/j.pain.2012.12.006.
 39. Holubkov R, Dean JM, Berger J, Anand KJ, Carcillo J, Meert K et al. Is “rescue” therapy ethical in 
randomized controlled trials? Pediatric critical care medicine : a journal of the Society of Critical 
Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2009; 
10(4): 431-8. doi: 10.1097/PCC.0b013e318198bd13.
 40. European Parliament and the Council of the Europan Union. Regulation (EU) No 536/2014 on 
clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Official 
Journal of the European Union. 2014; 57(L 158): 1-76.
 41. Protections for Children Involved as Subjects in Research (45 CFR Part 46, Subpart D), (2009).
 42. Kent G. Shared understandings for informed consent: the relevance of psychological research on 
the provision of information. Social science & medicine (1982). 1996; 43(10): 1517-23.
 43. Cuttini M. Proxy informed consent in pediatric research: a review. Early Hum Dev. 2000; 60(2): 
89-100. doi: 10.1016/S0378-3782(00)00106-7.
 44. Balluffi A, Kassam-Adams N, Kazak A, Tucker M, Dominguez T, Helfaer M. Traumatic stress in 
parents of children admitted to the pediatric intensive care unit. Pediatric critical care medicine : 
a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive 
and Critical Care Societies. 2004; 5(6): 547-53. doi: 10.1097/01.PCC.0000137354.19807.44.
 45. Rees G, Gledhill J, Garralda ME, Nadel S. Psychiatric outcome following paediatric intensive care 
unit (PICU) admission: a cohort study. Intensive care medicine. 2004; 30(8): 1607-14. doi: 10.1007/
s00134-004-2310-9.
 46. Woolfall K, Frith L, Gamble C, Young B. How experience makes a difference: practitioners’ views on 
the use of deferred consent in paediatric and neonatal emergency care trials. BMC medical ethics. 
2013; 14: 45. doi: 10.1186/1472-6939-14-45.
 47. Menon K, Ward RE, Gaboury I, Thomas M, Joffe A, Burns K et al. Factors affecting consent in 
pediatric critical care research. Intensive care medicine. 2012; 38(1): 153-9. doi: 10.1007/s00134-
011-2412-0.
 48. Thomas M, Menon K. Consenting to pediatric critical care research: understanding the perspec-
tive of parents. Dynamics. 2013; 24(3): 18-24.
 49. Hulst JM, Peters JW, van den Bos A, Joosten KF, van Goudoever JB, Zimmermann LJ et al. Illness 
severity and parental permission for clinical research in a pediatric ICU population. Intensive care 
medicine. 2005; 31(6): 880-4. doi: 10.1007/s00134-005-2647-8.
 50. Flanagan BM, Philpott S, Strosberg MA. Protecting participants of clinical trials conducted in the 
intensive care unit. J Intensive Care Med. 2011; 26(4): 237-49. doi: 10.1177/0885066610390867.
 51. Needle JS, O’Riordan M, Smith PG. Parental anxiety and medical comprehension within 24 hrs of a 
child’s admission to the pediatric intensive care unit*. Pediatric critical care medicine : a journal of 
Chapter 3
63
the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical 
Care Societies. 2009; 10(6): 668-74; quiz 74. doi: 10.1097/PCC.0b013e3181a706c9.
 52. Ballard HO, Shook LA, Desai NS, Anand KJ. Neonatal research and the validity of informed consent 
obtained in the perinatal period. Journal of perinatology : official journal of the California Perina-
tal Association. 2004; 24(7): 409-15. doi: 10.1038/sj.jp.7211142.
 53. Mason SA, Allmark PJ. Obtaining informed consent to neonatal randomised controlled trials: 
interviews with parents and clinicians in the Euricon study. Lancet. 2000; 356(9247): 2045-51.
 54. Chappuy H, Baruchel A, Leverger G, Oudot C, Brethon B, Haouy S et al. Parental comprehension 
and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood 
leukaemia. Archives of disease in childhood. 2010; 95(10): 800-4. doi: 10.1136/adc.2009.180695.
 55. Tait AR, Voepel-Lewis T, Malviya S. Do they understand? (part I): parental consent for children 
participating in clinical anesthesia and surgery research. Anesthesiology. 2003; 98(3): 603-8. doi: 
10.1097/00000542-200303000-00005.
 56. Raymond TT, Carroll TG, Sales G, Morris MC. Effectiveness of the informed consent process for a 
pediatric resuscitation trial. Pediatrics. 2010; 125(4): e866-75. doi: 10.1542/peds.2009-2427.
 57. US Department of Health and Human Services. Guidance for Institutional Review Boards, Clinical 
Investigators, and Sponsors: Exception from Informed Consent Requirements for Emergency 
Research. March 2011 (updated 2013).
 58. Koogler T. Legal and ethical policies regarding research involving critically ill children. The virtual 
mentor : VM. 2012; 14(10): 797-800. doi: 10.1001/virtualmentor.2012.14.10.pfor1-1210.
 59. Gamble C, Nadel S, Snape D, McKay A, Hickey H, Williamson P et al. What parents of children who 
have received emergency care think about deferring consent in randomised trials of emergency 
treatments: postal survey. PloS one. 2012; 7(5): e35982. doi: 10.1371/journal.pone.0035982.
 60. Woolfall K, Young B, Frith L, Appleton R, Iyer A, Messahel S et al. Doing challenging research studies 
in a patient-centred way: a qualitative study to inform a randomised controlled trial in the paedi-
atric emergency care setting. BMJ Open. 2014; 4(5): e005045. doi: 10.1136/bmjopen-2014-005045.
 61. Eltorki M, Uleryk E, Freedman SB. Waiver of informed consent in pediatric resuscitation research: 
a systematic review. Acad Emerg Med. 2013; 20(8): 822-34. doi: 10.1111/acem.12180.
 62. Duffett M, Burns KE, Kho ME, Lauzier F, Meade MO, Arnold DM et al. Consent in critical care trials: 
a survey of Canadian research ethics boards and critical care researchers. Journal of critical care. 
2011; 26(5): 533 e11-22. doi: 10.1016/j.jcrc.2010.12.009.
 63. Jansen TC, Bakker J, Kompanje EJ. Inability to obtain deferred consent due to early death in emer-
gency research: effect on validity of clinical trial results. Intensive care medicine. 2010; 36(11): 
1962-5. doi: 10.1007/s00134-010-1988-0.
 64. Jansen TC, Kompanje EJ, Druml C, Menon DK, Wiedermann CJ, Bakker J. Deferred consent in 
emergency intensive care research: what if the patient dies early? Use the data or not? Intensive 
care medicine. 2007; 33(5): 894-900. doi: 10.1007/s00134-007-0580-8.
 65. Maitland K, Molyneux S, Boga M, Kiguli S, Lang T. Use of deferred consent for severely ill children 
in a multi-centre phase III trial. Trials. 2011; 12: 90. doi: 10.1186/1745-6215-12-90.
 66. Simons SH, van Dijk M, van Lingen RA, Roofthooft D, Duivenvoorden HJ, Jongeneel N et al. Rou-
tine morphine infusion in preterm newborns who received ventilatory support: a randomized 
controlled trial. JAMA : the journal of the American Medical Association. 2003; 290(18): 2419-27. 
doi: 10.1001/jama.290.18.2419.
 67. van Dijk M, Bouwmeester NJ, Duivenvoorden HJ, Koot HM, Tibboel D, Passchier J et al. Efficacy 
of continuous versus intermittent morphine administration after major surgery in 0-3-year-old 
infants; a double-blind randomized controlled trial. Pain. 2002; 98(3): 305-13.
64
 68. Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M et al. Morphine 
glucuronidation in preterm neonates, infants and children younger than 3 years. Clinical pharma-
cokinetics. 2009; 48(6): 371-85. doi: 10.2165/00003088-200948060-00003.
 69. Krekels EH, Tibboel D, de Wildt SN, Ceelie I, Dahan A, van Dijk M et al. Evidence-Based Morphine 
Dosing for Postoperative Neonates and Infants. Clinical pharmacokinetics. 2014. doi: 10.1007/
s40262-014-0135-4.
 70. Ahsman MJ, Tibboel D, Mathot RA, de Wildt SN. Sample collection, biobanking, and analysis. 
Handbook of experimental pharmacology. 2011; 205: 203-17. doi: 10.1007/978-3-642-20195-0_10.
 71. Autmizguine J, Benjamin DK, Smith PB, Sampson M, Ovetchkine P, Cohen-Wolkowiez M et al. 
Pharmacokinetic Studies in Infants Using Minimal-risk Study Designs. Curr Clin Pharmacol. 2014.
 72. Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World Health 
Organ. 2011; 89(1): 46-53.
 73. Vogeser M, Seger C. A decade of HPLC-MS/MS in the routine clinical laboratory—goals for further 
developments. Clinical biochemistry. 2008; 41(9): 649-62. doi: 10.1016/j.clinbiochem.2008.02.017.
 74. Jebrail MJ, Bartsch MS, Patel KD. Digital microfluidics: a versatile tool for applications in chemistry, 
biology and medicine. Lab on a chip. 2012; 12(14): 2452-63. doi: 10.1039/c2lc40318h.
 75. Wootton RC, Demello AJ. Microfluidics: Analog-to-digital drug screening. Nature. 2012; 483(7387): 
43-4. doi: 10.1038/483043a.
 76. Lafreniere NM, Shih SC, Abu-Rabie P, Jebrail MJ, Spooner N, Wheeler AR. Multiplexed extraction 
and quantitative analysis of pharmaceuticals from DBS samples using digital microfluidics. Bio-
analysis. 2014; 6(3): 307-18. doi: 10.4155/bio.13.311.
 77. Li CG, Lee CY, Lee K, Jung H. An optimized hollow microneedle for minimally invasive blood 
extraction. Biomedical microdevices. 2013; 15(1): 17-25. doi: 10.1007/s10544-012-9683-2.
 78. Lehmann S, Delaby C, Vialaret J, Ducos J, Hirtz C. Current and future use of “dried blood spot” 
analyses in clinical chemistry. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2013; 
51(10): 1897-909. doi: 10.1515/cclm-2013-0228.
 79. Cohen-Wolkowiez M, Watt KM, Zhou C, Bloom BT, Poindexter B, Castro L et al. Developmental 
pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from 
infants. Antimicrobial agents and chemotherapy. 2014; 58(5): 2856-65. doi: 10.1128/AAC.02139-13.
 80. Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determi-
nation of pharmacokinetics in clinical studies: considerations for the validation of a quantitative 
bioanalytical method. Analytical chemistry. 2009; 81(4): 1557-63. doi: 10.1021/ac8022839.
 81. de Boer T, Wieling J, Meulman E, Reuvers M, Renkema G, den Daas I et al. Application of dried 
blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 
enzymes in healthy volunteers. Biomedical chromatography : BMC. 2011; 25(10): 1112-23. doi: 
10.1002/bmc.1580.
 82. Hollegaard MV, Grauholm J, Nielsen R, Grove J, Mandrup S, Hougaard DM. Archived neonatal 
dried blood spot samples can be used for accurate whole genome and exome-targeted next-
generation sequencing. Molecular genetics and metabolism. 2013; 110(1-2): 65-72. doi: 10.1016/j.
ymgme.2013.06.004.
 83. Hollegaard MV, Grauholm J, Norgaard-Pedersen B, Hougaard DM. DNA methylome profiling 
using neonatal dried blood spot samples: a proof-of-principle study. Molecular genetics and 
metabolism. 2013; 108(4): 225-31. doi: 10.1016/j.ymgme.2013.01.016.
 84. Admiraal R, van Kesteren C, Boelens JJ, Bredius RG, Tibboel D, Knibbe CA. Towards evidence-
based dosing regimens in children on the basis of population pharmacokinetic pharmacody-
Chapter 3
65
namic modelling. Archives of disease in childhood. 2014; 99(3): 267-72. doi: 10.1136/archdis-
child-2013-303721.
 85. Marsot A, Boulamery A, Bruguerolle B, Simon N. Population pharmacokinetic analysis during 
the first 2 years of life: an overview. Clinical pharmacokinetics. 2012; 51(12): 787-98. doi: 10.1007/
s40262-012-0015-8.
 86. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-PD 
modelling in paediatric clinical research. European journal of clinical pharmacology. 2011; 67 
Suppl 1: 5-16. doi: 10.1007/s00228-009-0782-9.
 87. Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA. Pharmacokinetics of cefotaxime and desacetyl-
cefotaxime in infants during extracorporeal membrane oxygenation. Antimicrobial agents and 
chemotherapy. 2010; 54(5): 1734-41. doi: 10.1128/AAC.01696-09.
 88. Vuong LT, Blood AB, Vogel JS, Anderson ME, Goldstein B. Applications of accelerator MS in pediat-
ric drug evaluation. Bioanalysis. 2012; 4(15): 1871-82. doi: 10.4155/bio.12.173.
 89. European Medicines Agency. ICH guideline M3(R2) on non-clinical safety studies for the conduct 
of human clinical trials and marketing authorisation for pharmaceuticals. December 2009.
 90. US Department of Health and Human Services. Guidance for industry, investigators and review-
ers: Exploratory IND studies. January 2006.
 91. Salehpour M, Possnert G, Bryhni H. Subattomole sensitivity in biological accelerator mass spec-
trometry. Analytical chemistry. 2008; 80(10): 3515-21. doi: 10.1021/ac800174j.
 92. Vet NJ, de Wildt SN, Verlaat CW, Knibbe CA, Mooij MG, Hop WC et al. Daily interruption of sedation 
in critically ill children: study protocol for a randomized controlled trial. Trials. 2014; 15: 55. doi: 
10.1186/1745-6215-15-55.
 93. Carroll TG, Dimas VV, Raymond TT. Vasopressin rescue for in-pediatric intensive care unit car-
diopulmonary arrest refractory to initial epinephrine dosing: a prospective feasibility pilot trial. 
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World 
Federation of Pediatric Intensive and Critical Care Societies. 2012; 13(3): 265-72. doi: 10.1097/
PCC.0b013e31822f1569.
 94. Mooij MG, van Duijn E, Knibbe CA, Windhorst AD, Hendrikse NH, Vaes WH et al. Pediatric Micro-
dose Study of [C]Paracetamol to Study Drug Metabolism Using Accelerated Mass Spectrometry: 
Proof of Concept. Clinical pharmacokinetics. 2014. doi: 10.1007/s40262-014-0176-8
We must be free not because we claim freedom, 
but because we practice it.
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To the Editor:
We read with great interest the paper of Ventura and colleagues on their randomized 
controlled trial (RCT) comparing the effect of first-line inotropic drug (dopamine ver-
sus epinephrine) on mortality in severe sepsis in children (1). Such trials are essential 
to generate evidence-based management guidelines to reduce mortality from this 
disease. The combined effect of higher prevalence and mortality rate of sepsis in Brazil 
compared to more economically developed countries allowed achieving a major chal-
lenge in pediatric intensive care (PICU) research: randomize enough patients in a timely 
manner to study a robust outcome.
We are nevertheless quite surprised by the high recruitment and informed consent 
rates reported: they were able to approach all eligible patients and 96.4 % of the parents 
gave informed consent. These figures differ a lot from our own experience and rates 
reported in other emergency trials. Previous research shows that up to one third of 
RCTs in the PICU are terminated before the needed sample size is achieved, often due 
to recruitment problems (2). Therefore, we would be very grateful if the authors could 
provide us information to help understand these surprising numbers. Approaching par-
ents and getting informed consent for research participation in emergency situations is 
challenging (3). The stress-inducing physical environment, illness severity of the child 
and possible time constraints influence recruitment and consent rates and challenge 
the validity of the obtained consent (4). For example, an important reason for refusal to 
consent in the PICU is parental feelings of ‘being overwhelmed’(4).
Ventura et al. asked informed consent within 3 hours of admission. Was dedicated 
research personnel available 24/7, as septic patients present at all times of the day? This 
3 hours period leaves little time for parents to receive information, process it and take 
an informed and consensual decision, while timely start of the intervention is of crucial 
importance.
We wonder if the authors considered using an alternative design for obtaining in-
formed consent from the parents. We would like to make the suggestion of deferred 
consent in this situation. This form of consent implies that patients are recruited without 
consent and consent is asked after enrolment for use of already collected information 
and ongoing participation. Research suggests that parents generally support this form 
of consent (5).
Another way of adapting to the time-constraints could be to use a continuous consent 
(or two-step consent): only most relevant information is given to seek consent for inclu-
sion in emergency setting but this short consent is followed by a deeper informed con-
sent conversation that gives an additional opportunity to parents to withdraw (3). Did 
the authors feel that their obtained consent was valid under the difficult circumstances? 
Was an alternative form of consent considered?
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To conclude, we encourage other researchers in emergency trials to provide detailed 
information on the recruitment and consent process in their papers and discuss the ra-
tionale for the chosen method. Learning from each other’s experiences may contribute 
to a lower failure rate than currently in pediatric emergency trials.
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“Each night, when I go to sleep, I die. 
And the next morning, when I wake up, I am reborn.” 
Mahatma Gandhi
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AbSTRACT
This article discusses the rationale of sedation in respiratory failure, sedation goals, how 
to assess the need for sedation as well as effectiveness of interventions in critically ill 
children, with validated observational sedation scales.
The drugs and non-pharmacological approaches used for optimal sedation in venti-
lated children are reviewed, and specifically the rationale for drug selection, including 
short- and long-term efficacy and safety aspects of the selected drugs. The specific 
pharmacokinetic and pharmacodynamic aspects of sedative drugs in the critically ill 
child and consequences for dosing are presented. Furthermore, we discuss different 
sedation strategies and their adverse events, such as iatrogenic withdrawal syndrome 
and delirium. These principles can guide clinicians in the choice of sedative drugs in 
pediatric respiratory failure.
Chapter 5
75
INTRODUCTION
Critically ill children who are mechanically ventilated often require sedative and/or 
analgesic drugs to diminish anxiety or pain and ensure comfort. Moreover, adequate 
sedation facilitates synchronization with mechanical ventilation and enables invasive 
procedures to be performed. Adequate sedation has been described as the level of 
sedation at which patients are asleep but easily arousable (1). In pediatric intensive care 
unit (PICU) practice this means that a child is conscious, breathes in synergy with the 
ventilator, and is tolerant of or compliant with other therapeutic procedures. However, 
the optimal level of sedation varies for each patient, depending on the type and severity 
of underlying disease and the need for certain therapeutic, invasive procedures.
To achieve the optimal level of sedation in individual patients, doses of sedatives 
are preferably titrated to effect based on observational sedation scales validated for 
the population in question. Nonetheless, it can be difficult to reach optimal sedation, 
because of variability in plasma drug levels and response, as well as in the patient’s 
clinical state. Both under- and oversedation are undesirable, as these conditions may 
adversely affect patient outcomes. Oversedation delays recovery, as greater sedatives 
consumption is associated with longer duration of ventilation as well as extubation fail-
ure (2). Part of this effect may be due to muscle weakness consequent to immobility (3). 
Oversedation also induces tolerance and withdrawal syndrome (4, 5). Undersedation, 
on the other hand, may cause distress and adverse events such as unintentional extuba-
tion or displacement of catheters, may lead to adverse memories (posttraumatic-stress 
syndrome) and increased need for nursing requirements. All this may lead to a longer 
PICU stay.
This article addresses how to assess the need for sedation, including relevant sedation 
scales, pharmacokinetic and pharmacodynamic considerations of analgosedative drugs, 
sedation strategies and long-term adverse effects of sedation, to guide clinicians to 
optimal sedation practice in pediatric respiratory failure. Moreover, we aim to elucidate 
the information gaps in current knowledge and propose future research directions.
Sedation assessment
In order to provide adequate sedation, the level of sedation in critically ill children 
should be regularly assessed and documented. Furthermore, sedation assessment is 
needed to both determine the efficacy of sedatives and related interventions and to 
facilitate inter-institutional comparisons. Thus, the use of formal sedation assessment is 
recommended using a validated sedation scoring scale. Several behavioral assessment 
tools are described. The Ramsay and the Richmond Agitation Sedation Scale (RASS) 
are frequently used in critically ill children, but are only validated for adult ICU patients 
(6–8). The COMFORT scale (9, 10), the COMFORT behavior scale (11, 12) and the State 
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Behavioral Scale (SBS) (13) are validated scores for PICU patients. The characteristics and 
psychometric properties of these scales are presented in Table 1.
The COMFORT scale was originally described in and validated for measuring discom-
fort in ventilated pediatric patients. This observational scale consists of two physiologi-
cal items - Heart rate and Arterial blood pressure - and six behavioral items - Alertness, 
Calmness/Agitation, Respiratory response, Physical movement, Muscle tension and 
Facial tension. Because the physiologic variables are affected by inotropic and other 
drugs often used in pediatric intensive care, it was questioned whether their use con-
tributes to the overall assessment of sedation in the individual patient. Therefore, the 
COMFORT scale was adapted in the COMFORT behavior scale, which does not include 
the two physiological items. Many psychometric properties of this scale have been 
tested (14–16). As well-sedated children do not always show unambiguous behavior, it 
was more realistic to define score ranges rather than cutoff points. Score range 6–10 was 
defined as oversedation; score range 23–30 as undersedation. Score range 11–22 was 
defined as a grey area in which a second assessment, for example the Nurse Interpreta-
tion of Sedation Score (NISS), is recommended for clinical purposes (12, 17).
The SBS appraises seven behavioral dimensions; ‘Respiratory drive/ response to 
ventilation’, ‘Coughing’, ‘Best response to stimulation’, ‘Attentiveness to care provider’, 
‘Tolerance to care’, ‘Consolability’ and ‘Movement after consoled’. The score range from -3 
to +3 and a score of 0 describes a patient who is alert and calm. Psychometric properties 
of this scale are good.
General considerations of pharmacokinetics and pharmacodynamics in 
critically ill children
The pharmacokinetic (PK) properties of a drug include the processes of absorption, 
distribution, metabolism and excretion, while the pharmacodynamic (PD) properties 
comprise the actual responses to the administered drug and therefore may represent 
both efficacy and safety. In addition to the age-related variation in PK, critical illness 
and its treatment modalities impact PK and PD. These factors are summarized in Fig-
ure 1. Intrinsic factors related to the patient’s clinical condition include shifts in body 
fluid (altering volume of distribution), inflammation (altering drug transport and me-
tabolism, clearance), and liver, renal and heart failure (altering absorption, distribution, 
drug metabolism and excretion). Extrinsic factors include treatment modalities such as 
extra-corporeal membrane oxygenation (ECMO), hypothermia, and continuous renal 
replacement therapy (18). Volume of distribution is often increased and clearance is 
altered either way in ECMO-patients (19). Hypothermia leads to changes in volume 
of distribution due to redistribution of blood flow and a decreased clearance due to a 
decreased drug metabolizing enzyme activity (20, 21).
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Furthermore, critical illness itself may be of infl uence on the eff ect of sedation. For 
instance, a critically ill child who is less reactive due to its underlying illness (e.g. sepsis) 
will respond diff erently to a sedative drug than a relatively healthy child who receives 
sedation for the acceptance of a tube after airway reconstruction.
Although the impact of separate aspects of critical illness on drug disposition is in-
creasingly recognized, only few factors are actually taken into account in current dosing 
such as dosing adjustments with renal failure. For sedative drugs, this underscores the 
importance of dosing and titrating the drugs to eff ect.
Figure 1. Illustration of the eff ect of critical illness on pharmacokinetics of analgosedative drugs
With intravenous administration (upper left), drugs are injected directly into the central compartment: bio-
availability is complete. With oral administration (lower left), gut absorption and fi rst by-pass metabolism 
limit bioavailability. Analgosedative drugs are metabolized by the liver into more water-soluble metabo-
lites that are excreted by the kidneys. Some analgosedatives have active metabolites (e.g morphine and 
midazolam) that may accumulate with decreased renal function.
A graphical representation of drug concentration over time depicts pharmacokinetics changes induced by 
critical illness: the dashed line represents the curve of a healthy individual while the solid line shows the 
change induced by critical illness.
* Liver fl ow aff ects clearance of drugs with a high hepatic extraction ratio (e.g. propofol)
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Commonly used agents (Table 2)
An ideal sedative drug exhibits anxiolysis, amnesia and analgesia qualities, should be 
easily titrated to effect, and without any adverse effects. However, none of the existing 
drugs does meet all these qualities. Therefore, medications are commonly co-adminis-
tered to compensate for any shortcomings and to achieve an optimal effect.
In PICU, benzodiazepines and opioids are frequently used agents. Despite the 
widespread use of sedatives in PICU, high-quality data supporting appropriate dos-
ing and safety are lacking (22). Many commonly used sedatives and analgesics in the 
PICU (e.g lorazepam, dexmedetomidine, fentanyl) are still used off-label, which means 
that their efficacy and safety have not been adequately proven (23). A rational choice 
for a particular agent is based on the desired effect of the drug the interaction of the 
patient’s disease and the side-effects of the drug. These systemic effects can be adverse 
effects (e.g. propofol is avoided in patients with unstable hemodynamics due to its 
cardiodepressive properties (24)) or desired effects (ketamine is a bronchodilator used 
in asthma (25)). Ideally the choice for a particular agent should include its long-term 
effect on neurodevelopment. Most commonly used sedative and analgesics are neu-
rotoxic in animals (26–28), which has caused uncertainty for their long-term safety in 
humans. Reassuringly, these animal data have not been confirmed in human studies. No 
adverse long-term effects of morphine administration at neonatal age were reported 
(29, 30). Moreover, short duration sevoflurane anaesthesia in infancy does not appear to 
increase the risk of adverse neurodevelopmental outcome at 2 years of age compared 
with awake-regional anaesthesia (31).
benzodiazepines
Benzodiazepines (midazolam, and to a lesser extent lorazepam) are the most commonly 
used sedatives and the sedative of choice in many pediatric intensive cares (32). Mid-
azolam is a central nervous system depressant that exerts its clinical effect by binding 
to a receptor complex, which facilitates the action of the inhibitory neurotransmitter 
gamma-amino butyric acid (GABA) in the brain. Through this effect, midazolam pos-
sesses sedative, anxiolytic, anticonvulsant, muscle relaxant and amnesic properties (33). 
The amnesic effects of midazolam probably play an important role in the low levels of 
unpleasant experiences recalled by survivors of PICU treated with this agent (34).
Midazolam is metabolized by CYP3A4/5 to a major hydroxylated active metabolite 
(1-OH midazolam), and subsequently metabolized to 1-OH-midazolam-glucuronide by 
UGTs and renally excreted (35). A reduction of CYP3A activity as a result of inflammation, 
organ failure (36) or concomitant administration of other therapeutic drugs (drug-drug 
interactions) (37) may account for the failure of critically ill children to metabolise mid-
azolam. In patients with renal failure prolonged sedative effects may be caused by the 
accumulation of the active metabolite, 1-OH midazolam-glucuronide (38).
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Although most commonly used, midazolam is certainly not an ideal sedative agent. 
Adverse events associated with its use are tolerance, dependence and withdrawal, but 
also paradoxical hyperactivity (4, 5). In adults, continuous benzodiazepine use is associ-
ated with prolonged mechanical ventilation and length of ICU stay (39). Also, hypoten-
sion may occur and is most likely with bolus administration, particularly in neonates, in 
the setting of hypovolemia or concomitant use of morphine (40).
Lorazepam is a long-acting benzodiazepine used orally and intravenously. The use 
of intravenous lorazepam is limited by the fact that it is dissolved in propylene glycol, 
which can accumulate to produce metabolic acidosis and renal dysfunction (41, 42). 
For weaning, oral lorazepam is a good alternative for midazolam, because of its long 
half-live.
opioids
Although opioids are analgesic drugs, they have sedative effects. Some PICUs use mor-
phine as a first line sedative while others favour sedatives (mainly benzodiazepine) in 
the absence of suspected pain (43). Morphine provides sedation as well as analgesia and 
can be used as a single agent for analgesia and sedation.
As morphine clearance is substantially reduced in neonates less than 10 days of age, 
1/3 to 1/2 of dosing in older children is needed to reach the same plasma levels as in 
older children. For analgesia this dose reduction is related to adequate analgesia, but se-
dation data are lacking (44). Morphine has a relatively long duration of action of around 
two hours when administered as a single dose intravenously (peak analgesic effect after 
20 minutes). Morphine is characterized by hepatic metabolism (glucuronidation) and 
renal excretion with intermediate volume of distribution. Therefore, its effects can be 
prolonged in patients with renal impairment. The impact of liver failure seems mild or 
moderate at best (45). Morphine stimulates the release of histamine and inhibits com-
pensatory sympathetic responses, leading to vasodilation and consequently hypoten-
sion, particularly following bolus administration (46). The opioid fentanyl has powerful 
analgesic properties and provides some sedation, as demonstrated in a randomized 
controlled trial comparing continuous fentanyl and remifentanil in postoperative 
orthopedic children (47). No studies are available for the use of fentanyl for long-term 
sedation in PICU. An important, but rare adverse effect is fentanyl-induced chest wall 
rigidity causing respiratory compromise, generally occurring after a large fentanyl bolus 
administration (48).
Alpha-agonists
Clonidine and dexmedetomidine are central α-2 agonists with sedative and analgesic 
properties (49) increasingly used as first line sedatives or as adjunct to other sedatives. 
Enthusiasm for these agents is driven by the absence of clinically significant respiratory 
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depression (49, 50), which is an advantage in the spontaneously breathing patient or 
when extubation is planned (51). Moreover, they do not show neurotoxicity in animals 
(52), have opioid and benzodiazepine sparing properties (53, 54) and may decrease the 
incidence of withdrawal and delirium (55). A RCT comparing continuous intravenous 
clonidine and midazolam in 129 ventilated children (30 days-15 years) showed a similar 
sedative effect (56). Sedation under dexmedetomidine may more closely resemble natu-
ral sleep than sedation under benzodiazepines, although these theoretical advantages 
have not yet been demonstrated to improve patients’ perception of sleep in adult ICU 
(57, 58). For children, the use of dexmedetomidine is still off-label; it is approved for 
continuous sedative infusion in adults for 24 hours.
The main adverse effect of alpha agonists is bradycardia/arythmia and hypotension 
(49, 59), but these effects are rarely of clinical significance (54, 56). Data in children with 
severe hemodynamic compromise is insufficient to recommend their use in this particu-
lar population. To date, no study compared dexmedetomidine to clonidine in the PICU.
Propofol
Propofol has sedative and hypnotic properties. It involves GABA receptor activation (60) 
although its mechanism of action is not fully understood. Due to its strong cardio-de-
pressant effect (24) its use should be avoided in the hemodynamically unstable patient. 
Long-term infusions in the PICU are contraindicated in the official drug label for children 
<  16 years due the risk of lethal propofol infusion syndrome (PRIS). Any suspicion of 
PRIS (clinical and biological signs: metabolic acidosis, increased liver enzymes, lipemia, 
rhabdomyolysis, renal and cardiac failure) should lead to an immediate interruption of 
propofol infusion but despite discontinuation, death can ensue (61). Propofol infusion 
rate and duration, the presence of traumatic brain injury and fever are factors associated 
with mortality in PRIS (62). The use of propofol should be limited; when used maximum 
infusion rate must not exceed 4 mg/kg/h with a maximum duration of 24 hours (62).
Propofol’s very short half-live offers an advantage around the time of extubation 
(mainly in agitated patients): it allows weaning from the longer acting sedative induc-
ing respiratory depression, control sedation during the time of extubation and ensure 
a quick recovery after. Therefore, in this special case, a short-term infusion of propofol 
can be considered.
Ketamine
Ketamine is an NMDA receptor antagonist (63) with cataleptic, amnestic and analgesic 
properties. It maintains hemodynamics (64, 65) by inducing release of endogenous cate-
cholamine (65). However, in patients with hemodynamic compromise and chronic illness 
or stress who have depleted catecholamine stores, it can decrease myocardial contractil-
ity and even induce collapse (66, 67). Ketamine is used in the PICU as a co-analgesic 
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with opioids for pain control (low dose, around 0.1 mg/kg/h) (68) and occasionally when 
usual sedative agents fail to provide adequate sedation (high dose, 1–3 mg/kg/h). Due 
to its bronchodilatory properties, it is the first line analgosedative in status asthmaticus 
(25, 69). A very common adverse effect of ketamine is the occurrence of hallucinations, 
and therefore low dose of benzodiazepines should be co-administered. Early work hints 
at its potential to elevate intracranial pressure (70) and many physicians still avoid its use 
in traumatic brain injury despite more recent work not showing this effect (71).
Antihistamines
Promethazine, alimemazine and diphenhydramine are first generation antihistamines 
with anti-dopaminergic and anticholinergic drug actions. These drugs may produce 
significant sedation as well as quiescence. A combination of oral chloral hydrate and 
promethazine was more effective than midazolam infusion for maintenance sedation in 
critically ill children, but less than half the patients in each study arm reached target se-
dation during study period (72). No other studies are available, and therefore, evidence 
to use antihistamines for (long-term) sedation in PICU is low.
barbiturates
Pentobarbital and thiopental are primarily used for therapy resistant status epilepticus, 
but its use as sedative in therapy resistant agitation has also been reported (73, 74). 
Barbiturates are highly lipid-soluble. Given by infusion it accumulates in adipose tissue 
whence it diffuses slowly back to the blood after infusion cessation. This, coupled with 
a long half-life (5–10 h), is responsible for the persistence of sedation after infusion 
cessation. Barbiturates are also associated with high rates of adverse events, including 
hypotension, depression of cardiac contractility, severe skin and mucous reactions 
(Stevens Johnson syndrome and Toxic Epidermal Necrolysis) and neurologic sequelae 
(73). Life-threatening hypokalemia and rebound hyperkalemia has been observed after 
cessation of thiopentone coma for intracranial hypertension. As this has not been ob-
served with other underlying diseases or with pentobarbital, its cause is likely due to an 
association between the underlying clinical symptoms and thiopentone (75).
Neuro-muscular blockers
Analgesia and profound sedation have to be ensured before starting neuromuscular 
blockade. Neuromuscular blocking agents are associated to critical illness polyneuropa-
thy and myopathy and therefore should be restricted to special circumstances, discon-
tinued as soon as possible and used at the smallest possible dose (76, 77). The level 
of evidence supporting their prolonged use for particular indications is poor (76, 78). 
They are recommended if effective mechanical ventilation cannot be achieved despite 
profound sedation (e.g ARDS (77), severe asthma (25, 79)). They are often used in case of 
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severe cardio-vascular instability but their benefit may be limited because only modest 
decrease in energy consumption is achieved compared to profound sedation (80, 81). 
Other common uses are refractory pulmonary and intracranial hypertension (82).
Sedation strategies
Optimizing sedation in the critically ill is of major importance. In general, the current 
tendency is to lighten sedation in the intensive care to avoid delayed recovery with 
longer duration of ventilation (83), tolerance and withdrawal (5, 84). Despite the aware-
ness of the adverse effects of oversedation, it remains common practice in the PICU (85). 
Sedation strategies play a key role to achieve adequate sedation.
Protocolized sedation
To optimize sedation in critically ill children, it is recommended to assess levels of seda-
tion and to titrate sedatives and analgesics on the guidance of sedation protocols or 
algorithms. Implementing a sedation protocol allows targeting patient-specific sedation 
goals. In the adult intensive care, protocol implementation decreases days of mechani-
cal ventilation and ICU stay (86). But more recently, adult studies failed to show these 
positive effects (87). These changes in results over time may be explained by the grow-
ing awareness of the deleterious effect of oversedation and general tendency to avoid 
it. In the PICU, the effect of protocolizing sedation is less clear, but studies are recent 
and avoidance of oversedation may already have entered the practice. Several non-
randomized trials reported conflicting results on the impact of protocolized sedation 
on outcomes like length of PICU stay, duration of mechanical ventilation or the need for 
analgesia and sedation (88). Recently, in a large cluster randomized trial among children 
undergoing mechanical ventilation for acute respiratory failure, the use of a sedation 
protocol compared to usual sedation practice did not improve clinical outcome (89).
Daily sedation interruption
Another approach to potentially avoid the negative effects of oversedation, and espe-
cially the adverse effects of continuous benzodiazepine use, is daily sedation interruption 
(DSI). In adults, clinical trials have shown that DSI can reduce the duration of mechanical 
ventilation, hospital stay and amount of sedatives administered, without compromising 
patient comfort or safety (90). Several later studies have confirmed this beneficial effect 
(91), whereas other studies, in different settings, showed no benefit (92, 93).
In critically ill children, two pilot studies showed that DSI is feasible and safe, even in 
ECMO patients, but both studies were not designed to detect differences in clinical out-
come (94, 95). Another study, comparing DSI with continuous sedation in children, DSI 
led to improved clinical outcomes, including shorter durations of mechanical ventilation 
and PICU stay (96). In a recent study comparing DSI + protocolized sedation to proto-
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colized sedation only, no beneficial effect of daily sedation interruption was found (97). 
DSI did not reduce the duration of mechanical ventilation, length of stay, or the amounts 
of sedative drugs administered. There are important differences between these studies 
in study design (DSI and Standard of Care arm versus DSI + protocolized sedation and 
protocolized sedation arm), setting (India versus Europe), patient population (e.g. high 
incidence of neurotrauma versus respiratory infection) and ICU practices (e.g. longer 
mean duration of mechanical ventilation, more sedatives and neuromuscular blockers 
administered in the first study) (98). For the latter study (DSI+PS vs PS), the effect of 
protocolized sedation itself on the clinical endpoints might have outweighed the effect 
of DSI, as also demonstrated in adults (92).
Drug cycling
Some PICUs use drug ‘cycling’ or ‘rotation’ as a method of decreasing the adverse ef-
fects of continuous sedation (99). This strategy is aimed at preventing tachyphylaxis and 
tolerance by ‘cycling’ drug combinations. For example, an opioid and benzodiazepine 
regimen can be changed to ketamine and promethazine, followed by clonidine and 
chloral hydrate, all on a weekly basis. However, to our knowledge, evidence supporting 
the beneficial effects of ‘cycling’ are lacking.
Adverse effects
Withdrawal
Prolonged administration of analgesics and sedatives in critically ill children may induce 
drug tolerance and physical dependency. Abrupt discontinuation or too rapid weaning 
of these drugs in physically dependent children may cause withdrawal syndrome. Symp-
toms of benzodiazepines- and opiates withdrawal can broadly be distinguished into 
three groups: 1) overstimulation of the central nervous system (e.g. agitation, tremors, 
anxiety, hallucinations), 2) autonomous dysregulation (e.g. sweating, fever, tachycardia 
and tachypnea), and 3) gastro-intestinal symptoms, which have only been described 
in opiate withdrawal (100). Withdrawal syndrome has been particularly reported after 
administration of opioids and benzodiazepines. The onset of withdrawal syndrome 
depends on the half-life of the drug and can be after 1 hour or up to several days after 
discontinuation of these drugs (101). Both longer duration of administration and high 
total doses of opioids and/or benzodiazepines are clearly related with the occurrence of 
withdrawal syndrome in critically ill children, and may therefore be considered risk fac-
tors (84, 100). Moreover, the exact biochemical mechanisms responsible for the devel-
opment of withdrawal syndrome remain unclear. The reported prevalence of withdrawal 
syndrome in critically ill children who had received benzodiazepines and/or opioids for 
5 or more days range from 17 to 57 % (100, 102).
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The development of pediatric scoring tools for withdrawal syndrome is a huge step 
forward. Two validated assessment tools for observing and identifying withdrawal 
syndrome after long-term use of benzodiazepines and opioids in PICU patients have 
been described. These are the Withdrawal Assessment Tool version-1 (WAT-1), and the 
Sophia Observation Withdrawal Symptoms-scale (SOS) (103–106). Table  3 provides 
details on symptoms and psychometric properties of the WAT-1 and SOS. The WAT-1 is 
an 11-item scale and scores of three or higher (on a scale of 0–12) indicates that the child 
is suspected for withdrawal. The SOS consists of 15 items and is based on the underlying 
empirical structure of co-occurrences of withdrawal symptoms that experts considered 
relevant. A SOS score of 4 or higher reflect a high probability of withdrawal.
Strategies to reduce the prevalence of withdrawal syndrome should begin by mak-
ing active efforts to reduce doses of benzodiazepines and/or opioids during the whole 
ICU course, and thereby preventing oversedation. As discussed above, daily sedation 
interruption does not appear to add to protocolized sedation to reach this goal. Proto-
colized sedation targeting at conscious sedation appears at this time the best available 
approach.
A weaning strategy for gradual decreasing of opioid and/or benzodiazepine dos-
ages once the patient is recovering may be effective to prevent withdrawal syndrome. 
Strategies include slowly tapering off the intravenous infusion rate over time, using an 
alternative route, e.g. enteral or subcutaneous, or transition to long acting drugs like 
methadone from morphine/fentanyl or lorazepam from midazolam. Disappointingly, 
little evidence is available on efficacy or safety of different weaning strategies. Weaning 
strategies ranging from 10 days to several months have been evaluated in observational 
(retrospective and prospective) studies (107–111). Two negative RCTs evaluated metha-
done weaning in 5 vs 10-days (112), and a high- vs low-dose methadone schedule in 
children (113). And while target drug levels for sedative and opioid dependence have 
been established for adults, they are lacking for children, as are pharmacokinetic data. 
Hence, we can not advise on the optimal weaning strategy or preferred drugs in pediat-
ric ICU withdrawal.
Nevertheless, some suggestions to reduce withdrawal syndrome while avoiding un-
necessary prolonged drug use can be made. First, awareness among clinicians on the 
risk factors for withdrawal symptoms may aid to prevent a too rapid reduction in drug 
doses. Moreover, it may lead to a faster switch from IV, short half life drugs to oral or 
subcutaneous, long half-life drugs. This may also facilitate faster ICU discharge. Second, 
regular monitoring of withdrawal symptoms with validated scales, will also help to faster 
diagnose and treat withdrawal as well monitoring of the effect of interventions.
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Pediatric Delirium
Pediatric intensive care staff has become more alert to the occurrence of delirium in 
their patients – not least since studies showed an estimated incidence of 4 to 29 % 
(114–116). The core diagnostic criteria for delirium are: a) disturbance of consciousness 
with reduced ability to focus, shift or maintain attention; b) change in cognition (such as 
memory deficit, disorientation, language disturbance) or development of a perceptual 
disturbance; c) the disturbance develops over a short period of time and tends to fluctu-
ate during the course of the day. The pathogenesis of delirium is largely unknown. The 
sufferers may be hyperactive, hypoactive or show signs of both states. Typical for the 
hypoactive delirium are slowed or sparse speech, hypoactive or slowed motor activ-
ity as well as lethargy or also described as reduced awareness or apathy. A number of 
delirium symptoms overlap with those observed in other conditions, such as pain and 
withdrawal syndrome (100).
Adults and children largely show the same symptoms although hallucinations, 
cognitive changes and hypoactive delirium are difficult to diagnose in the very young, 
preverbal PICU population. For this reason, PD is underdiagnosed in this age group 
(114, 116). Another reason is that nurses and physicians may not specifically focus on 
the symptoms of PD. Still, it is also possible to assess PD in this vulnerable age group 
by carefully observing behavior (114, 117, 118). Diagnosing of PD in the PICU setting 
requires a reliable, validated and clinically useful bedside tool that may also serve for 
screening and guiding of treatment. This is an area in full development but several suit-
able instruments are already available: the pediatric Confusion Assessment Method for 
ICU (pCAM-ICU) (116); the Cornwell Assessment Pediatric Delirium tool (CAP-D) (115, 
119), and the Sophia Observation withdrawal Symptoms-Pediatric Delirium scale (SOS-
PD) (120). Haloperidol and risperidone are antipsychotics used for delirium in critically ill 
children and also adults. To date, studies showing benefit of antipsychotics to prevent or 
treat ICU delirium are lacking. Moreover, in a retrospective cohort of critically ill children, 
almost 10 % of children showed severe adverse events associated with haloperidol treat-
ment, including extrapyramidal syndrome (121). Hence, while ICU delirium has been 
associated with an increased risk of mortality, it is unclear if the benefits of antipsychotic 
treatment outweigh the risks. In the Netherlands, the Dutch Pediatric Drug Handbook 
(www.kinderformularium.nl) advices a low haloperidol starting dose to be carefully 
titrated to effect, while diligently monitoring potential side effects.
Non-pharmacological approach
Drug therapy is the most obvious treatment modality of distress, withdrawal syndrome 
and delirium in critically ill children. Increasingly, the importance of non-pharmacological 
interventions is recognized. Such interventions use a multi-component approach, which 
including repeated reorientation, early mobilization, noise reduction (use of ear plugs), 
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and a non-pharmacological sleep management. We suppose that these interventions 
could reduce distress and delirium, but evidence is limited. However, common sense 
suggests that these interventions (for example promoting orientation and day-night 
rhythm, and avoiding overstimulation by light and sounds) may be effective for children 
as well.
Another strategy is adaptation of the environment, like noise reduction. Noise is a 
major environmental factor to cause anxiety and sleep disturbance in critically ill pa-
tients (32). In a way, noise reduction could well be effective in decreasing anxiety. It 
would be worthwhile, therefore, to reduce noise in the PICU as much as possible. All 
in all, based on the limited evidence it is difficult to extrapolate the effectiveness from 
adults to children. However, common sense has it that most of the interventions, for 
example promoting orientation and day-night rhythm and avoiding overstimulation by 
light and sounds, may be suitable for children as well, so as to create a comfortably calm 
environment for child and parents. Adult data show a reduction in delirium rates with 
a multifaceted approach, not only including lighter sedation approaches, but also non-
pharmacological changes as noise reduction and aids for patients to better orientate 
themselves (122).
Future research
Despite the widespread use of sedatives to facilitate mechanical ventilation in pediatric 
intensive care, evidence to guide clinical practice is remarkably scarce. Only few ad-
equately powered, well-designed RCTs to study efficacy and safety of individual drugs 
or their combinations have been performed. Several roadblocks to the conduct of these 
trails have been identified and should be taken into account with the design of future 
studies.
Hence, robust study design including adequate power calculation, randomization 
procedures and blinding. (International) multi-center design is very likely needed to 
reach adequate sample size and high likelihood of generalizability. This adds complexity 
to the trial and asks a tremendous effort in training of local nurses, physicians and other 
study personnel. Validated sedation scales for the specific population, e.g. also taking 
into account age of patient and patient-controlled or nurse-controlled, must be used to 
assess sedation level in children.
Further, especially in critically ill children, ‘gate keeping’, i.e. not including the sickest 
patients for fear of overburdening patients and parents, presents an important chal-
lenge towards adequate recruitment. But, previous studies have shown that these chal-
lenges can be overcome and taking them into account, future research could focus on 
the following aspects of pediatric sedation in the ICU:
- Does protocolized sedation indeed improve clinical outcome? Preferably, short-term 
outcomes like as ventilator-free days, extubation readiness, withdrawal syndrome 
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and long-term outcomes, like neurodevelopmental outcome, occurrence of PTSD 
and quality of life should be evaluated. This should also be evaluated in RCTs aiming 
to study non-pharmacological and pharmacological interventions.
- What are optimal drug doses to be used in pharmacological trials? Can we target 
similar drug concentrations in all patients, or do different patients need different 
target concentrations, e.g. based on severity of disease, underlying disease? Before a 
RCT can start, pharmacokinetic data should be available, from the literature or from 
prospective observational studies to explore PK and PD of the future study drugs. 
Especially, data is missing to guide dosing during critical illness and associated treat-
ment modalities (e.g CVVH, ECMO).
- Using a good understanding of the drug’s PK and preferably target concentration, 
these data should be used to design RCT’s comparing sedation regimens. Ideally, the 
pharmacokinetics of the sedative drugs are also studied in these trials to validate the 
dosing assumptions and better understand variability in response.
- Another underrated aspect of drug trials is the recording of adverse events. A 
prospective, well-designed approach to document adverse events, may also aid to 
balance efficacy and safety of the different sedation approaches and guide future 
treatment decisions.
- Industry-initiated trials follow strict regulatory guidelines for the performance of 
clinical trials, including adequate documentation of adverse events, according to 
good clinical practice guidelines with extensive monitoring. Traditionally this have 
been weaker in investigator-initiated trials, due to a lack of oversight and funds. 
Hence, consulting with experts in regulatory drug trials is important to safe-guard 
the quality and thereby also the safety of participants, as well as the generalizability 
of the results.
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PART III
PHARMACOKINETICS OF 
ANALGOSEDATION IN THE PICU
“ L’homme est plus dur que le fer, plus solide que le roc et plus fragile qu’une rose.”
Proverbe turc
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STRUCTURED SUMMARY
Aims
Clonidine is used for sedation in the pediatric intensive care unit. Extracorporeal mem-
brane oxygenation (ECMO) provides temporary support if respiratory and cardiac func-
tion is threatened. ECMO influences the pharmacokinetics of drugs. Clonidine during 
pediatric ECMO cannot be effectively titrated as PK data are lacking. The aim of this study 
is to describe clonidine PK in a particular ECMO system and propose dosing guidelines 
for children on this particular ECMO circuit.
Methods
All children below the age of 18 who received clonidine during ECMO were eligible. The 
pharmacokinetic analysis was conducted by non-linear mixed effect modeling (NON-
MEM) which enables to establish the separate influences of determinants on drug blood 
level and to provide individualized dosing.
Results
Twenty-two patients, median age 1 month (IQR 6.4) and weight at inclusion 4 kg (IQR 
3.1) were included of whom 90 % in addition to ECMO received pre-emptive continu-
ous veno-venous hemofiltration to optimize fluid balance. The clonidine clearance rate 
was twofold that measured in patients not on ECMO. Clearance increased steeply with 
postnatal age: at days 6, 8 and 10, respectively 30 %, 50 % and 70 % of the adult clearance 
rate was reached. The use of diuretics was associated with a lower clearance. The volume 
of distribution increased by 55 % during ECMO support.
Conclusion
Our findings suggest that a higher dose of clonidine may be needed during ECMO. 
The PK parameters on ECMO and the dosing guidelines proposed hold the potential 
to improve sedation practices on ECMO but need to be repeated with different ECMO 
systems.
what is already known about this subject:
•	 Extracorporeal	membrane	oxygenation	(ECMO)	influences	pharmacokinetics.
	•	 Clonidine	pharmacokinetics	during	ECMO	has	never	been	reported.
what this study adds:
•	 Clearance	 of	 clonidine	 during	 ECMO	 is	 twice	 higher	 compared	 to	 values	 in	 non-
ECMO patients and volume of distribution increases by 55 %.
•	 Clonidine	may	need	dosing	adjustment	during	ECMO.
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INTRODUCTION
Extracorporeal membrane oxygenation (ECMO) is an extracorporeal technique provid-
ing temporary respiratory and cardiac support when survival is compromised. To date, 
it has been mostly used to support children, and in particular neonates (1). The ECMO 
system pumps blood from a central venous site, which then flows through an oxygen-
ator and is redirected to the patient. Two main types are distinguished. The veno-venous 
type (VV-ECMO) ensures only lung function; the blood is returned to the right atrium. 
The veno-arterial type (VA-ECMO) temporarily replaces both heart and lung function; 
the blood is ejected into the carotid to ensure organ perfusion. Furthermore, continuous 
veno-venous hemofiltration (CVVH) can be added to the ECMO circuit to optimize fluid 
balance and support renal function (2).
Patients on ECMO require optimal analgesia and sedation but effective dosing is 
hard to establish because the pharmacokinetics (PK) of commonly used medications 
is altered by the ECMO system (3). One of these medications is clonidine, a central α-2-
agonist with both sedative and analgesic properties (4, 5). Enthusiasm for this agent is 
driven by concerns about the neurotoxic effects of most other sedatives noted in animal 
studies (6) and by the absence of clinically significant respiratory depression with central 
α-2 agonists (7).
PK data are needed to rationalize drug dosing during ECMO (8, 9) but these have not 
yet been established for clonidine. Population pharmacokinetic studies delineate the 
influence of various determinants on drug blood level (e.g. age, organ failure, inflam-
mation, co-medication) and provide dosing guidelines adapted to a patient’s individual 
characteristics. The aim of this study is to describe clonidine PK in a particular neonatal 
and pediatric ECMO and CVVH system and propose dosing guidelines for children on 
this particular ECMO circuit.
METHODS
Setting
The Erasmus MC - Sophia pediatric intensive care unit (PICU) is a level 3 ICU and pro-
vides ECMO support to on an average 30 patients per year. This pharmacokinetic study 
included neonates and children up to 18 years of age treated with veno-venous (VV-
ECMO) and veno-arterial ECMO (VA-ECMO). It was approved by the Erasmus MC ethics 
review board considering that ECMO and administration of clonidine and other drugs 
are standard clinical care. Parental informed consent was obtained for blood sampling 
and PK analysis.
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ECMO standard of care
The criteria for ECMO were: gestational age >  34 weeks, weight >  2 kg, mechanical 
ventilation < 7 days and an oxygenation index > 25. A clonidine infusion (0.1–1 mcg/
kg/h) was added when continuous morphine and midazolam failed to achieve adequate 
sedation and then incremented stepwise to reach adequate sedation measured by the 
COMFORT-B scale, a validated pain and sedation scale for critically ill PICU patients (10). 
On the physician’s discretion, clonidine boluses (1–2 mcg/kg) were given at start of the 
infusion or when the infusion rate was increased due to breakthrough distress.
The ECMO circuit was composed of cannulas (Medtronic®, Kerkrade, the Netherlands), 
polyvinyl chloride tubing (Bentley Bypass 70 tubing; Baxter, the Netherlands), a silicone 
rubber membrane oxygenator (Medtronic®; for neonatal system: 1.5m2 Paediatric Ex-
tended Capacity Membrane Oxygenator; for pediatric system: 2.5m2 I-2500–2A silicone 
Surgical Membrane Oxygenator) and a heat exchanger (Medtronic® Heat Exchanger 
Monitoring adapter and Luer-lock). The neonatal system was applied in children < 10–12 
kg; the pediatric system in children with higher weight. Priming volume was 350 ml in 
the neonatal and 900 ml in the pediatric system. Ninety per cent of the patients were 
pre-emptively treated with continuous veno-venous hemofiltration (CVVH) while on 
ECMO (2). The filter (Multiflow 100; Hospal, Lyon, France) was placed parallel to the 
ECMO circuit, distal to the ECMO roller pump.
blood sampling
Blood samples for PK analysis were collected concomitantly with routine blood sampling 
three times daily. In addition, blood was sampled, if possible, before, at the time of ECMO 
cannulation, 1 and 3 hours thereafter and after decannulation. Blood was sampled from 
the preoxygenator access point and collected in EDTA-decoagulation tubes.
Laboratory analysis
After centrifugation (5 minutes, 4000 x g), the supernatant serum was stored at -80°C 
until the assay was performed. Clonidine was analyzed using LC-MS/MS in the posi-
tive ionisation mode. To precipitate proteins, 50 µl tri-chloroacetic acid containing the 
internal standard clonidine-d4 was added to 20 µl of plasma. Samples were vortexed, 
stored at -20°C for 30 minutes, vortexed again and centrifuged (4 minutes at 2750 x 
g). For the determination of clonidine 5 µl of the sample solution was injected onto a 
Thermo Scientific Hypersil Gold (50 x 2.1 mm, 1.9 µm) column. A chromatographic gradi-
ent was applied using an acetonitrile and water mixture with a constant 5 % addition of 
1 % ammonium formate / 2 % formic acid in water. The flow was 600 µl/min. Clonidine 
was measured as [M+H]+, using the mass transition 232.1/44.0 and Clonidine-d4 with 
mass transition 236.1 / 48.0. The method was validated over a range of 0.100 – 20.0 µg/L. 
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The accuracy ranged from 98.6 % to 113.8 % across the validated range, the intra-day 
precision was below 6.4 % and the inter-day precisions was below 6.4 %.
Clinical parameters
Demographic data (weight, date of birth, gender, gestational age where applicable) 
were retrieved from the electronic patient data management system. The most recently 
measured bodyweight prior to ECMO was used for drug dosing and PK analysis. In ad-
dition, the following data were retrieved: exact dose and time of clonidine infusion and 
boluses, laboratory parameters, indication for ECMO, ECMO type (VV or VA) and ECMO 
flows, CVVH flows (if applicable), urine output, fluid balance, use of diuretics and inotro-
pic drugs, and body temperature. Concomitant medications included other analgesics 
and sedatives (morphine, midazolam, pentobarbital), vecuronium, antibiotics, inotropes 
and vasoactive drugs and diuretics (furosemide, bumetanide, spironolactone).
PK model development
The pharmacokinetic analysis was conducted with nonlinear mixed effect modeling 
software (NONMEM 7.2.0; Icon Development Solutions, Ellicott City, Maryland, USA). 
Nonlinear mixed effects modelling allows determination of fixed (typical values for PK 
parameters) and random parameters (inter- and intra- individual variability and residual 
variability). The first-order conditional estimation (FOCE) with interaction between inter-
individual and residual random effect was used during the entire model development. 
R (version 3.1.2) (11) and Pirana (version 2.7.1) (12) were used to visualize the results and 
evaluate the output. The log-likelihood ratio test was the main tool for the selection 
between two hierarchical models, using the objective function value (OFV) produced by 
NONMEM. The OFV is a measurement of goodness of fit of the model and is proportional 
to minus two times the logarithm of the likelihood (-2 log likelihood) of the data. During 
basic model building and covariate analysis, a difference in objective function value 
(OFV) of more than 10.8 (corresponding to a p-value of 0.001 assuming a Chi-square 
distribution) was considered statistically significant when the models differed by one 
parameter. Goodness of fit plots and confidence interval in parameter estimates were 
also evaluated during basic model building and covariate analysis.
The population model was built in 3 steps:
1.)  Structural model
One, two and three compartment models were evaluated. Between-subject variability in 
clearance (Cl) and volume of distribution (V) were evaluated with exponential models:
Eq 1:  Cli= θpop * expηi
Eq 2:  Vi= θpop * expηi
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Where θpop is the population parameter for clearance and volume of distribution, respectively, 
and ηi the normally distributed between-subject variability with mean 0 and variance ω2.
The error model characterizing the residual variability (unexplained by the model) 
was defined by a proportional and an additive term:
Eq 3:  Cobs,ik = Cpred,ik * (1 + ε prop,ik ) + ε add,ik
Where Cobs,ik is the kth observed plasma concentration for the individual i, Cpred,ik the pre-
dicted plasma concentration and ε prop,ik and ε add,ik are the residual random proportional 
and residual errors with a mean of 0 and a variance σ2.
To account for variability in pharmacokinetic parameters due to the varying sizes of 
individual children, the parameter values were standardized a priori to a bodyweight 
(WT) of 70 kg using an allometric power model using equation 4 and 5:
Eq 4:  Cli=Cl * (WT/70)0.75
Eq 5:  Vi=V *(WT/70)
2.) covariate analysis
We expected that PK parameters would be influenced by:
1. Demographic and clinical condition (gender, main diagnosis leading to ECMO).
2. Maturation: Age-related maturation is a major factor influencing PK (clearance) in 
children (13). This was expected to have a major impact because the study population 
had a broad age range. Postmenstrual, postnatal and gestational age were tested.
3. EcMO: Physico-chemical interactions between clonidine and the ECMO circuit, such 
as increased clearance due to adsorption to the circuit and increase in volume of 
distribution (VD) due to the added extracorporeal circuit (3).
4. Disease progression: indications for ECMO, organ dysfunction or systemic inflam-
mation may affect PK (14). Laboratory values served as surrogate markers of organ 
function (liver function test, urea and creatinine, lactate, albumin).
The covariate analysis was performed using the formulas described in table 1.
Multivariate analysis was carried out stepwise, including first the parameter leading 
to the highest decrease in OFV. All significant parameters in the univariate analysis were 
tested. A decrease in OFV of 10.8 (corresponding to a p-value of 0.001) was considered 
significant.
3.) Model validation
Bootstrap analysis was performed on the final model by the use of Perl speaks NONMEM 
(15). 1000 bootstrap data sets were generated by random sampling and replacement. Me-
dian parameter values, 2.5th and 97.5th percentiles of parameter distribution and standard 
error of the estimates generated, were compared to the parameters of the final model.
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The model was also validated using normalized prediction distribution errors (NPDEs) 
that simulate prediction discrepancies between the distribution predicted and the 
observations from the same individual. NPDEs were calculated using a commonly-used 
an R-package (16).
Table 1 : Covariate analysis
Equations Covariate tested
Eq 6: Cl= Clbase * θ CATEG
Where :   - Clbase corresponded to the Cl in individuals with CATEG = 0
Example:   When testing gender, females were assigned CATEG = 0 
and males CATEG = 1. The clearance in females was equal to 
Clbase, and θ is the Cl ratio of males over females.
1.)  Demographics and patient’s 
characteristics: Gender, ECMO-
indication
3.)  EcMO
Type of ECMO: VV-ECMO vs VA-ECMO
4.)  Disease progression
CVVH: yes/no, use of inotrops: yes/no 
and diuretics: yes/no
Eq 7: Cl= θpop * (GAi /median GApop)θGA
Where:   - GAi is Gestational age of the an individual patient
  - Median GApop is median Gestational age of all patients
Example:   An individual with a GAi value equal to the median of the 
population had a clearance value θpop.
2.)  Maturation of clearance:
Gestational age (GA)
4.)  Disease progression:
Continuous variables like temperature, 
laboratory values (e.g creatinine, ALT), 
CVVH and ECMO flow, urine output
Where:   - Hill refers to the Hill coefficient (shape)
  -  T50PNA is the post-natal age (in weeks) at 50 % of adult (full) 
maturation
2.)  Maturation of clearance:
Post-natal age (PNA) and post-menstrual 
age (PMA)
)
Where:   -  Cli is the clearance of an individual at different time 
aftercannulation (tEC)
  -  delta Cl is the maximal fractional increase or decrease of 
the PK parameter during ECMO
  - T50CL is the time to half of the maximal effect
  -  θtEC corresponds to the Hill exponent determining the 
steepness of the change in clearance.
3.)  EcMO *
The ECMO effect on clearance and 
volume was tested with 3 different 
temporal covariates:
  A.)  Time since start of the ECMO 
support (tEC)
  B.)  Time since start of the clonidine 
while on ECMO support 
(tECCLO)
  C.)  Time since discontinuation of 
ECMO support (tEND)
Eq 10**: V= VECMO - (VECMO- VNON) * e (-tEC*0.693/ t1/2)
Where:  -  V is the volume of distribution at different time after 
cannulation (tEC)
  - VEcMO is the maximal volume on EcMO
  - VNON is the volume of distribution off EcMO
  -  t1/2 is the half-life of the change in volume of distribution.
3.)  EcMO *
Change in volume of distribution on 
ECMO
*= Several other functions (linear, exponential and half-life model) were applied to evaluate possible rela-
tionships between the temporal covariates and CL and V.
**= from half-life model described by Ahsman et al. Population pharmacokinetics of midazolam and its 
metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clinical pharmacoki-
netics. 2010;49(6):407–79
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Table 2 Patient’s characteristics and treatment (n = 22)
Age (month) 1.0 (6.4)
GA (week) 38.9 (5.6)
PMA (weeks) 42.8 (17.6)
Weight (kg) 4 (3.1)
Sex, male/female; n (%) 11/11 (50/50)
Survival; n (%) 17 (77.3 %)
Diagnostic; n (%)
•	 cardiac 4 (18.2 %)
•	 congenital diaphragmatic hernia 3 (13.6 %)
•	 Meconium aspiration syndrome 5 (22.7 %)
•	 PPHN 1 (4.5 %)
•	 Pulmonary 7 (31.8 %)
•	 Sepsis 2 (9.1 %)
Clonidine use
•	 Mean infusion dose, mcg/kg/h 0.24 (0.15)
•	 Time of start, days since EcMO start 2.9 (4.4)
•	 Patients on clonidine at EcMO start 3 (13.6 %)
•	 Patients on clonidine at EcMO stop 17 (77.3 %)
Continuous sedative started after clonidine
•	 Pentobarbital 3 (13.6 %)
•	 Propofol 1 (4.5 %)
•	 Ketamine 5 (22.7 %)
Level of sedation (total number of observations = 706)
•	 Oversedation (cOMFORT-B< 11) 297 (42.1 %)
•	 Optimal sedation (cOMFORT-B 11–12) 398 (56.4 %)
•	 undersedation (cOMFORT-B > 22) 11 (1.5 %)
Therapeutic Hypothermia, n (%) 1 (4.5 %)
Use of Diuretics 
•	 Patient exposed to any diuretic, n (%) 16 (72.7 %)
•	 Start prior to EcMO 10 (45.4 %)
•	 Furosemide intermittent, n (%) 14 (63.6 %)
Dose (mg/kg/day) 1.3 (2.0)
•	 Furosemide infusion, n (%) 4 (18 %)
Dose (mg/kg/h) 0.10 (0.07)
•	 Spironolactone, n (%) 7 (31.8 %)
Dose (mg/kg/day) 2.1 (0.7)
•	 Bumetanide, n (%) 2 (9.1 %)
Dose (mg/kg/day) 0.4 (0.1)
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Dosing simulations
Average curves for representative patients were simulated. Interpatient variability was 
not simulated due to the limited number of patients. Parameters were fixed to 3 differ-
ent age values: 3 days, 1 month and 6 years. A start of clonidine infusion 24 hours after 
ECMO cannulation was assumed.
RESULTS
Twenty-two patients were included, with median age 1 month (IQR 6.4) and median 
weight 4 kg (IQR 3.1) at initiation of ECMO support. Demographics and treatment details 
are presented in Table  2. The median number of blood samples per patient was 12.5 
(IQR: 13).
Plasma clonidine concentrations were obtained from 375 samples. Concentrations 
below the level of quantification (LOQ) represented 4.2 % of all observations (n = 16: 
15 during ECMO, 1 after ECMO) and were ignored during model building. In 4 patients 
(18.2 %), a clonidine level was determined prior to ECMO start (5 samples) and in 8 pa-
tients (36.4 %) samples were available after decannulation (17 samples) until 54 hours 
after ECMO decannulation. Figure 1 shows the individual clonidine concentrations plot-
ted against time profiles.
Table 2 Patient’s characteristics and treatment (n = 22) (continued)
Age (month) 1.0 (6.4)
CVVH
•	 Patient with cVVH, n (%) 20 (90.9 %)
•	 cVVH flow (ml/min) 300 (200)
ECMO
Modality :
•	 VA, n(%) 7 (31.8 %)
•	 VV, n(%) 15 (68.2 %)
Duration (day) 6.2 (7.1)
2nd run, n (%) 2 (9.1 %)
Circuit change 1 (4.5 %)
Laboratory values
•	 creatinine (μmol/L) 27 (10)
•	 Albumin (g/L) 32 (9)
•	 AST (iu/L) 49 (143)
•	 ALT (iu/L) 19 (70)
•	 GGT (iu/L) 31 (46)
Values are expressed as median and interquartile range unless specified otherwise
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Model development
Structural model
A one-compartment model was superior to a two-compartment model. The OFVs did 
not differ but in the latter model the precision of the estimated parameter was poor. The 
proportional error in the residual error model was very small and could be eliminated 
from the model without an increase of OFV. The a priori allometric scaling on clearance 
and volume resulted in a statistically significant improvement (decreases in OFV: -35.3; 
p-value<  0.001). Typical values and inter-patient variability for clearance and volume 
were 18.2 L/h/70kg and 33 % (Clpop, IIV) and 470 L/70kg and 52 % (Vpop, IIV) (Table 3).
uni-covariate analysis
Table  3 gives an overview of the main models tested and their performance during 
univariate analysis.
1. Demographics
Gender and diagnosis were not significant covariates.
2. Maturation
Among all models accounting for the effect of age on clearance, the Hill equation using 
postnatal age gave the best fit to the data: OFV decreased by 158; the standard error 
of the estimate (SE) and goodness of fit plots were adequate. A relationship between 
gestational age and clearance was not detected.
3. EcMO
The increase in clearance and VD with time on ECMO were best described with sigmoidal 
Emax models. Time dependent changes in clearance or volume after ECMO decannula-
Figure 1: Individual clonidine concentration versus time profiles
For every patient the individual data are connected by a solid line.
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tion were not detected. Moreover, no relationship was found between the type of ECMO 
(VA vs VV) and volume or clearance.
4. Disease progression
Laboratory values were not significant covariates. Urinary output was proportional to 
clonidine clearance while the use of diuretics was negatively associated with clearance. 
The use of CVVH modelled as in Equation 6 increased the volume of distribution by 33 % 
but did not statistically significantly improve the model (decrease in OFV 7.9). Therefore, 
it was not added to the final model.
multi-covariate analysis
The Hill equation using PNA was the first implemented in the structural allometric model 
because it was the most significant (Table 4). Adding the effect of time on ECMO using 
the sigmoidal Emax model on clearance did not improve the OFV and time on ECMO 
was therefore not included in the model. Figure 2 shows the population and individual 
Table 3 Parameter estimates and bootstrap results
Final model
Cli=Clpop*(wT/70)0.75 *(PNAΘ1 / (T50PNA Θ1+ PNAΘ1)) *Θ2DIURETIC
Vi=Vpop*(wT/70) * (1+Emax*tec Θ3/ T50EC Θ3+ tecΘ3)
Structural model Final model estimates bootstrap (1000 replicates)
Parameter Value (RSE) Value (RSE) Shrinkage Median 2.5–57.5th 
percentile
Fixed effects
Clpop (L/h/70kg) 18.2 (8.3 %) 29.9 (11.5 %) 29.3 21.9–99.7
Θ1 - 3.02 (22.1 %) 3.22 0.13–3.41
T50PNA (week) - 1.13 (6.5 %) 1.15 0.39–96*109
Θ2 - 0.659 (7.5 %) 0.675 0.567–7.852
Vpop (L/70kg) 470 (16.9 %) 454 (12.2 %) 440 335–558
Emax on V - 0.55 (32.9 %) 0,55 0.30–0.53
T50EC on V - 51.7 (4.6 %) 52.1 45.9–96.6
Θ3 - 18.5 (53.5 %) 18.0 5.0–01.1
Random effects
 Interindividual variability
Cl (%) 33 (16 %) 40 (27 %) 3 37 16–61
V (%) 52 (53 %) 44 (19 %) 11 43 21–12
Error
Proportional 0.281 (18.8 %) 0.208 (6.5 %) 0.204 0.179–9.231
Abbreviations: Clpop=clearance population; Cli=clearance individual; DIURETIC refers to the 
use of diuretic; Emax=maximal effect; OFV=objective function value; PNA=post-natal age  ; 
T50=time to half of maximal effect; tec =time on ECMO; V=volume of distribution ; WT=weight
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predictions versus observed clonidine levels (goodness of fit plots) on and off ECMO 
of the final model. Both urine output and use of diuretics further decreased the OFV 
but including both variables resulted in inflated residual standard error. Only the use 
of diuretics was included in the final model based on a lower standard error of the esti-
mate. It was associated with decreased clearance (Θ DIUR = 0.66). The empirical Bayesian 
estimates of clearances during and off ECMO and CVVH, respectively, are depicted in 
Figure 3.
ECMO significantly increased VD by 55 %. Maximal VD was reached 72 hours after 
initiation of ECMO.
Table 4: Covariate analysis
Model/Covariate OFV p-value Remark
Structural model:
1 compartment model -943,4 NA
+ allometric scaling with fixed exponents -978,7 < 0.001 Used in further model building
Univariate analysis
Maturation
GA (Eq. 7) -979,2 NS
PNA (Eq. 8) -1136,7 < 0.001 First covariate included in the model
EcMO-effect
On Clearance
Sigmoidal Emax model (Eq. 9)
•	 tEC -999,4 < 0.001
•	 tECCLO -1033,1 < 0.001
On Volume
Sigmoidal Emax model (Eq. 9)
•	 tEC -1007,1 < 0.001
•	 tECCLO -1024,6 < 0.001
Covariate
•	 Use	of	diuretics	(Eq.	6) -991,8 < 0.001
•	 Urine	output	(Eq.	7) -1023,9 < 0.001 Eq: (UO/Medianpop )ΘUO
Multivariate analysis (stepwise inclusion)
Base model with allometric scaling -978,7 NA
+ PNA (Hill equation) on Cl -1136,7 < 0.001 Half of adult clearance at 1.2 weeks of age
+ Sigmoidal Emax model on V (tEC) -1166,6 < 0.001 V á by 55 % on ECMO
+ Diuretic use on Cl -1185,9 < 0.001 Cl â by 34 % with use of diuretics
Only the model giving the best fit to the data is reported for each parameter
Cl: clearance; Emax; Maximal effect, GA: gestational age, NS: not significant, PNA post-natal age, tEC: time 
since ECMO start, tECCLO: time since clonidine start on ECMO
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Figure 2: Population predicted (left) and individual predicted (right) plasma concentrations versus ob-
served clonidine levels on (bottom) and off (top) ECMO.
Figure 3: Empirical Bayesian estimates (EBE) of clearances during presence and absence of both ECMO 
(top) and CVVH (bottom). EBEs are plotted for every time point of blood sampling. Clearance values are 
allometrically scaled. For every patient the individual data are connected by a solid line.
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Table 3 describes the parameter values and their corresponding interpatient variabil-
ity. Goodness of fit plots of the final model are depicted in Figure 4. Typical values for 
clearance and VD were 29.9 L/70kg/h and 454 L/70kg. Introduction of the covariates to 
the structural model increased interpatient variability of clearance from 33 to 40 % and 
reduced that of VD from 52 to 44 %. The residual error decreased from 28 % to 20 %.
model validation
The final model was tested with a bootstrap analysis; results are given in Table 4. 284 
bootstrap runs were prematurely terminated. Validation with NPDEs resulted in a global 
adjusted p-value of 0.925, a normal distribution of errors and no trend in NPDE versus 
time and versus prediction.
Clearance simulations
Figure 5 shows the body-weight normalized clearance plotted against age, as predicted 
by the final model and two pediatric studies in non-ECMO patients (17, 18). The mature 
clearance in ECMO patients is double the clearance in patients not on ECMO.
Dosing simulations
When clonidine is started at 24 hours of ECMO support, a therapeutic clonidine plasma 
concentration (2ng/ml) can be reached within 1 hour as follows:
•	 in a 3-day-old patient (3 kg): with 3 boluses of 5 mcg/kg (20 minutes intervals) and an 
infusion of 0.12 mcg/kg/h.
•	 in a 1-month-old child (4 kg): with 3 boluses of 5 mcg/kg (20 minutes intervals) and an 
infusion of 2 mcg/kg/h.
•	 in a 12-year–old child (35 kg): with 3 boluses of 5 mcg/kg (20 minutes intervals) and 
an infusion of 1 mcg/kg/h.
DISCUSSION
This study is the first to describe the population PK of clonidine after intravenous admin-
istration to neonates and children on ECMO. The developed PK model shows that allo-
metrically scaled clonidine clearance increases steeply with postnatal age, and reaches 
70 % of adult clearance at 10 days of postnatal age. Interestingly, the use of diuretics is 
associated with a lower clearance. The volume of distribution increases by 55 % during 
ECMO.
A one-compartment model was superior to a two-compartment model. Clonidine 
PK in paediatrics has previously been described with one (18) and two-compartments 
models (17, 19). In the study by Potts et al (17) and Larsson et al (19), samples were avail-
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able late after a single clonidine dose (until 24 hours), which might have made it easier 
to distinguish a second phase in the elimination (17). The clearance of clonidine in our 
study is double that reported in previous studies in non-ECMO patients. For other drugs 
studied this increase was maximally 50 % (20). The use of CVVH in 90 % of our patients 
may have influenced the clearance. The estimated clearance on ECMO was estimated at 
30 L/h/70kg in our study while it was around 15 L/h/70kg in two previous pediatric stud-
ies (17, 18) (Figure 5). One of these two studies reported an apparent clearance value in 
36 newborns (PNA: 8.8 ± 5.5 days) treated with oral clonidine for neonatal abstinence 
syndrome (18). To our knowledge, the bioavailability of clonidine in neonates has not 
yet been reported. Values of 50 % and 90 % have been reported for children and adults, 
respectively (19) (21). The other study (17) pooled data from 5 studies including 83 
patients ranging from neonatal to adolescent age treated by intravenous, rectal and 
epidural clonidine for sedation prior or during general surgery and after heart surgery. 
In studies in adults not on ECMO, oral and sublingual clonidine clearance values were 
similar to those found in children (14 L/h/70 kg (22, 23)).
Figure 4: Goodness of fits plots for the final model of clonidine on ECMO
A: Population predicted clonidine concentration versus observed clonidine concentration
B: Individual predicted clonidine concentration versus observed clonidine concentration
C: Individual predicted concentration versus individual weighted residuals
D: Conditional weighted residuals versus time
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Several factors may explain the higher clearance values during ECMO. One factor is 
the extracorporeal technique. The blood in the ECMO circuit is in contact with a large 
surface of synthetic material that adsorbs drugs (24) and thereby increases clearance. 
Ex vivo studies of ECMO systems show that rapidity and extent of drug adsorption 
increases with lipophilicity (24, 25) and amount of protein bound (26). The adsorption 
of clonidine may be expected to be high: it is moderately lipophilic (log P = 1.6) (27) and 
slightly protein-bound (20–40 %) (28). Ex-vivo studies on clonidine are lacking; still it 
would be useful to delineate the losses in the ECMO and CVVH circuits and compare ad-
sorptive capacities of different type of ECMO system. Second, 90 % of the patients were 
on continuous renal replacement therapy. Clonidine is considered poorly dialyzable and 
no dosing adjustment is recommended on dialysis (29, 30). However, its extraction ratio 
of 0.2–0.3 (30) and its physico-chemical properties (low molecular weight and slightly 
protein bound) suggest considerable clearance when renal replacement therapy is con-
tinuous, despite its large VD. The concentration of clonidine in the ultrafiltrate should be 
determined in future studies.
We found that postnatal age was the main determinant of bodyweight normalized 
clearance. This is in line with previous studies described in Figure 5 (17, 18). Interestingly, 
the sigmoidal model with PNA was described earlier by Xie et al. in a neonatal popula-
tion treated with oral clonidine for neonatal abstinence syndrome. (18). These models 
using PNA should be interpreted with caution in the first days of life because they imply 
absent clearance at birth and therefore do not reflect the liver metabolism and renal 
clearance that start long before birth. ECMO is rarely initiated on the first day of life: the 
Figure 5: Predicted body-weight normalized clearance profile according to postnatal age in ECMO versus 
non-ECMO pediatric studies. Clearance is depicted only from day 3 (age of the youngest patients).
A: Predicted clearance during neonatal period
B: Predicted clearance from birth to 500 days of life
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youngest patients in our study were 3 days old (n = 4) and our results likely cannot be 
transposed to younger neonates.
Interestingly, maturation of clearance with postnatal age shows a different pattern in 
our study: it starts at a smaller baseline value and reaches adult value at an earlier age. 
In our ECMO-patients, 70 % of adult clearance was reached at 1.5 weeks compared to 1 
month (18) and 9 months (17) in previous pediatric studies. These various patterns of 
clearance maturation may at least be partially explained by different age distribution: 
the first study included only neonates (18) while the second included only a few neo-
nates (17). The derived PK parameters should only be used within the age range studied. 
The oldest patient in our study was 6 years old and these parameters therefore cannot 
be applied to older children.
Like ECMO and clinical condition, age may affect two clearance pathways: GFR and 
CYP2D6 mediated drug metabolism. The expression and activity of CYP2D6 mature 
rapidly between birth and 1 week of age and reaches 85 % of adult activity at a PNA of 2 
weeks (31, 32). We found a similar pattern. However, renal function reaches adult values 
not until by 8 to 12 months of age (13), which corresponds to the pattern of clearance 
maturation in non-ECMO patients but is not supported by our study.
High collinearity between time-dependent variables is expected: the predominant 
effect of age on clearance may mask influential factors such as clinical condition, ECMO 
or CVVH. This confounding effect is inherent to ECMO studies. Postnatal age reliably esti-
mates clearance but shouldn’t be interpreted as the etiology of the increase in clearance 
with time. The low baseline clearance may reflect the patients’ critical clinical condition 
at ECMO start, after which their renal and liver function recovered (14, 33). Moreover, 
the inflammatory response triggered by the disease or the start of ECMO (34) known to 
induce cytochrome 2D6 downregulation could contribute to the lower baseline clear-
ance (14, 35). The influence of ECMO and CVVH on clearance probably drives the rapid 
increase of clearance with age.
Diuretics use was associated with a 34 % lower clearance. Creatinine is cleared by CVVH 
and creatinine level could therefore not be used to estimate renal function. In our PICU, 
CVVH is used early or pre-emptively in patients on ECMO (2) and adequate urine output 
is aimed for while on CVVH. Our team has reported diuretic use as risk factor of acute 
kidney injury (AKI) post-ECMO in the same population (36). The doses of loop diuretics 
were the only factor associated with AKI. During ECMO, diuretics are used for oliguria 
that may be caused by excessive CVVH fluid removal or to AKI related to the patient’s 
medical condition. Similarly, the decreased clonidine clearance associated with diuretic 
use in this study can reflect both conditions.
The VD was 454 L/70kg at ECMO start and increased by 55 % during ECMO. In a study 
using a one-compartment pharmacokinetic model the VD of oral clonidine in non-
ECMO neonates was 391 L/70kg (18)). High increases of VD have also been reported for 
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other drugs administered during ECMO (20, 37). To illustrate this: a doubling in case of 
a hydrophilic drug and a 400 % increase for a lipophilic drug such as midazolam. ECMO 
can increase VD by several mechanisms. For hydrophilic drugs, the added volume of the 
circuit increases the central VD at ECMO initiation. But alternate hypotheses are more 
likely for a lipophilic drug like clonidine. Adsorption to the ECMO circuit may mimic an 
increase in VD. Moreover, a systemic inflammatory response, either associated with the 
patient’s clinical condition or triggered by the ECMO system (34), induces a capillary 
leak and fluid retention that can change drug distribution and increase VD. While fluid 
retention is more likely to affect VD of hydrophilic drugs, the inflammatory response also 
involves the central nervous system and alters permeability of the blood-brain barrier 
(38) and may therefore impact VD of lipophilic drugs. Possible causes of the increase in 
VD of lipophilic drugs need to be further studied.
The composition of the ECMO system has an impact on plasma drug level (24) and 
may have influenced the pharmacokinetics of clonidine. At the time of the study a circuit 
with a high adsorptive capacity was used. Many PICUs have switched to circuits made 
from polymethylpentene hollow fibre, which are associated with less adsorption. Clear-
ance may therefore be lower with the new generation of ECMO circuits. Moreover, the 
priming volume was higher than in the newer ECMO systems. Furthermore, the newer 
ECMO systems are likely to lead to less inflammation. Each of these properties may 
potentially influence clonidine PK.
In many PICUs the clonidine infusion rate has increased in recent years. At the time of 
our study it was 0.1–1 mcg/kg/h in our PICU versus 1–3 mcg/kg/h in a recent PICU trial 
(4, 39). The clonidine level obtained in this study can therefore not be compared with 
that obtained in more recent studies. The targeted clonidine plasma concentrations in 
the PICU have not yet been formally determined with PK/PD studies. Studies in healthy 
adult volunteers (40) and limited data in critically ill children (41) suggest a level of 2 
ng/ml to ensure sedation and analgesia. The rapid increase in clearance during the first 
2 weeks of life suggests that the infusion should regularly be incremented in early life. 
As we found that the clonidine clearance in children older than one month was twofold 
the adult clearance the infusion rate may need to be doubled from one month of PNA to 
reach the same steady state concentration. Currently, the maximal recommended bolus 
dose is 5 mcg/kg. We simulated the number of bolus doses of 5 mcg/kg needed to reach 
the target concentration of 2 ng/ml within one hour: three repeated bolus doses of 5 
mcg/kg were needed. Our study proposes dosing recommendations based on available 
PK/PD data, and suggests that higher doses of clonidine infusion may be needed when 
ECMO is coupled to CVVH. This study draws a framework to delineate clonidine PK in 
other populations on different extracorporeal systems.
Chapter 6
123
Limitations of the study
First, the single center nature of this study may limit its generalizability. Second, the 
newer generation of ECMO systems may have different influence on pharmacokinetics 
of clonidine. Moreover, this study involved a limited number of patients.
CONCLUSION
This study demonstrates that in children on the studied ECMO system combined with 
CVVH, the clonidine clearance is doubled and the volume of distribution is higher than 
reported in critically ill adults and children not on ECMO. Postnatal age is the main deter-
minant of clearance maturation; the rapidity and extent of this maturation suggests an 
influence of ECMO, CVVH, CYP2D6 maturation and patient clinical condition.
This study delineates a framework for studies on pharmacokinetics of clonidine on 
other extracorporeal systems and illustrates how dosing guidelines should be devel-
oped to account for the diversity of situations encountered in the PICU.
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KEY POINTS:
question: Are critically ill children at risk of suboptimal dosing with oral acetamino-
phen?
Finding: The bioavailability of oral acetaminophen in stable critically ill children is lower 
than generally assumed: 72 % vs 90 %, with individual values ranging from 11 % to 91 %. 
Hence, oral acetaminophen dosing leads to highly variable blood concentrations, which 
may put patients at risk of underdosing or toxicity.
Meaning: To ensure adequate pain treatment, intravenous dosing should be considered 
more often.
AbSTRACT:
Importance: The oral bioavailability of acetaminophen is thought to be almost com-
plete, but it has never been determined in children. This may put children at risk of 
suboptimal acetaminophen dosing.
Objective: To determine oral acetaminophen bioavailability and its interindividual vari-
ability in stable children in the intensive care unit and to simulate exposure after oral 
and intravenous dosing.
Design: An innovative microtracer study design with concomitant administration of an 
oral 14C radiolabeled acetaminophen microtracer in patients already receiving intrave-
nous acetaminophen therapeutically. Patients were included from January 2014 until 
July 2015. Blood was drawn at 10 and 30 minutes, and 1, 2, 4, 6, 12 and 24 hours after 
acetaminophen administration. Population pharmacokinetic analysis of both thera-
peutic and oral microtracer doses of acetaminophen was conducted with NONMEM. 
Current dosing guidelines were used to simulate exposure and determine attainment of 
therapeutic concentrations.
Setting: Pediatric intensive care unit of a tertiary care hospital in the Netherlands.
Participants: Children up to 6 years who were prescribed intravenous acetaminophen 
were eligible. Exclusion criteria were: no arterial or central venous catheter in place, 
kidney or liver failure, gastrointestinal disorder or administration of more than one 
vasopressor. Of 232 potentially eligible patients, 118 were excluded and parents of 64 
declined participation. Because two patients vomited the microtracer dose and one had 
missing dosing data, data of 47 patients were analyzed.
Exposure: A single oral 14C-labelled acetaminophen microtracer (3 ng/kg) was admin-
istered concomitantly with therapeutically dosed intravenous acetaminophen adminis-
tered per standard of care.
Main outcome and measure: Oral acetaminophen bioavailability
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Results: The median age was 6.1 month (Q1-Q3: 1.8–20); the median body weight was 
7.4 kg (Q1-Q3: 4.3–10.5). The median PRISM score was 16 (Q1-Q3: 5–29) and 20 patients 
(42.6 %) were mechanically ventilated. Oral bioavailability was 72 % (range 11 % to 91 %). 
With a standard dose of 15mg/kg 4 times daily, therapeutic steady-state concentrations 
(10 ng/ml) were 2.5 times more likely to be reached with intravenous than with oral 
acetaminophen.
Conclusions: Oral acetaminophen results in unpredictable and generally inadequate 
exposure in young children. To ensure adequate pain treatment, intravenous dosing 
may be preferable.
INTRODUCTION:
Acetaminophen is an effective analgesic 1 and antipyretic that is among the most com-
monly administered drugs to sick children. The intravenous (iv) route of administration 
is increasingly used, but it is unclear whether this should be preferred to the oral route2. 
One argument in favour of the iv route is a more predictable systemic exposure, as the 
oral absorption of drugs may be erratic 3. This argument is a theoretical one, as its oral 
bioavailability has never been determined in children. Oral bioavailability is the fraction 
of the administered oral dose reaching the systemic circulation. It is generally assumed 
that acetaminophen oral bioavailability in children is almost complete 4 and therefore, 
most physicians prescribe the same oral and iv doses as recommended in labelled dos-
ing guidelines (60 mg/kg/d; maximal dose: 1 gram) 5,6. Interestingly, the assumption of 
almost complete oral bioavailability (91–97 %) stems from a study in 30 healthy adults 7. 
In other studies, bioavailability estimations were between 63 and 89 % and 60–70 % in 
6 and 9 volunteers, respectively 8,9. This suggests that oral bioavailability may be much 
lower and show more interindividual variability than currently assumed, which may af-
fect the efficacy of oral acetaminophen in children. While previous efficacy studies have 
shown an analgesic or fever-reducing effect of oral acetaminophen in children with the 
use of current dosing guidelines, therapeutic failure in underdosed children may have 
been overlooked 4,10.
The study reported here was aimed to estimate the oral bioavailability of acetamino-
phen and its interindividual variability in children using the innovative microtracer bio-
availability study design, with the ultimate goal to optimize current dosing guidelines. 
We have previously shown that microdosing is practically and ethically feasible to study 
acetaminophen pharmacokinetics in children 11.
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METHODS:
Setting
This oral bioavailability study was part of a larger 14C-microtracer study 11–13 carried out 
in the level III pediatric intensive care unit (PICU) of the Erasmus MC–Sophia Children’s 
Hospital. The study was approved by the Dutch Central Committee on Research Involv-
ing Human Subjects (EudraCT 2011–005497–28). Parental written informed consent was 
obtained.
Population
The same patients as in the original study 11,12 were described, that is all patients up to 
6 years of age admitted to the PICU who were prescribed iv acetaminophen and had an 
arterial or central venous catheter in place. To minimize interindividual variability due 
to severe critical illness, exclusion criteria were kidney and liver failure, gastrointestinal 
disorder, co-administration of drugs known to interact with acetaminophen pharmaco-
kinetics (PK), the use of more than one vasopressor drug and extracorporeal membrane 
oxygenation (ECMO).
Study design
Traditionally, oral bioavailability is estimated by giving a drug dose via oral or iv route 
in the same person and then repeating this after an adequate wash-out period via the 
alternate route. After each dose, multiple blood samples are taken for estimation of 
pharmacokinetic parameters. The ratio of area under the curves after oral and iv dosing 
is considered to reflect the oral bioavailability
In children, a therapeutic drug dose only for research purposes, combined with re-
peated blood sampling is mostly neither ethically acceptable nor feasible 14. Moreover, 
crossover studies do not provide an accurate estimation of bioavailability in individual 
children admitted to an intensive care unit because critical illness which influences 
pharmacokinetics, changes over time 15–17. We chose to overcome these hurdles by the 
use of labelled non-therapeutic microtracer (< 1/1000 of therapeutic dose) given orally, 
while the patient receives the therapeutic drug via iv route at the same time.
Children were administered a single radiolabeled microtracer dose of acetamino-
phen (14Cacetaminophen at 3.3 ng/kg, 60 Bq/kg, 0.25 ml/kg) orally at the same time 
therapeutic acetaminophen dose was given as per standard of care intravenously. 
The 14Cacetaminophen formulation was prepared by adding 14Cacetaminophen to 
a acetaminophen formulation for iv use; details on preparation have been previously 
described 11. To ensure proper delivery to patients fed by a naso-gastic tube, adhesion 
studies were carried out by running the 14Cacetaminophen formulation followed by 1 
ml of saline through the gastric tube (all tubes in use at our PICU). Recovery was greater 
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than 95 %. The therapeutic iv acetaminophen was dosed according to the Dutch Pediat-
ric Handbook 18: 20 mg/kg loading dose, followed by 10 mg/kg q6h (< 1 month of age) or 
15 mg/kg q6h (≥ one month of age). Some children had already received multiple doses 
before the microtracer dose was given and information on these doses was included in 
the pharmacokinetic analyses.
Blood samples were drawn from the indwelling catheter just before administration 
of the acetaminophen microtracer dose and at 10 and 30 minutes, and 1, 2, 4, 6, 12, 
24 hours after administration. After centrifugation, plasma was stored at -80°C until 
analysis.
Measurements
14Cacetaminophen plasma concentrations were measured by liquid chromatography-
accelerator mass spectrometry (LC+AMS) as previously described 11,19. The LC+AMS 
qualification was performed in accordance with the recommendation of the European 
Bioanalytical Forum 20. Therapeutic acetaminophen plasma concentrations were mea-
sured by liquid chromatography–mass spectrometry (LC-MS/MS)21.
Data collection
Doses of therapeutic and radiolabeled acetaminophen and the respective timings of 
administration were collected. Patient characteristics and relevant clinical and labora-
tory measurements were prospectively collected.
DATA ANALYSIS
Pharmacokinetic analysis
Population pharmacokinetic (popPK) analysis was performed using the nonlinear mixed 
effect modeling NONMEM 7.3.0 software (Icon Development Solutions, Ellicott City, 
Maryland, USA). Log transformed therapeutic and 14Cacetaminophen concentrations 
were modeled simultaneously. A structural pharmacokinetic model was developed 
to describe the typical pharmacokinetic parameters, together with a statistical model 
providing for the interindividual and unexplained variability. Then, potential covariates 
(Table 1) were tested for statistical significance. Covariates that were found to explain 
a part of the interindividual variability of pharmacokinetic parameters were included 
in the model. These covariates are clinical characteristics to be taken into account for 
an individual dosing regimen (e.g.: if weight is a significant covariate then doses are 
calculated per kg). The details of the analysis are available in the supplementary material 
(eMethods).
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Dosing simulations
To compare exposure after oral and iv administration, the concentration-time profiles 
until 24 hours after administration and mean steady-state concentrations were simu-
lated using the model estimates from the current analysis. A mean steady-state concen-
tration (Css) of 10mg/L (+/- 20 % deviation) was targeted, as this is a threshold associated 
with adequate analgesia 22–24. The dosing was as follows: similar oral and iv doses of 
15mg/kg per dose every 6 hours (60 mg/kg/day) 5. The highest recommended oral dos-
ing regimen of 22.5 mg/kg/dose every 6 hours (90 mg/kg/day) was also simulated 25. 
Simulations were performed for four age groups: 1 month, 6 month, one year and five 
years, assuming a typical weight of 4.5, 8, 10 and 18 kg, respectively, according to the 
CDC growth charts. For each dosing regimen and age group, 1000 simulations were per-
Table 1: Covariates tested for their influence on PK parameters
Type of data collected Reason for collection Potential covariates
Weight Weight is often found a major predictor of 
PK variability in pediatric patients
•	 	Weight	at	study	day
•	 	Weight	Standard	deviation	from	50th	
percentile for age and sex
Maturation Age often found a major predictor of PK 
variability in pediatric patients 43,44
•	 	Post-natal	age	(PNA)
•	 	Post-menstrual	age	(PMA)
•	 	Gestational	age	(GA)
Diagnostic Surgery and associated opioid use induced 
ileus that may influence oral absorption 15
•	 	Surgery
Abdominal surgery induces gut edema 
and alters intestinal perfusion
•	 	Abdominal	surgery
Severity of disease Severity of disease is associated to ileus, 
gut, edema and altered gut perfusion
•	 	Severity	scores:	PELOD	score,	PRISM,	
PIM
Organ function Organ failure may influence PK 45 •	 	Renal	function:	urea,	creatinine	
z-score adjusted for gender and age
•	 	Liver	function:	ALT,	AST,	PA,	Bilirubin,	
GGT
•	 	Number	of	organ	dysfunction:	
defined as the number of organ with 
a positive PELOD score 46
•	 	Other:	albumin,	lactate
Inflammation Inflammation may have a major impact 
on PK 47
•	 	CRP
•	 	Leucocytes
Way of oral dose 
administration
Drug absorption is influenced by the place 
of administration
•	 	Oral,	naso-gastric	tube,	gastrostomy,	
duodenal tube
Oral feeding status Critical illness is associated to gastro-
intestinal dysmotility and food intolerance 
17,48
•	 	Oral	feeding	status	within	the	24	
hours prior to microtracer
Comedication Slowing absorption 15 •	 	Opioids
Increasing absorption 49,50 •	 	Prokinetics
Influences absorption 15,51 •	 	Inotropes
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formed taking interindividual variability in the model parameters into account. Based on 
these simulations, the percentage of patients reaching the targeted mean Css of 10mg/
L+/-20 % in the iv acetaminophen group compared to the oral groups was computed.
RESULTS
Population
Of the 232 eligible patients in the original study, 118 were excluded. Sixty were excluded 
on the basis of exclusion criteria; for 21 patients the study drug was unavailable (outside 
office hours of pharmacy) and 37 patients participated in another clinical trial)12. Of the 
114 parents/care-givers approached, 64 declined participation of their child and thus 
50 patients were enrolled. Two patients were excluded as they threw up the microdose 
and for one dosing information was missing, leaving 47 patients with a median age 
of 6.1 month (Q1-Q3: 1.8–20) and a median body weight of 7.4 kg (Q1-Q3: 4.3–10.5). 
Thirty-seven patients (78.7 %) had been admitted for postoperative care, and 12 of those 
(25.5 %) had undergone abdominal surgery. The median PRISM score was 16 (Q1-Q3: 
5–29) and 20 patients (42.6 %) were mechanically ventilated. Patient characteristics and 
treatment are described in Table 2.
Dataset
The complete dataset included 250 and 314 radiolabeled and therapeutic acetamino-
phen concentrations, respectively. Twenty-three measurements below (BLOQ) and two 
above the limit of quantification (ULOQ) for radiolabelled and therapeutic acetamino-
phen, respectively, were excluded from the dataset as these measurements represented 
less than 10 % of the total number of available measurements (8.4 % and 0.6 % for 
14Cacetaminophen and therapeutic acetaminophen, respectively). The median numbers 
of concentrations per patient included in the analysis were 6 (Q1-Q3: 5–6) and 7 (Q1-Q3: 
6–8) for 14Cacetaminophen and therapeutic acetaminophen, respectively.
PK model
A two-compartment model best described the time course of oral radiolabelled and iv 
therapeutic acetaminophen blood concentrations.
The mean oral bioavailability in the population was 72 % (bootstrap confidence inter-
val: 64–79 %) with a high interindividual variability: individual bioavailability estimates 
ranged from 11 % to 91 %, implying that some patients absorbed only around 10 % of the 
oral doses while in others the absorption was almost complete. The other PK parameters 
are provided in Table 3.
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Table 2: Patients’ characteristics and treatment (n = 47)
Patient characteristic
Age (month) 6.1 (1.8–80)
Weight (kg) 7.4 (4.3–30.5)
Normalized weight for age (z-score), mean (SD) -0.7 (1.2)
Sex, male, n (%) 38 (80.9 %)
Gestational age (week) 39.9 (38–80)
Mortality rate; n (%) 0 (0 %)
Mechanical ventilation on study day, n (%) 20 (42.6 %)
Duration of PICU stay, days 3.8 (0.9–9.2)
Severity scores
•	 PELOD	(on	study	day) 10 (1–11)
•	 PIM	II	score 0.92 (0.2–2.88)
•	 PRISM 16 (5–59)
Diagnostic; n (%)
•	 Surgical	(total) 37 (78.7 %)
 o Of which Abdominal surgery 12 (25.5 %)
•	 Medical 10 (21.3 %)
way of oral acetaminophen administration, n (%)
•	 Oral 14 (29.8 %)
•	 naso-gastric	tube 22 (46.8 %)
•	 duodenal 8 (17.0 %)
•	 gastrostomy 3 (6.4 %)
Orally fed patients* 23 (48.9 %)
Comedications
•	 Prokinetics 0 (0 %)
•	 Opioids 43 (91.5 %) 
•	 Vasoactive-inotropic	drugs 13 (27.7 %)
Laboratory values at infusion start
•	 Urea	(mmol/L) 3.5 (2.3–3.9)
•	 Creatinine	(μmol/L) 23 (18–84)
•	 ALT	(U/L) 16 (10–04)
•	 GGT	(U/L) 20 (10–01)
•	 Alkaline	phosphatase	(U/L) 151 (127–797)
•	 Leucocyte	count	(109 per L) 10.6 (8.1–13.8)
•	 CRP	(mg/L) 5.9 (1.2–22)
Values are expressed as median and (Q1-Q3) unless specified otherwise
*= Feeding status was defined as oral feeding until 24 hours before microtracer dose
Abbreviations: ALT: alanine aminotransferase; CRP: C reactive protein; GGT: gamma-glutamyl transferase
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Table 3: Parameter estimates from the structural and final model with bootstrap results
Parameter
Model parameters estimates 
(RSE%) [shrinkage %]
bootstrap mean  
(bootstrap RSE%)
bioavailability
F 0.718 (6 %) 0.718 (6 %)
Absorption rate constant
ka (h-1) 2.15 (27 %) 2.25 (32 %)
Clearance
CL
TVCL (L.h-1.7.4kg-1) 1.95 (6 %) 1.94 (7 %)
ΘCL 1.05 (12 %) 1.06 (12 %)
Inter-compartmental Clearance
Q
TVQ (L.h-1.8.6kg-1) 0.346 (12 %) 0.372 (44 %)
Volumes of distribution
V1
TVV1 (L.8.6kg-1) 6.67 (5 %) 6.62 (6 %)
ΘV1 0.702 (15 %) 0.715 (16 %)
V2
ΘV2 (L.8.6kg-1) 0.502 (21 %) 0.549 (30 %)
Inter-individual variability
ω CL 0.114 (23 %) [7 %] 0.109 (24 %)
ω ka 2.45 (30 %) [20 %] 2.44 (32 %)
ω F 1.31 (35 %) [22 %] 1.28 (37 %)
Residual error
Exponential error therapeutic acetaminophen 0.224 (16 %) [5 %] 0.218 (16 %)
Exponential error radiolabeled acetaminophen 0.102 (19 %) [16 %] 0.101 (18 %)
Abbreviations : RSE=residual standard error; BW= body weight; CL = population clearance; TVCL= typical 
population clearance for a 7.4kg child; ΘCL= estimated allometric exponent for clearance; Q = population 
inter-compartmental clearance; TVQ = typical population inter-compartmental clearance; V1 = population 
central volume of distribution; TVV1 = typical population central volume of distribution; ΘV1 = estimated 
allometric exponent for the central volume f distribution; V2 = population peripheral volume of distribu-
tion; ΘV2 = fraction of the population central volume of distribution representing the population peripheral 
volume of distribution. Typical population values (TV) correspond to the population parameter for a child 
of 7.4kg.
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Bodyweight was the best predictor of clearance and volume of distribution and was 
therefore included in the structural model. After inclusion of bodyweight, age and other 
potential covariates tested were not found to be significant.
The interindividual variability in bioavailability could not be explained by any patient 
characteristic. Feeding status was also not a significant explanatory variable for bioavail-
ability. Table 3 describes parameter estimates of the final model. All internal validation 
presented in the supplementary
eResults shows that the model described the data accurately and precisely.
Figure 1: Simulated acetaminophen concentration time profiles over 24 hours after standard oral dose 
(60mg/kg/day - left), high oral doses (90mg/kg/day - middle) and iv dosing (right)
in four age groups, i.e. 1 month, 6 month, one year and five years of 4.5, 8, 10 and 18 kg. The dashed line 
shows the median of the mean steady-state concentration and the lower and upper dotted lines indicate 
the 5th and the 95th percentiles of the mean steady-state concentration respectively. The red line repre-
sents the targeted steady-state concentrations. Doses recommended by the Lexicomp Pediatric and Neo-
natal Handbook 5 were used for the oral and iv standard doses and the Dutch Pediatric Drug Handbook 18,34 
for the high oral dose (90mg/kg/day).
Wide variability is seen with oral dosing while iv dosing leads to less variable steady-state concentrations. 
The mean targeted steady-state concentrations of 10mg/L are not reached with an oral dosing of 60 mg/
kg/day while the same intravenous dosing allows reaching adequate systemic exposure. With the highest 
recommended oral dose, the mean targeted steady-state concentrations are reached but the important 
interindividual variability implies that some patients are underexposed and other overexposed.
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Simulation
Figure 1 shows the median and the 90 % prediction intervals of the simulated plasma 
concentrations over 24 hours after acetaminophen administration. Exposure after 
standard similar iv and oral doses (15mg/kg every 6 hours) led to adequate steady-state 
concentrations with the iv route (median mean Css corresponded to the targeted mean 
Css of 10mg/L) but most patients were underdosed with the same oral standard doses 
(median mean Css around 6.5mg/L). Patients were 2.5 times more likely to reach thera-
peutic blood concentrations with iv than with oral acetaminophen. Compared to the iv 
dosing, the highest oral dosing of 90mg/kg/day led to both higher and lower exposure 
in patients with bioavailability in the upper and lower range, respectively. Due to the 
high interindividual variability in oral bioavailability, patients were still 1.4 times more 
likely to be within the therapeutic range after iv dosing than after high oral doses.
DISCUSSION:
This innovative pediatric microtracer study enabled accurate estimation of acetaminophen 
oral bioavailability and its related interindividual variability. The mean oral bioavailability 
of acetaminophen in this stable PICU population was 72 %. The very wide interindividual 
variability in bioavailability led to extremely variable acetaminophen exposure after oral 
dosing, which could not be explained by relevant patient characteristics.
The estimated oral and iv PK parameters are in line with previous estimates in children 
24,26. The wide interpatient variability in exposure after oral dosing has previously been 
shown in infants younger than 3 month admitted to the PICU 26. Also in adults undergo-
ing surgery, oral acetaminophen leads to more variable blood concentration than iv 
27. The present study disentangles for the first time the influence of bioavailability and 
clearance on drug exposure and shows that bioavailability is responsible for the widely 
variable acetaminophen exposure.
This first estimation of mean oral acetaminophen bioavailability in children is 72 %. 
Reported estimations of oral bioavailability in adults as calculated by AUC range from 
63 % to 97 % 7–9. Lower exposure with oral versus iv acetaminophen has been shown in 
adults receiving acetaminophen for premedication before surgery 28.
One would expect that dosing guidelines reflect the oral bioavailability and resulting 
systemic exposure. If 72 % of the oral dose reaches the systemic circulation, a one-third 
higher oral dose would be needed to reach the same blood level as an iv dose. The mean 
targeted steady-state concentrations are indeed reached with the highest recommended 
oral dose of 90 mg/kg/day (table 4) and an intravenous dose of 60 mg/kg/day. However, 
the variability in oral bioavailability is also important. Compared to intravenous, oral 
acetaminophen can lead to under and overdosing in patients with low and high oral 
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bioavailability, respectively. The high oral dose (90 mg/kg/day) is recommended for 
short-term use only (max 2–3 days), which seems a rational decision in the light of our 
findings. Indeed, the wide interpatient variability found in this study implies a risk of 
overdosing in patients with oral bioavailability within the upper range. Acute liver failure 
in children receiving regular acetaminophen within the therapeutic dose range has been 
described 29,30. Our data suggest over-exposure in some patients, although it cannot be 
ruled out that the reported cases were due to accidental overdosing. Known risk factors 
Table 4 Comparison between different dosing guidelines for acetaminophen in children (from birth until 
6 years)
Intravenous dosing
Maximal 
daily iv dose Oral dosing
Maximal 
oral daily 
dose
Ratio 
maximal 
iv/oral 
dose
Perfalgan official label (EU)
< 10kg 7.5 mg/kg every 6 h 30 mg/kg Age based in all official 
product label
NA
> 10 kg to ≤ 33kg 15 mg/kg every 6 h 60mg/kg NA
Ofirmev (USA)
≥ 2 to 12 years old: 15 mg/kg every 6 h or 
12.5 mg/kg every 4 h
75 mg/kg Age based in all official 
product label
NA
british National Formulary 32
•	 	Neonate 10 mg/kg every 4–6 h 30 mg/kg Loading: 20 mg/kg
Maintenance: 10–15 
mg/kg every 6–8 h
60 mg/kg 50 %
•	 	Infant	until	10kg 10 mg/kg every 4–6 h 30 mg/kg
Loading: 20–00 mg/kg
Maintenance: 15–20 
mg/kg every 4–6 h
75 mg/kg
40 %
•	 	Child	weight	10–50	kg 15 mg/kg every 4–6 h 60 mg/kg 80 %
Lexicomp 5
•	 	Neonate Loading: 20 mg/kg
Maintenance: 10mg/kg 
every 6 h
40 mg/kg 10 to 15 mg/kg/dose 
every 4 to 6 hours
75 mg/kg 53 %
•	 	Infant	until	2	years 7.5–55 mg/kg/dose 
every 6 h
60 mg/kg
10 to 15 mg/kg/dose 
every 4 to 6 hours
75 mg/kg
80 %
•	 	Children	up	to	50kg 15 mg/kg every 6 h or
12.5 mg/kg every 4 h
75 mg/kg 100 %
Dutch Pediatric Drug Handbook 18,34
•	 	Neonate Loading: 20 mg/kg
Maintenance: 10mg/kg 
every 6 h
40 mg/kg Loading: 30 mg/kg
Maintenance: 60 mg/
kg/day in 3 doses (max 
2–2 days)
60 mg/kg 67 %
•	 	1	month	to	18	years Loading: 20 mg/kg
Maintenance: 15mg/kg 
every 6 h
60 mg/kg Loading: 40 mg/kg
Maintenance: 90 mg/
kg/day in 3 doses (max 
2–2 days)
90 mg/kg 67 %
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for acetaminophen-induced liver failure are acute illness, fasting and co-medication 
with a CYP2E1 inducer 29,31. Therefore, critically ill patients in particular may be at risk 
of acetaminophen-induced liver toxicity. Our findings suggest that oral acetaminophen 
doses higher than 60mg/kg/dose should be used only for short periods of time.
In the current study, oral bioavailability did not change in the age range studied from 
0 to 6 years of age. This contrasts the practice in most dosing guidelines in which the 
ratio of oral to iv dosing increases with age (Table 4) 5,32.
Clinicians often assume that conditions for good oral drug absorption are met when 
patients are orally fed and have low disease severity. Our study suggests, however, that 
oral bioavailability of acetaminophen is independent of feeding status and disease se-
verity, thus challenging the clinicians’ reluctance to favour iv in stable patients or those 
tolerating oral food.
The risk of under-dosing and toxicity with oral dosing of acetaminophen suggests 
that the iv route should be preferred when safe and effective pain relief is warranted. 
Interestingly, and in contrast to Europe, iv acetaminophen is not licenced for children in 
Canada 33 and not for children below the age of 2 years in the United States 6.
This study has several strengths. First, it is novel in that it presents the first estima-
tion of oral bioavailability of acetaminophen in children. While the results cannot be 
generalized to the very ill PICU population in view of the relatively low degree of disease 
severity, generalization to stable, hospitalized children may be acceptable. Second, the 
innovative study design may well serve as a blueprint to study dermal, rectal and nasal 
bioavailability of other drugs.
The following limitations should be addressed. First, we cannot exclude that the oral 
microtracer dose has contributed to the lower bioavailability and large interindividual 
variability observed. Such a low dose may contribute to more unexplained variability than 
does a therapeutic dose. However, uncompleted oral drug administration is highly unlikely 
as recovery from the feeding tube was almost complete 11. Also saturation of intestinal drug 
metabolism with a therapeutic dose could result in higher systemic exposure than with a 
microtracer dose alone. Both scenarios are unlikely, however, as our results are in line with 
previous pediatric PK studies on oral and iv acetaminophen. These showed an oral to iv 
exposure ratio of 40 % to 100 %, which is within the range of the bioavailability data in the 
current study 5,18,32,34. Moreover, similar PK results, i.e. dose-linearity, have been obtained 
with acetaminophen oral microdose and therapeutic dose in adults 35,36. The current study 
was not designed to assess intra-individual variability in bioavailability that may influence 
acetaminophen exposure after multiple oral doses. Indeed, bioavailability was assessed 
on a single oral dose and then extrapolated to obtain steady-state concentrations. Third, 
we could not simultaneously study the impact of the different routes of administration 
on drug effectiveness. Considering that a clear concentration-effect relationship has been 
established for acetaminophen 37, we believe that our dosing simulations provide convinc-
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ing evidence to support our claim that iv acetaminophen will lead to more effective and 
predictable systemic concentrations and consequently to better analgesia.
A limitation of our study design is the lack of comparative efficacy and safety data. 
A recent systematic review on the efficacy of oral versus intravenous acetaminophen 
in adults, concluded that evidence is lacking to favour intravenous over oral acet-
aminophen 2. This conclusion was however based on only 3 randomized efficacy trials in 
adults: i.e. one open-label study, one underpowered study and one in day-case surgery. 
In contrast, data from our group showed a very significant morphine sparing effect with 
IV acetaminophen (approximately 70 % less) in neonates and infants after major surgery, 
which we did not find with rectal acetaminophen, showing a similar variable absorption 
and bioavailability to our current oral data 38,39. Another review showed opioid sparing 
effects of perioperative acetaminophen and NSAIDs in children but concluded that 
insufficient data are present to distinguish between drugs and/or formulations 10.
Significant decreases in blood pressure have been reported in an observational study 
40 and two recent placebo controlled trials in adults 41,42. While in the observational study, 
half of the critically ill patients showed a > 15 % decrease in blood pressure and a third 
needed therapeutic intervention (increased inotropic support, filling requirements), the 
placebo-controlled trials are much more reassuring. In critically ill patients with fever, blood 
pressure was normal or high before dosing and resulted in normotensive blood pressure 
after acetaminophen IV 41. In the other study in healthy adults, only a small and transient 
decrease in blood pressure was found 42. In addition, no serious hemodynamic adverse 
events were reported in our randomized controlled trial comparing acetaminophen IV vs 
morphine IV for pre-emptive anesthesia after major surgery 1. Hence, these data are rather 
reassuring as to the hemodynamic safety of IV acetaminophen, in both adults and children.
CONCLUSION
Our innovative microtracer study design made clear that acetaminophen bioavailability 
is lower than generally assumed and shows a large inter-individual variability in stable 
pediatric intensive care patients until 6 years. Oral dosing will result in an unpredictable, 
likely lower systemic exposure with increased risks of therapeutic failure and increased 
risk of toxicity when oral doses are increased to overcome the low bioavailability. These 
PK data suggest that iv acetaminophen should be preferred over oral acetaminophen 
for the treatment of acute pain in hospitalized children.
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SUPPLEMENTARY EMETHODS
Population pharmacokinetic analyses
Before log transformation, radiolabeled concentrations in mBq/mL were transformed 
in mg/L of paracetamol equivalent, with 1 mBq corresponding to 5,31–14 gram of 
paracetamol. R (version 3.0.2) (1) and Pirana (version 2.7.1) software (2) were used to 
build the database, visualize the results and evaluate the output. The final model con-
sisted of 1) a structural submodel, 2) a statistical submodel, 3) covariate submodel.
 For the covariate submodel, covariates as described in table 1 (original manuscript) were 
tested in order to explain the interindividual variability of the PK parameters. A p-value of 
< 0.001 assuming a χ2 distribution was chosen as statistically significant, corresponding 
to a decrease in objective function of 10.8 or more between nested models. Goodness of 
fit plots, shrinkage and confidence interval in parameter estimates were also evaluated 
during model building and covariate analysis. The model was validated internally.
1. Structural model
The structural model was parameterised using population pharmacokinetic parameters 
describing the absorption, distribution and elimination of the drug using ADVAN6 (with 
differential equations). Therapeutic (cold) paracetamol had been given rectally to 12 pa-
tients (10 prior and 2 during the study) and orally to 2 patients prior to study inclusion. 
To account for exposure from the rectal doses given prior to inclusion, the absorption 
rate and lag-time for this administration route were fixed to literature values (3) and 
bioavailability was estimated. One, two, and three compartment models, first and zero 
order oral absorption and an oral absorption lag time were tested.
2. Statistical model
For the statistical model, log-normally distributed inter-individual variability was tested 
on each parameter. The interindividual variability reflects the differences in pharmaco-
kinetic parameters between patients due to their individual characteristics. The residual 
error corresponds to the remaining unexplained variability, including for instance mea-
surement error. For the residual error, separate exponential errors were estimated for 
14Cparacetamol and cold paracetamol.
3. Covariate analysis
Bodyweight and age (PMA and GA) were tested first. Then, other covariates were tested 
in a stepwise manner (forward inclusion and backward exclusion). Covariates leading to a 
significant decrease in objective function value (p value < 0.001 assuming a χ2 distribution) 
and a decrease in the interindividual variability or residual error were included in the model.
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4. Internal model validation
Internal validation was performed using a framework for the evaluation of paediatric 
population models (4). The condition number was computed to assess ill-conditioning 
(a condition number of 1000 or greater indicates a serious ill-conditioning). Goodness 
of fit was assessed by visualization of population and individual predicted concentra-
tions versus observed concentrations of cold and radiolabelled paracetamol for the 
total population as well as for subsets stratified on body weight. Conditional weighted 
residual errors (CWRES) versus time and versus population predicted concentrations 
were assessed to evaluate the residual error model adequacy and structural model 
bias. In order to asses model stability and obtain reliable standard error estimates, a 
bootstrap was performed. Bootstrap analysis was performed on the final model by the 
use of Perl speaks NONMEM (5) in order to obtain reliable estimates of the model pa-
rameter uncertainty. 1000 bootstrap data sets were generated by random sampling with 
replacement, with stratification on the covariates included in the final model. Histogram 
of NPDE (normalised prediction distribution errors) distribution, scatter plots of the 
NPDE versus time and of the NPDE versus log population predicted concentrations for 
cold and radiolabelled paracetamol were performed using an R-package (6). These allow 
to verify the model adequacy by comparison of the distribution of NPDE to the theoreti-
cal distribution. Finally, plots of the etas versus the model covariates were assessed to 
verify the covariate model adequacy.
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SUPPLEMENTARY ERESULTS
Model validation results
The condition number of the final model was 30.4, which is below the serious ill-
conditioning threshold of 1000.
Population and individual predicted concentrations versus observed concentrations for 
the total population as well as for subsets based on body weight did not show any trends 
except for very low concentrations of cold paracetamol, indicating that the final model 
was able to predict oral and intravenous paracetamol level without bias (eFigure 1 to 4).
The plot of CWRES (conditional weighted residual error) versus time and versus popu-
lation predictions with and without stratification of bodyweight did not show any trends, 
meaning that the error model chosen appropriately describes the error distribution and 
no model bias is compensated by the residual error (eFigure 5 to 8). For all parameters, 
bootstrap estimates were close to the NONMEM run values and the bootstrap percentile 
95 % confidence interval did not include 0. The variability estimates from the bootstrap 
were all lower than 40 %. Shrinkage on CL was low (7 %) and shrinkage on other param-
eters (ka and F) was around 20 %. NPDE showed no trends with time or concentrations 
for both radiolabelled and cold paracetamol (eFigure 10). The mean and variance of the 
NPDE for cold and radiolabelled paracetamol were not statistically significantly different 
from 0 and 1 respectively. The comparison of the distribution of NPDE to the theoretical 
distribution therefore confirm the model adequacy.
No trends of eta clearance, eta bioavailability and eta absorption rate versus body-
weight were observed after inclusion of body weight as covariate (eFigure 9), confirming 
that the covariate submodel well describes the observed trends with bodyweight.
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eFigure 1  Population predicted concentrations versus observed concentrations for cold (A) and 
radiolabelled (B) paracetamol. 
 
eFigure 2  Population predicted concentrations versus observed concentrations stratified on 
bodyweight. Stratification was performed with 3 body weight (BW) groups: patients from 2 to 5 kg 
corresponding to BW inferior to the 1st interquartile (BW<Q1), patients from 5 to 11kg corresponding 
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eFigure 2  Population predicted concentrations versus observed concentrations stratified on 
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eFigure 2 Population predicted concentrations versus observed concentrations stratified on bodyweight. 
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eFigure 9 Eta on clearance, absorption rate and bioavailability versus body weight.
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eFigure 10 Histogram of NPDE distribution, scatter plots of the NPDE versus time and of the NPDE 
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the median respectively. Y pred is the empirical mean of the simulated predicted distribution for each 
observation on the log domain. 
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AbSTRACT
Objective:
To compare the effect of two sedation practices on cardiovascular stability during the 
early post-operative period in young infants following cardiac surgery: the routine early 
use of midazolam infusion (pre-emptive sedation) and the discretionary use of sedatives 
tailored to the patient’s clinical condition (targeted sedation).
Design:
Retrospective cohort study with matched controls.
Setting:
A 15 bedded pediatric cardiac ICU.
Patients:
Sedation strategies were compared by matching patients before and after the introduc-
tion of a targeted sedation guideline, replacing the existing practice of pre-emptive se-
dation. Inclusion criteria were age < 6 months and cardiopulmonary bypass time > 150 
minutes. Matching criteria were surgical procedure, age, duration of cardiopulmonary 
bypass and cross-clamp.
The main outcome was cardiovascular instability, defined by the presence of one 
of the following criteria in the first 12 hours after PICU admission: 1) simultaneous 
administration of ≥  2 inotropic or vasopressor drugs; 2) administration of >  60ml/kg 
fluid boluses. Secondary outcomes were: 1) markers of cardiac output adequacy (heart 
rate, blood pressure, vasoactive inotropic score, urine output, volume of fluid boluses, 
central venous oxygen saturation, lactate); 2) occurrence of adverse events (cardiac 
arrest, extracorporeal membrane oxygenation, death); 3) sedatives administered and 
depth of sedation.
Interventions:
Introduction of a guideline of targeted sedation
Measurements and Main results:
Thirty-three patients with pre-emptive sedation were matched to 33 patients with 
targeted sedation. Targeted sedation resulted in less frequent oversedation, without 
compromising cardiovascular stability, as indicated by similar occurrence of cardiovas-
cular instability (68.8 % with pre-emptive sedation vs. 62.5 % with targeted sedation; 
p = 0.53) and adverse events, and similar markers of cardiac output adequacy. While all 
pre-emptively sedated patients received an infusion of midazolam in the first 12 hours 
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after surgery, only 19.4 % of patients in the targeted sedation group received a sedative 
infusion (p < 0.001).
Conclusion:
Our data suggest that after high-risk cardiac surgery in young infants, routine sedation 
with midazolam may not prevent low cardiac output syndrome. When accompanied by a 
careful assessment of level of sedation, routine sedation of infants after high risk cardiac 
surgery can be avoided without compromising hemodynamic stability or patient safety. 
The potential benefit of this approach is reduced exposure to sedative.
INTRODUCTION
Despite significant advances in surgical, perioperative and intensive care, infants un-
dergoing major heart surgery remain at high risk for adverse events like cardiac arrest, 
need for extracorporeal membrane oxygenation (ECMO) or death (1). Young age (2, 3), 
long cardiopulmonary bypass time (4) and complex surgery (2) are risk factors for these 
negative outcomes.
After open-heart surgery with cardiopulmonary bypass (CPB), cardiac output de-
creases significantly, the nadir being usually between 9 and 12 hours after CPB (5). Car-
diac surgery and CPB increase oxygen consumption (6). This combination of decreased 
cardiac output and increased oxygen requirements can lead to a state of insufficient 
oxygen delivery - low cardiac output syndrome - that results in increased morbidity (7).
After high-risk heart surgery, sedation is not only indicated to reduce anxiety and 
distress, but profound sedation is also routinely used to prevent low cardiac output 
syndrome (7) by blunting stress response (8) and decreasing energy expenditure and 
myocardial oxygen demand (9).
On the other hand, accumulating data suggest that profound sedation may be detri-
mental. It is associated with increased duration of mechanical ventilation and ICU stay 
(10) and increased risk of tolerance and withdrawal (11, 12). Moreover, benzodiazepines, 
commonly used for sedation after heart surgery, may have adverse hemodynamic and 
respiratory effects (13, 14) and concerns are rising about their neurotoxicity (15–17). 
Dosing is usually not based on solid pharmacokinetic data and does not take the 
changes in the volume of distribution and/or clearance into account.
Whether sedating every patient after high risk surgery improves hemodynamic 
stability compared to the use of sedation tailored to the patient’s clinical condition is 
unknown. This absence of data may contribute to the wide use of routine sedation in 
this setting that contrasts with the general tendency to avoid oversedation in the PICU 
to prevent withdrawal (11). Therefore, we compared cardiovascular stability of young 
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infants at high risk of low cardiac output syndrome receiving two sedation practices: the 
routine early use of continuous midazolam infusions (pre-emptive sedation) and the 
discretionary use of sedative drugs tailored to the patient’s clinical condition (targeted 
sedation).
METHODS
Setting
The cardiac ICU at the Royal Children’s Hospital Melbourne is a 15 bedded tertiary and 
quaternary referral unit. The institutional ethics review committee at the Royal Children’s 
Hospital Melbourne approved the study and waived the need for patient consent.
Study design:
Retrospective cohort study with matched controls, comparing patients receiving routine 
midazolam infusion with patients treated with discretionary use of sedatives.
Patients
We identified, between January 2011 (when medical records became available elec-
tronically) and October 2013, all patients with a postconceptional age > 37 weeks and 
postnatal age < 6 months who underwent cardiac surgery with a CPB time greater than 
150 minutes. We selected high-risk surgeries based on this cut-off point of CPB duration 
as it is an independent predictor of major adverse events (4).
The study period included 10 months before and 24 months after the introduction of 
a targeted sedation guideline (TARG), replacing the pre-emptive routine use of continu-
ous midazolam infusions (PES) following cardiac surgery. Each patient identified from 
the PES group was matched with a patient from the TARG group (1:1 matching) with the 
same congenital heart lesion and surgery. They were also matched on the basis of age, 
duration of CPB and aortic cross-clamp. Patients were first matched by surgery and then 
matches were selected by classifying patients in ascending order of duration of CPB and 
by selecting the patient with the most similar combination of age and duration of CPB 
and cross-clamp. Patients who came back from the operating room on extracorporeal 
life support were excluded.
During the study period, the only change to the postoperative management was the 
introduction of the new sedation guideline. There were no changes to anaesthetic or 
operative management or procedures. The cardiac surgical team was composed of three 
cardiac surgeons that did not change during the study period. Although perioperative 
anaesthetic management was not strictly protocolized, the following approach is stan-
dard at our institution for this patient group: Sevoflurane was administered to facilitate 
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venous and arterial cannulation and then discontinued. Fentanyl was used for induction 
and sternotomy (total dose 75–100 mcg/kg) and morphine (500 mcg/kg) was given as a 
loading dose while on bypass. Isoflurane 1–2 % was administered by the perfusionist to 
control hypertension and provide myocardial pre-conditioning.
Differences in preemptive and targeted sedation practices are summarized in table 1. 
The main difference is avoidance of routine use of midazolam infusion with the targeted 
sedation practice (TARG).
Targeted sedation guideline (TARG)
With the introduction of this guideline, sedative drugs were titrated by bedside nurses 
to target optimal sedation as defined by a COMFORT Behavior © (COMFORT-B) score (18) 
between 10 and 20. Education about the targeted sedation guideline and COMFORT-B 
assessment was provided with theoretical courses and bedside teaching to nursing and 
medical teams prior to implementation. COMFORT-B score was assessed every 4 hours.
In infants, differentiating pain from anxiety can be difficult. Aggressive pain control 
was prioritized in the post-operative period and then sedation was optimized. Morphine 
was the first agent used because it provides pain relief and sedation. When pain relief 
was ensured by adequate doses of morphine, clonidine was started. This drug was 
favoured over midazolam because no data point to neurotoxicity (16, 19).
The targeted sedation guideline is shown in Figure  1. Patients came back from the 
operating room on an infusion of morphine (10–40mcg/kg/h). If 3 boluses of morphine 
(0.1mg/kg) were needed for sedation or treatment of pain, the infusion was increased 
Table 1 : Differences in sedation practices between group treated with routine midazolam infusion (PES) 
and discretionary use of sedatives (TARG)
Preemptive sedation (PES) Discretionary sedation (TARG)
Sedation practice:
 - Use of a guideline No Yes
 - Scale used Movements in response to stimulation
(0 - absence, P – purposeful, N - normal)*
COMFORT-B score
 - Definition of adequate sedation Clinical assessment 10–00
 - Titration by:
	 •	 Nurses According to doctor’s prescription Within boundary of protocol
	 •	 Doctors When deemed necessary to insure patient’s safety
Analgesia and sedation:
 - Routine morphine infusion Yes Yes
 - Routine sedative infusion Yes No
 - Recommended sedative Midazolam Clonidine
* = 11 patient in the preemptive sedation group were assessed by COMFORT-B score (because the introduc-
tion of this score predated the introduction of the sedation guideline).
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incrementally to a maximum of 40 mcg/kg/h. Bolus doses of clonidine (0.5–1mcg/kg/
dose) were administered each hour until adequate sedation was achieved. If the tar-
geted COMFORT-B scores were not achieved despite a total bolus dose of clonidine of 2 
mcg/kg in 4 hours, an infusion of clonidine was started at 0.5 mcg/kg/h and increased if 
necessary to a maximum of 2 mcg/kg/h. If sedation remained inadequate, a midazolam 
infusion was started (60 mcg/kg/h). Prior to start of the infusion, a bolus of midazolam 
(0.1 mg/kg) was considered in hemodynamically stable patients.
Pre-emptive sedation practice (PES)
This sedation practice was used prior to the introduction of the new guideline. (October 
2011). The sedation and analgesia were managed according to physician’s orders. Simple 
scoring of response to stimulation was used: 0 - absence, P - purposeful and N - normal 
movements. Patients with a score of 0 were considered to be oversedated. This scale 
only provides assessment of the level of consciousness and did not guide titration of 
sedation that relied on the clinical judgement of nurses and physicians. The introduction 
of the COMFORT-B score was part of the new unit sedation practice and predated the 
Figure 1: Sedation guideline for ventilated children less than one year
This figure describes the dose escalation used to get Comfort B scores between 10 and 20 or to target pro-
found sedation in an unstable child.
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TARG sedation guideline by a short time. Therefore, some patients in the PES group were 
assessed with COMFORT-B scores.
A combination of morphine (20–40mcg/kg/h) and midazolam infusions (60–180 
mcg/kg/h) was given routinely to all infants after complex heart surgery. Boluses of 
morphine (0.1mg/kg) or fentanyl (1–2mcg/kg) were used for analgesia, while boluses of 
midazolam (0.1 mg/kg) were occasionally given for sedation in stable patients. The infu-
sion of midazolam was usually titrated to achieve profound sedation during the night 
after the surgery. Usually, if the patient remained hemodynamically stable, weaning was 
commenced in the morning, otherwise the midazolam infusion was continued.
management of the patient with low cardiac output syndrome
A guideline for management of low cardiac output following heart surgery was in place 
during the study period. First line measures were fluid expansion, increased inotropy 
and/or afterload reduction, target haemoglobin levels, optimization of heart rate and 
maintenance of normothermia. Deep sedation was advocated as a second-line therapy, 
with neuromuscular blockade in persistent cases.
Data collection:
Patient characteristics
The following patient characteristics were collected: age, sex, weight, diagnosis, surgi-
cal procedure, CPB and cross-clamp time, associated anomalies, delayed chest closure. 
RACHS-1 score was used to classify surgical risk (20).
Primary outcome: Cardiovascular instability
Cardiovascular instability was defined as the presence of at least one of the following 
criteria in the 12 hours following admission to PICU:
•	 Simultaneous	administration	of	≥ 2	inotropic	or	vasopressor	infusions
•	 Administration	of	> 60ml/kg	of	volume	boluses.
Secondary outcomes: Cardiovascular parameters and markers of Co adequacy
The following hourly hemodynamic variables and indirect cardiovascular markers from 
the first 12 hours following PICU admission were retrieved from the ICU paper chart: 
heart rate, blood pressure, fluid bolus administration, urine output and fluid balance. All 
fluids administered by bolus were recorded, including crystalloids, colloids and blood 
products. Vasoactive-inotropic score (VIS) was calculated using the formula: 1*(dopa-
mine + dobutamine (mcg/kg/min)) + 10 * milrinone (mcg/kg/min) + 100 * (epinephrine 
+ norepinephrine (mcg/kg/min)) + 10 000 * vasopressin (U/kg/min) (21).
Central venous saturation and arterial lactate values for the same period were col-
lected from the electronic laboratory reporting system.
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Secondary outcome: sedation and analgesia
Hourly doses of continuous sedative and opioid drugs were extracted from the ICU 
paper chart and bolus doses of sedatives, analgesics and muscle relaxants from the 
paper medical prescription charts. Fentanyl was converted to morphine equivalent by 
multiplying the dose by 100 as previously reported (22). The need for continuous seda-
tives was recorded during the entire PICU stay.
Sedation scores reported during the first 12 hours following PICU admission were 
extracted.
For comparison of depth of sedation, only patients with available COMFORT-B scores 
were included. A COMFORT-B score <  10 was considered oversedation, scores rang-
ing from 10 to 20 were considered optimal sedation and scores > 20 were considered 
undersedation. Some patients did not have COMFORT-B scores due to regular use of 
neuro-muscular blocking agents. In the PES group, some patients were assessed on the 
previous sedation scale (and not with COMFORT-B scores).
To take the change in the sedation scale into account, oversedation was defined as either:
•	 COMFORT-B	score	< 10
•	 ‘Absent	movement	 to	 stimulation’	 on	 the	 previous	 sedation	 scale	 (as	 this	 reflects	
decreased level of consciousness).
•	 Regular	use	of	neuro-muscular	blockade	(as	this	implies	profound	sedation)
Secondary outcomes: others
Sedation scores and administration of analgesic, sedative and neuromuscular blocking 
drugs were recorded for the first 12 hours after PICU admission. Other outcomes (time 
to chest closure, use of peritoneal dialysis and temporary cardiac pacing, duration of 
intubation and PICU stay) and adverse events (unplanned extubation, ECMO, cardiac 
arrest and death) were recorded for the entire PICU admission.
Statistical analysis
The average value of hourly hemodynamic parameters, indirect cardiovascular markers 
and COMFORT-B score in the first 12 hours of PICU admission was used for between 
group comparisons. The distribution of the data was compared between the patients in 
the PES and TARG groups using statistical tests for paired data, to take into account the 
effects of the matching procedure, for all variables except the sedation scores. Normally 
distributed data were described using mean and SD and analysed using the paired t-test. 
Continuous data that were not normally distributed were described using median and 
interquartile range (IQR) and analysed using the Wilcoxon signed-rank test. Sedation 
scores were analyzed using the Mann-Whitney test due to the non-normal distribution 
and the presence of many missing values.
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The McNemar’s test was used for categorical variables. All analyses were conducted 
using STATA 13.0 (College Station, TX). All statistical tests were two-sided and used a 
significance level of 5 %.
RESULTS
Patients
We identified 41 patients who received pre-emptive sedation (PES). Three were excluded 
because they were on extracorporeal life support on admission to the PICU, three were 
premature and for two no match could be found in the TARG group. The remaining 33 
patients were matched to 33 patients (among 100 potential matches) in the TARG group.
Surgeries performed are described in Table  2. The mean RACHS score was 4. Other 
patient characteristics are shown in Table 3. There was no significant difference in age 
between the two groups, however patients in the PES group weighed less than patients 
in the TARG group (mean weight 3.4 vs 3.8 kg, p = 0.026).
Table 2: Cardiac pathologies with the number of pairs from the two sedation protocols and corresponding 
RACHS-1 scores (n = 33 pairs)
Pathology n of pairs RACHS-1*
Arterial swith operation for TGA
•	 with	IVS 	 7 3 
•	 with	VSD	repair	 4 4 
•	 VSD	closure	and	hypoplastic	aortic	arch	repair	 1 4 
Truncus arteriosus repair 1 4
•	 with	aortic	arch	repair	 1 5 
Complete AVSD repair 3 3
•	 with	pulmonary	valve	repair	 1 3 
RV-PA conduit and PA repair for Pulmonary Atresia 1 3
TOF: complete repair 2 2
HLHS:
•	 Norwood	stage	1	repair	 7 6 
•	 Glenn	shunt	 1 2 
Hypoplastic Aortic Arch repair 3 4
•	 with	tricuspid	valve	repair	 1 4 
*=RACHS-1 score evaluates risk of mortality for children after heart surgery and divides surgical procedures 
into 6 risk categories. 1 is the lowest and 6 the maximal risk category (20).
Abbreviations of congenital heart disease: AVSD : atrio-ventricular septal defect ; DORV : double outlet right 
ventricule ; HLHS: Hypoplastic left heart syndrome; IVS : intact ventricular septum ; PA: pulmonary artery; 
RV-PA conduit: right ventricular to pulmonary artery conduit; TGA: Transposition of the great arteries; TOF : 
tetralogy of Fallot ; VSD : ventricular septal defect
166
Cardiovascular outcomes
The proportion of patients with cardiovascular instability was not significantly different 
between groups; 68.8 % in the PES vs 62.5 % in the TARG group (p = 0.53), as shown in 
Figure 2. Table 4 describes secondary outcome: cardiovascular parameters and indirect 
Table 3: Patients characteristics (n = 66)
Elective sedation
Group (PES)
n = 33
Targeted sedation
Group (TARG)
n = 33 p-value
Matching variables:
•	 Age	in	days,	median	(IQR) 8 (62) 9 (44) 0.12
•	 Duration	of	CBP	in	minutes,	median	(IQR) 193 (49) 191(62) 0.50
•	 Duration	of	cross-clamp	in	minutes,	mean	(SD) 114 (38) 116 (40) 0.52
Age categories, n (%)
0–0 month 23 (69.7 %) 24 (72.7 %) 0.32 
1–1 months 10 (30.3 %) 9 (27.3 %) 
Sex, male, n (%) 24 (72.7 %) 15 (45.5 %) 0.020
Weight in kg, median (IQR) 3.4 (0.8) 3.8 (1.3) 0.026
Associated anomalies, n (%) 8 (24.2 %) 5 (15.2 %) 0.18
Delayed sternal closure, n (%) 14 (42.4 %) 12 (36.4 %) 0.53
Abbreviations: CPB: cardio-pulmonary bypass; IQR: interquartile range; SD: standard deviation
Figure 2: Occurrence of oversedation according to cardiovascular instability
Cardiovascular instability was defined as presence of at least one of the following criteria in the 12 hours 
following admission to PICU: 1.) need for ≥ 2 inotropic or vasopressor agent; 2.) > 60ml/kg of filling.
Oversedation was defined as either neuromuscular blockade or absence of movement on previous seda-
tion scale or Comfort-B score < 10 on all observations in the first 12h of PICU admission.
Data of patients on ECMO were omitted (n = 1 per group) and 2 patients had no sedation scoring recorded 
(n = 1 per group).
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markers of cardiovascular stability. Vital signs were not significantly different between 
groups. Amount of fluid bolus administration, fluid balance, urine output, vasoactive 
inotropic score, ScvO2 and lactate were not statistically different between groups.
Secondary outcomes
Sedation and analgesia
Figure 3 describes infusion of analgesics and sedatives at PICU admission and divides 
patients according to the need for opioids and sedatives in addition to infusions started 
on admission. All patients in the PES group received a midazolam infusion on PICU 
Table 4: Cardiovascular parameters and markers of CO adequacy and other secondary outcomes
Elective sedation 
group (PES)
n = 33
Targeted sedation
group (TARG)
n = 33 p-value
Cardiovascular parameters and markers of CO adequacy$
Heart Rate, mean (SD) 149 (14.8) 153 (13.5) 0.13
Blood pressure (mmHg), median (IQR)
 systolic 65.4 (5.6) 66.4 (10.4) 0.25
 mean 50.1 (4.8) 49.2 (6.7) 0.64
 diastolic 40.1 (5.4) 38.3 (8.8) 0.45
Central venous pressure (mmHg), median (IQR) 6.3 (2.8) 7.7 (4.3) 0.43
Left Atrial Pressure (mmHg)*, median (IQR) 6.3 (3.1) 5.4 (2.3) 0.38
Vasoactive Inotropic Score, median (IQR) 6.8 (4.3) 5.9 (4.3) 0.54
Urine output (ml/kg/h), median (IQR) 1.4 (1.0) 0.8 (1.0) 0.07
Fluid balance (ml/kg), mean (SD) 23.1 (29.7) 29.7 (25.7) 0.35
Amount of filling (ml/kg), mean (SD) 38.0 (25.5) 30.8 (25.3) 0.18
Lactate, median (IQR) 2.0 (1.5) 1.9 (1.3) 0.30
Central Mixed venous saturation (ScvO2), mean (SD) 56.6 (9.7) 57.5 (10.5) 0.85
Patient management:
•	 	Duration	until	chest	closure	(Days),	median	(IQR) 0 (2) 0 (2) 0.50
•	 	Number	of	patient	with	peritoneal	Dialysis,	n	(%) 18 (54.5 %) 13 (39.4 %) 0.17
•	 	Temporary	cardiac	pacing,	n	(%) 10 (30.3 %) 7 (21.2 %) 0.26
Adverse events, n (%)
Unplanned extubation 1 (3.0 %) 1 (3.0 %) 1.00
ECMO 3 (9.1 %) 2 (6.1 %) 0.65
Cardiac arrest 3 (9.1 %) 3 (9.1 %) 1.00
Death 0 (0 %) 0 (0 %) NA
Days of mechanical ventilation, median (IQR) 3.3 (4.0) 2.8 (4.0) 0.87
Days of PICU stay, median (IQR) 4.9 (4.7) 4.8 (4.9) 0.56
$ One patient per group has been excluded due to ECMO started early after admission
* Left atrial pressure was available in 19 patients in PES group and 17 patients in TARG group
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admission while none did in TARG group. The infusion rate at which morphine was com-
menced was higher in the PES compared to the TARG group. 37.5 % of patients in the PES 
group did not receive any bolus of opioid or sedative during the first 12 hours compared 
to 9.4 % in TARG group (p = 0.013). More patients in the TARG group received any ad-
ditional sedative during the first 12 hours of admission. The number of patients exposed 
to a sedative decreased with the introduction of the targeted sedation guideline: all 
patients in PES group were exposed to a sedative (midazolam infusion) compared to 
34.4 % in the TARG group (p < 0.001).
Table 5 compares amount of opioids, sedatives and neuromuscular blockers received, 
along with COMFORT-B scores and incidence of oversedation during the first 12 hours 
of PICU admission. Fewer patients in the PES group received morphine boluses, and 
the amount received was lower than in the TARG group. However, there was no statisti-
cally significant difference in the total cumulative amount of morphine (infusion plus 
boluses). The cumulative doses of sedatives were lower in the TARG group: high dose 
midazolam were used before the introduction of targeted sedation guideline (median 
midazolam dose in 12 hours: 1440 mcg/kg in PES vs 0 in TARG group (p < 0.001) while 
small doses of clonidine were used after (mean clonidine dose: 0+/-0 mcg/kg in PES 
compared to 0.81+/-2.40 in TARG group; p < 0.015). While all patients in the PES group 
Figure 3: Need for additional analgesic and sedative medication and proportion of profoundly sedated 
patients during first 12 hours of PICU admission by group.
Oversedation was defined as either neuromuscular blockade or absence of movement on previous seda-
tion scale or Comfort-B score < 10 on all observations in the first 12h of PICU admission.
*= one patient on Fentanyl 3mcg/kg/h was excluded from the comparison of morphine doses
# = p value calculated using McNemar’s test on 31 pairs (2 patients on ECMO excluded)
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Table 5: Use of analgesic, sedative, and neuromuscular blocking agents and sedation scores during the first 
12 hours of PICU admission.
Elective sedation 
Group (PES) n = 32$
Targeted sedation
Group (TARG) n = 32$ p-value
Analgosedative and neuromuscular blocking drugs
Number of patients exposed to a bolus
Morphine; n (%) 2 (6.5 %) 20 (64.5 %) < 0.001
Fentanyl; n (%) 17 (54.8 %) 12 (38.7 %) 0.25
Midazolam; n (%) 1 (3.2 %) 2 (6.5 %) 0.56
Clonidine; n (%) 0 (0 %) 5 (16.1 %) 0.025
Vecuronium; n (%) 18 (58.1 %) 17 (54.8 %) 0.78
Total amount of bolus
Morphine (mcg/kg); median (IQR) 0 (0) 163 (631) < 0.001
Fentanyl (mcg/kg); median (IQR) 3.4 (8.6) 0 (8.2) 0.21
Midazolam (mg/kg) mean (SD), median (IQR)* 0.01 (0.05); 0 (0) 0.027 (0.13); 0 (0) 0.56
Clonidine (mcg/kg) mean (SD), median (IQR)* 0 (0); 0 (0) 0.4 (1.1); 0 (0) 0.026
Vecuronium (mg/kg); mean (SD) 0.18 (0.21) 0.18 (0.21) 0.88
Total amount (continuous and bolus)
Morphine (mcg/kg); median (IQR) 480 (90) 461 (603) 0.08
Morphine equivalent (mcg/kg); median (IQR) 705.8 (862.2) 881.4 (764.6) 0.69
Clonidine (mcg/kg) mean (SD); median (IQR)* 0 (0); 0 (0) 0.81 (2.40); 0 (0) 0.015
Midazolam (mcg/kg); median (IQR) 1440 (300) 0 (0) < 0.001
Sedative infusion
in the first 12 hours
Patient exposed to a sedative infusion n (%) 33 (100 %) 6 (19.4 %) < 0.001
Midazolam 33 (100 %) 4 (12.9 %) < 0.001
Clonidine 0 (0 %) 2 (6.5 %) 0.16
Timing of start (h after PICU admission); median (IQR) 0 (0) 6.5 (7) < 0.001
During entire Picu stay
Patient exposed to a sedative infusion, n (%) 33 (100 %)  15 (46.9 %) < 0.001
Timing of start (h after PICU admission), median (IQR) 0 (0) 23 (32) < 0.001
Comfort b score per patient, median (IQR)
Mean score 6 (2.5) 8 (5.3) 0.18
% of score per patient indicating oversedation 100 (17) 100 (67) 0.26
n = 11# n = 24##
Incidence of Oversedation, n (%)
Patients with only COMFORT-B scores < 10 8 (72.7 %) 13 (54.2 %) _
Absent movement on previous sedation scale 11 (35.5 %) - -
Regular use of neuro-muscular blockade 9 (29.0 %) 6 (19.4 %) 0.41
Total 28 (90.3 %) 19 (61.3 %) 0.007
$ One patient per group has been excluded due to ECMO started early after admission
* data were not normally distributed and comparison were done with Wilcoxon signed-rank test, Mean and 
SD are mentioned for improving clarity.
# only patients with Comfort B scores were included in this analysis. Since this sedation scale was intro-
duced around the time of the sedation protocol, many patients do not have any available Comfort-B score.
## missing patients are patients without observation of Comfort B scores due to missing data or when Com-
fort-B score could not be assessed the regular use of neuro-muscular blocker. Data on ECMO were omitted.
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received a continuous infusion of sedative in the first 12h of PICU, only six patients 
(19.4 %) did in the TARG group; p < 0.0001. The TARG guideline was violated in four of 
these who received an infusion of midazolam instead of clonidine. Patients in the PES 
group were more deeply sedated, with oversedation occurring in 90.3 % of patients in 
PES group compared to 61.3 % in TARG group (p = 0.007).
Duration of intubation, length of stay and adverse events
Durations of mechanical ventilation and PICU stay were not significantly different 
between groups (Table 4). Finally, there was no difference in the incidence of adverse 
events throughout the PICU admission: three patients (9.1 %) needed ECMO in the PES 
group compared to two in the TARG group (6.1 %); p = 0.65. In both groups, three pa-
tients (9.1 %) had a cardiac arrest; p = 1.00. No deaths occurred in either group.
DISCUSSION
Our data show that in young infants after high-risk cardiac surgery avoiding routine 
midazolam use by introducing a sedation guideline is feasible and does not compromise 
cardiovascular stability. Sedation practice tailored to the patient’s clinical condition 
(targeted sedation) may also reduce sedative exposure and occurrence of oversedation.
The constraints of the retrospective design meant that we were not able to diagnose 
low cardiac output syndrome. Therefore, we used cardiovascular-targeted treatment, 
physiological and laboratory variables and occurrence of adverse events to infer car-
diovascular instability. The study focused on the first 12 hours after admission from 
the operating room because this is the time of maximum potential instability and the 
period during which most infants are deeply sedated. The two treatment criteria used 
as primary outcome to define cardiovascular instability (administration of >  60 ml/
kg fluid bolus, or the use of more than one inotropic or vasopressor infusion) indicate 
deviation from the usual routine postoperative care consisting of prophylactic use of a 
single vasoactive agent and restrictive fluid management (23). A second inotrope and 
volume expansion are standard approaches to the management of low cardiac output 
syndrome following cardiac surgery. The absence of difference in primary outcome 
suggests that the occurrence of this complication is comparable between groups. The 
similar cardiovascular parameters further indicate that avoiding routine midazolam is 
safe in this high-risk population. 70 % of our patients were neonates, known for their 
limited ability to increase stroke volume in response to higher preload (24). The main 
mechanism to increase cardiac output in this population is heart rate acceleration and 
inotropic drug administration. The absence of any difference in heart rate and vasoac-
tive inotropic score in the presence of similar blood pressure and ScvO2 (known to vary 
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with cardiac index) suggests that discretionary use of sedation does not compromise 
cardiac output. Adverse events usually follow hemodynamic deterioration. Therefore 
it is not surprising that in the presence of comparable cardiovascular parameters the 
occurrence of major adverse events was similar in both groups.
There is growing interest in management of analgesia and sedation after heart sur-
gery (25), but studies using a pharmacokinetic and pharmacodynamic approach are still 
missing (26). The cardiovascular effect of various sedative agents in the post-operative 
period has been reported (13, 25) but our study is the first to address the effect of rou-
tine pre-emptive use of sedation compared to individualized sedation on cardiovascular 
stability.
The introduction of the targeted sedation (TARG) guideline discouraged the use of 
routine midazolam infusion. Instead, the discretionary use of a targeted clonidine infu-
sion and lower doses of continuous morphine were recommended. We observed very 
good adherence to this guideline with complete avoidance of routine sedative infusion 
on PICU admission and lower continuous morphine rates. With the new approach, seda-
tion could be better individualized as suggested by fewer patients not needing any bo-
lus (i.e less oversedation by routine infusions) and more patients treated with sedatives 
given in addition to baseline infusions (i.e targeted instead of routine sedation). The 
higher clonidine use reflected the TARG guideline. However, even in the TARG group, 
midazolam was favoured over clonidine when continuous sedation was started early 
after surgery. This deviation from guideline with otherwise good adherence may reflect 
concerns about clonidine-induced bradycardia and hypotension in unstable patients. 
Duffett et al. reported factors influencing treatment choice in the PICU (27) and showed 
that published guidelines have less influence on treatment choice than severity of ill-
ness, physiologic rationale and potential for adverse effects. The same reasons may have 
influenced the instances of out-of- guideline choice of sedative infusion in our study.
Despite the use of clonidine, which has documented bradycardic and hypotensive 
effects, in the TARG group, heart rate and blood pressure were similar between groups. 
The absence of difference may be due to the relatively small proportion (around 20 %) of 
patients exposed to clonidine. Moreover, a clonidine-induced decrease in heart rate and 
blood pressure is likely to take many hours to develop and may not have been evident 
this early after surgery (28).
Interestingly, the reduction in continuous morphine resulted in higher use of boluses 
while the total amount was comparable. This was not the case with sedation: avoidance 
of routine midazolam reduced exposure to sedative: only one third of the patients were 
exposed to a sedative (mainly clonidine) and the cumulative dose decreased. In PICU 
patients, exposure to midazolam is associated with increased risk of withdrawal (11), 
whereas clonidine is frequently used for prevention (29) and treatment of withdrawal 
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states (30). Further studies will be needed to assess if this approach to sedation decreases 
sedative withdrawal.
Decreasing the use of analgesic and sedative drugs is of major importance in neonates 
and young infants. The neurotoxic effect of benzodiazepines have been demonstrated 
in animal studies (16, 17). Before more evidence becomes available from large prospec-
tive pediatric studies, the animal data should motivate a decrease in sedative exposure 
(31). Our study suggests that cardiovascular safety can be preserved while a) minimising 
sedative exposure and b) favouring a drug that has not thus far been linked to neuro-
toxicity (19), over a benzodiazepine. Both of these benefits are in accordance with the 
Food and Drug Administration (FDA) and the International Anesthesia Research Society 
(IARS) sponsored SmartTots (Strategies for Mitigating Anesthesia-Related Neurotoxicity 
in Tots) recommended approach to design of clinical studies (31). This is also important 
to the parents who are increasingly aware of the recommendation to avoid anesthesia 
at an early age.
We found a high prevalence of oversedation: 61.3 % of the patients in the targeted 
group were oversedated, compared to 90.3 % in PES group. Vet et al. showed that overse-
dation is still prevalent in the PICU: most studies report oversedation in the range of 
40–65 % of patients or measurements (32). The incidence of oversedation in the TARG 
group was at the upper limit of this range, while in the PES group it was even higher. 
However, this is in accordance with previously reported sedation levels after pediatric 
heart surgery (33) and is probably reflective of the high-risk infant population studied: 
deep sedation is a common approach to the infant with post-operative cardiovascular 
instability. The aim of sedation is to decrease energy expenditure and improve the bal-
ance between oxygen consumption and delivery. However, sedatives also have adverse 
hemodynamic effects (e.g vasodilation, myocardial depression) that may compromise 
cardiovascular stability (13). Therefore, the impact of level of sedation on hemodynamics 
may depend on the balance between desired (sedative) and unwanted (hemodynamic) 
effects of sedatives, and may vary with depth of sedation. Future studies will be needed 
to assess the effect of further lightening sedation in this group.
Implementing a sedation guideline is a way of targeting predefined sedation goals. 
In adult intensive care, implementation of a guideline has been shown to decrease days 
of mechanical ventilation and ICU stay (34). However, more recent adult studies have 
not confirmed these findings (35). The growing awareness of the deleterious effect of 
oversedation and general tendency to avoid it may explain these differences in results 
over time. The effect of protocolizing sedation is not clear in paediatric ICU, but all stud-
ies are recent and therefore avoidance of oversedation may already have entered PICU 
practice. A recent large, cluster randomized trial of protocolized sedation compared to 
usual practice in PICU did not show any difference in days of mechanical ventilation (36). 
Several non-randomized trials conducted in children have reported conflicting results 
Chapter 8
173
on outcomes like length of PICU stay, duration of mechanical ventilation or the need 
for analgesia and sedation (37). Our study was not primarily designed to study such 
outcomes, but does show the absence of deleterious cardiovascular effects of avoiding 
routine midazolam infusion and tailoring sedation to patient’s clinical condition. This is 
of importance since this particular indication for routine sedation is common and has 
not yet been systematically studied.
Our study has several limitations. Its single-centre nature may limit generalizability 
of the results to other units. We did not have measurements of cardiac output and so 
relied on bed-side tools used by the clinician to infer adequacy of cardiac output. 
Moreover, the main sedative used changed with the onset of the guideline (from high 
dose midazolam to low dose clonidine), which conflates the effects of sedative agents 
and sedation strategies. The COMFORT-B score was essentially introduced contempo-
raneously with the new guideline, and we concede that comparison of sedation level 
between groups is compromised by the use of two different methods. Oversedation 
was defined using parameters from whichever sedation scale was used for each patient. 
Since these scales have not been equilibrated with each other, this comparison has 
an inherent imprecision and should be interpreted with some caution. On the other 
hand both sedation scales were used by experienced ICU staff members, and there is 
a high degree of correlation between COMFORT-B scale scores and the expert opinion 
of ICU staff (18, 38). The introduction of the COMFORT-B score with the new sedation 
guideline may have enhanced the awareness of oversedation and undersedation, as it 
demands a careful evaluation of the patient’s behavioral response. Our study can not 
differentiate between the effects of the dosing of analgosedative drugs and the greater 
attention given to sedation practice. As with any retrospective study, conditions were 
not controlled during the study period. Nevertheless, the relatively short period of study 
and the absence of other changes to patient management confer a degree of reliability 
on the data. The very high-risk population and matched groups design further improve 
the quality of the data.
CONCLUSION
Our data suggest that after high-risk cardiac surgery in young infants, routine sedation 
with midazolam may not prevent low cardiac output syndrome. When accompanied by a 
careful assessment of level of sedation, routine sedation of infants after high risk cardiac 
surgery can be avoided without compromising hemodynamic stability or patient safety. 
The potential benefit of this approach is reduced exposure to sedative.
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Celui qui vit sans folie n’est pas si sage qu’il le croit.
François, duc de La Rochefoucauld
 Chapter 9
Clonidine as a ﬁ rst line sedative agent 
after neonatal cardiac surgery: 
retrospective cohort study
NiiNa Kleiber
SaSKia N. De WilDT
GÉrarD COrTiNa
MiKe CliFFOrD
THierrY DUCrUeT
DiCK TibbOel
JOHNNY Millar
PeDiaTr CriT Care MeD. 2016 aPr;17(4):332-41
178
AbSTRACT
Objective:
To determine the cardiovascular tolerance of clonidine used as a first line sedative after 
cardiac surgery in small infants.
Design:
Retrospective chart review.
Setting:
A tertiary and quaternary referral cardiac pediatric intensive care unit.
Patients:
All infants younger than 2 months who received a clonidine infusion for sedation after 
cardiac surgery from October 2011 to July 2013.
Interventions:
None
Measurement and Main results:
Heart rate, blood pressure, central venous and left atrial pressure, vasoactive inotropic 
score, volume of fluid bolus, lactate and central mixed venous saturation were assessed. 
Pre-infusion values were compared to post-infusion values. Of 224 potentially eligible 
patients, only 23 infants met inclusion criteria, as most patients only received high doses 
morphine, and some midazolam instead of clonidine. Clonidine was started at a median 
of 12 hours after surgery (Q1-Q3: 5–23), infusion rate was 0.5–2mcg/kg/h for a median 
duration of 30 hours (Q1-Q3: 12–54). Heart rate decreased (maximal mean decrease: 12 % 
(149 bpm (SD17) to 131 bpm (SD17); p < 0.0001). Apart from a transient and limited drop 
in diastolic blood pressure of 13 % (maximal mean decrease: from 42.8mmHg (SD5.9) to 
37.1 mmHg (SD 4.0); p = 0.018), all other cardiovascular parameters were stable or im-
proved. A contemporaneous cohort of patients who received midazolam, did so sooner 
after surgery, stayed longer in the PICU and showed less favorable hemodynamics.
Conclusion:
Intravenous clonidine as sedative added to morphine in selected patients appears 
hemodynamically safe. The observed decrease in heart rate and diastolic blood pressure 
seem of minimal clinical importance as all other hemodynamic parameters remained 
stable or improved. The safety of clonidine given early after cardiac surgery as alterna-
tive to midazolam merits further study.
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INTRODUCTION
Following cardiac surgery in children, pain is controlled with an opioid. While opioids 
may also provide sedation, a benzodiazepine is often added if adequate sedation is 
not achieved with an opioid alone (1, 2). The use of alpha-2 agonists, which have both 
analgesic and sedative properties, is increasing in the PICU (3–6). Enthusiasm for these 
agents is driven by concerns about the neurotoxic effects of benzodiazepines (3) and by 
the absence of clinically significant respiratory depression with α-2-agonists (4). How-
ever, their use in the early post-operative period after cardiac surgery raises concerns. 
Myocardial function decreases in the early postoperative period after cardiac surgery 
and the consequent low cardiac output syndrome is associated with worse outcome (5). 
Maximal decrease in cardiac output occurs in most patients by 12 hours but may happen 
as late as 24 hours (5). Because these agents induce bradycardia and hypotension (6–8), 
they could further compromise CO (9). On the other hand, decreasing heart rate and 
blood pressure may be beneficial when cardiac output is limited by high afterload or 
when tachycardia leads to impaired force–frequency relation (10).
Dexmedetomidine is increasingly used for sedation after cardiac surgery. Available 
studies document good sedative effect and a well-tolerated decrease in heart rate (HR) 
and blood pressure (BP) (6, 11–13). However, the hemodynamic side effects occasionally 
necessitate discontinuation of dexmedetomidine or additional cardiovascular support 
(6, 11–13).
We can find only two studies documenting the sedative effects of clonidine following 
cardiac surgery. Both used smaller doses than currently recommended (maximal dose 
in previous studies: 1 mcg/kg/h for 6 hours (2); actual dosing: 2–3 mcg/kg/h for longer 
than 24 hours) (14)). On these relatively low doses, no changes in heart rate and blood 
pressure have been reported. Moreover, these studies targeted a specific population: 
they included only hemodynamically stable patients and neither included neonates (2, 
15).
Neonates may be more susceptible to the adverse effects of clonidine. Approximately 
half of a clonidine dose undergoes renal elimination and the other half is metabolized in 
the liver (16) (mainly by CYP2D6 (17)). At 1 month of age, neonates have 30–70 % of body 
weight corrected adult clearance (18, 19) due to immaturity of renal excretion and liver 
metabolism. Moreover, cardiac surgery with cardiopulmonary bypass has the potential 
to produce acute kidney injury that may further decrease clearance (20). Assuming a 
concentration-response relationship for the hemodynamic adverse events of clonidine 
and the precarious hemodynamics of neonates following cardiac surgery, this group is 
probably the most vulnerable to adverse effects.
In October 2011 we introduced a nurse-tailored sedation protocol advocating cloni-
dine, rather than midazolam, as the primary sedative in children less than 12 months 
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old in PICU. Considering the potential detrimental hemodynamic effects of clonidine, 
we conducted a study in the most at risk population: neonates and young infants who 
received a clonidine infusion in the first 48 hours after cardiac surgery. We also com-
pared the hemodynamic stability of patients treated with clonidine as per protocol with 
children who received another sedative as deviation from protocol.
MATERIALS AND METHODS
The institutional ethics review committee at the Royal Children’s Hospital Melbourne 
approved the study. The cardiac ICU at the Royal Children’s Hospital Melbourne is a 15 
bedded tertiary and quaternary referral unit.
Patients
We identified all consecutively admitted infants with a post-natal age of > 37 weeks and 
under the age of 2 months who underwent a cardiac surgery from October 2011 to July 
2013. Sedatives received within 48 hours of admission were recorded and patients were 
divided into 2 groups according to adherence to protocol:
1. Adherent to protocol:
- Only opioid: no infusion of sedative was used
- Clonidine: clonidine was added to the opioid infusion
2. Protocol deviation:
- Other sedative: an infusion of another sedative was added to the opioid infusion
Patients on extracorporeal membrane oxygenation (ECMO) or receiving cardiac pac-
ing on arrival to the PICU were excluded.
Sedation protocol
With the introduction of the new protocol in October 2011, sedative drugs were titrated 
by bedside nurses to target optimal sedation as defined by the COMFORT Behavior © 
(COMFORT-B) scale (21). Nurses assessed COMFORT-B scores (21) every 4 hours or when 
clinically indicated. A COMFORT-B score between 10 and 20 was targeted in stable 
patients while highly unstable patients (e.g. low cardiac output syndrome or pulmonary 
hypertensive crisis) were routinely more deeply sedated (COMFORT-B < 10). Nurses were 
allowed to titrate medication within the boundaries of the protocol, while physicians 
were allowed to deviate from the protocol when they considered that this was safer for 
the patient.
Patients came back from the operating room on an infusion of morphine (10–40 mcg/
kg/h). If the patient was in pain or undersedated, a bolus of morphine (0.1mg/kg) was 
administered; if 3 boluses were needed, the infusion was increased in increments of 5 
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mcg/kg/h to a maximum of 40 mcg/kg/h. The first line sedative was clonidine. Bolus 
doses (0.5–1mcg/kg/dose) were given initially up to a cumulative dose of 2 mcg/kg, 
after which an infusion was started (at 0.5 mcg/kg/h) and incrementally increased to 
a maximum of 2 mcg/kg/h. If COMFORT-B scores remained > 20, a midazolam infusion 
was started (at 1 mcg/kg/min) and the physician was notified.
Anaesthetic and general post-operative PICU management
Anesthesia with high-dose opioids technique is used in our institution for neonates 
and small infants in whom post-operative mechanical ventilation is planned. Although 
anaesthetic management is not strictly protocolized, the following approach is standard 
at our institution for this patient group: sevoflurane is administered to facilitate venous 
and arterial cannulation and then discontinued. Fentanyl is used for induction and ster-
notomy (total dose 75–100 mcg/kg) and morphine (500 mcg/kg) is given as a loading 
dose while on bypass. Isoflurane 1–2 % is administered by the perfusionist to control 
hypertension and provide myocardial pre-conditioning.
All young infants returned from the operating theatre with a peritoneal dialysis 
catheter and temporary epicardial pacing wires. Right atrial pressure and central venous 
oxygen saturation (ScvO2) were measured via an internal jugular catheter.
General post-operative management was not strictly protocolized. Dobutamine was 
the standard inotrope used for prevention and treatment of low cardiac output syn-
drome. Other inotropes, vasodilators and vasopressors were used at the discretion of 
the treating intensivist.
Primary outcome measure
Cardiovascular tolerance of clonidine infusion as assessed by:
•	 Hemodynamic	parameters:	heart	rate	(HR),	blood	pressure	(BP),	left	atrial	and	central	
venous pressure, vasoactive inotropic score (VIS), volume of fluid bolus administered
•	 Laboratory	markers	of	cardiac	output:	ScvO2,	serum	lactate
•	 Indirect	markers	of	organ	perfusion:	urine	output
The start of the infusion or first clonidine bolus (whichever the first) was considered 
time 0 (t0). Summary measures of hemodynamic parameters (the mean of 4 hourly 
values) were calculated for baseline (before t0) and for each 4 hour interval thereafter 
until 48 hours.
Secondary outcome measures
•	 Sedation	scores	and	analgesic	needs	after	starting	clonidine	infusion.
•	 Adverse	events	defined	as:	need	for	cardiac	pacing;	arrhythmias;	cardiac	arrest;	ac-
cidental extubation; ECMO or death.
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Other Secondary outcome measure
•	 Comparison	of	 the	post-operative	course	of	 the	cardio-vascular	parameters	of	 the	
clonidine group (as per protocol) with a group that received another sedative agent 
(protocol deviation). The mean of 4 hourly values of hemodynamic parameters was 
calculated from PICU admission until 48 hours after.
Procedure
Data were retrieved from the paper ICU chart. Vasoactive-inotropic score (VIS) was 
calculated as previously reported using the formula: 1*(dopamine + dobutamine (mcg/
kg/min)) + 10 * milrinone (mcg/kg/min) + 100 * (epinephrine + norepinephrine mcg/kg/
min) + 10 000 * vasopressin U/kg/min (22).
Laboratory data (ScvO2, lactate, creatinine) were transcribed from the electronic labo-
ratory results system. Bolus doses of sedatives and analgesics were extracted from the 
medical prescription charts.
Data were collected from PICU admission until 48 hours after the start of clonidine.
Statistics
Normality was tested on continuous variables. Normally distributed continuous data 
are presented as mean and standard deviation (SD) and non-normally distributed are 
presented as median and 1st and 3rd quartile (Q1-Q3). Discrete data are presented as 
number (%). Non-normally distributed data were analysed with Wilcoxon signed-rank 
test, while normally distributed data were analyzed with t-test. Categorical variables 
were analysed with Fischer’s exact test and Pearson chi square tests. A mixed effects 
model was performed for intragroup differences over time. Repeated times were con-
trasted to the pre-treatment value. Between-group differences were assessed using a 
mixed model. To account for multiplicity, a conservative Bonferroni correction was ap-
plied. A p-value < 0.05 was considered significant. Analysis was conducted using STATA 
13.0 (College Station, TX).
RESULTS
Patients
224 infants less than 2 months underwent cardiac surgery during the study period. 9 
were excluded due to missing data.
The 215 remaining patient were divided in 2 groups as follows:
1. Adherent to protocol:
- Only opioid: 157 patients (73 %): morphine n = 154, fentanyl n = 3
- Clonidine: 32 patients (14.9 %)
Chapter 9
183
2. Protocol deviation:
- Other sedative: 26 patients (12.1 %). The sedatives received were: midazolam (n = 16), 
dexmedetomidine (n = 7), propofol (n = 1) and a combination of clonidine and mid-
azolam (n = 2).
Patient’s characteristics of each group are described in table 1.
In the clonidine group, 9 were excluded: 2 had cardiac pacing, 4 were on ECMO on PICU 
admission and 5 were premature, leaving a total of 23 patients. Table 2 describes their 
cardiac pathologies and operative procedures. Median age was 22 days (Q1-Q3: 6–47) 
and mean weight was 3.6 kg (SD 0.6). Six patients (26.1 %) had associated anomalies. Five 
Table 1. Demographics of eligible and included patients
Per-protocol group
Out of protocol 
group
Only opioids Clonidine Other sedatives p-value 
clonidine 
vs other 
sedatives
p-value 
clonidine 
vs opioids
Eligible patients n = 157 n = 32 n = 26
Age (day) 8 (3–38) 22 (6.5–58.5) 11.5 (2–25) 0.21 0.028
PICU stay (h) 4.8 (2.9–9.9) 5.0 (3.0–0.4) 8.8 (4.2–23.7) 0.05 0.99
Hospital stay (h) 18.3 (11.7–77.8) 19.9 (10.9–91.6) 29.8 (14.3–33.6) 0.23 0.47
Duration intubation (h) 2.6 (1.6–6.9) 3.4 (1.9–9.9) 6.2 (2.0–03.0) 0.25 0.12
RACHS score 3 (3–3) 3 (2.5–5.5) 3 (3–3) 0.25 0.14
Included patients n = 23 n = 10
Age (Days), Median (IQR) - 22 (6–67) 6 (0–06) 0.16
Sex (male), n (%) - 13 (56.5 %) 4 (40 %) 0.47
Weight (kg), Mean (SD) - 3.6 (0.6) 3.5 (0.6) 0.48
Associated anomalies, n (%) - 6 (26.1 %) 2 (20) 1.00
RACHS score - 3 (2–2) 3 (3–3) 0.40
Minutes of : -
•	 	CPB,	Mean	(SD) - 126 (82) 140 (79) 0.65
•	 	Cross-clamp,	Mean	(SD) - 71 (57) 70 (48) 0.94
Delayed sternal closure, n (%) - 5 (21.7 %) 4 (40 %) 0.40
Sedation start, h after PICU 
admission
- 12 (5–53) 4 (1–1) 0.010
Peritoneal dialysis, n (%) - 8 (34.8 %) 6 (60 %) 0.26
Duration of intubation (Days)
Median (IQR)
- 2.0 (1.6–6.7) 3.7 (2.0–0.7) 0.13
Days of:
•	 	PICU	stay,	Median	(IQR) - 5 (3–3) 10 (4–43) 0.036
•	 	Hospital	stay,	Median	(IQR) -  18 (10–09) 22 (14–42) 0.22
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(21.7 %) had delayed sternum closure. Median duration of stay was 5 days (Q1-Q3: 3–7) 
and duration of mechanical ventilation was 2.0 days (Q1-Q3: 1.6–3.7).
In the protocol deviation group, midazolam was chosen for comparison based on 
its frequency of administration. Among 16 patients in the midazolam group, 6 were 
excluded (2 were paced, 2 were on ECMO and 2 were premature). Patients in the 
midazolam group had similar demographic (age, weight, associated anomalies) and 
operative characteristics (RACHS score, duration CPB and cross-clamp) as the clonidine 
group. Midazolam was started earlier after PICU admission than clonidine (median time 
of start in midazolam vs clonidine group: 4 hours (Q1-Q3: 1–6) vs 12 hours (Q1-Q3: 5–23); 
p = 0.010). PICU stay was shorter in clonidine group compared to midazolam group: 5 
days (Q1-Q3: 3–7) compared to 10 days (Q1-Q3: 4–13); p = 0.036.
Sedation and analgesia
Table 3 describes level of sedation and sedatives and analgesics in the clonidine group. 
Clonidine infusion rate was 0.5–2mcg/kg/h, with a median total dose of 21.5 mcg/kg 
(Q1-Q3: 11–55.5) and duration 30 hours (Q1-Q3: 12–54). 52 % of patients received a bolus 
dose prior to commencement of infusion (median dose: 1.5 mcg/kg (Q1-Q3: 1.0–2.2). 
The median delay between bolus and infusion was 3 hours (Q1-Q3: 0–4). No other seda-
tive was used prior to clonidine but 3 patients received midazolam while on clonidine 
(3 received boluses and in one patient, the bolus was followed by an infusion). All bolus 
doses were within the range recommended in the protocol, but infusion rates were 
Table 2: Cardiac pathologies in clonidine group
Pathology n
Arterial switch operation
•	 with	intact	ventricular	septum  5
•	 with	VSD	repair 2
Repair of truncus arteriosus 1
VSD, ASD closure 4
Complete AVSD repair
•	 simple	 1 
•	 unbalanced	with	pulmonary	atresia	and	TAPVD	 1 
Modified BT shunt 4
Tetralogy of Fallot and aortic arch repair 1
Aortic valve repair 1
Complete repair TAPVD 1
End to side repair of coarctation of the aorta 2
Abbreviations of cardiac anomalies: ASD : Atrial septal defect ; AVSD : Atrio-ventricular septal defect ; BT 
shunt: Blalock-Taussig shunt; TAPVD : Total anomalous pulmonary venous drainage ; VSD : Ventricular septal 
defect
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Table 3: Sedation scores, analgesics, sedatives and neuromuscular blockers
LEVEL OF SEDATION
Mean COMFORT-b score Mean (SD)
Before clonidine (up to 4h before) (n = 10) 11.3 (9.5–52)
After clonidine (until end of infusion) (n = 10) 11.3 (10.5–53.2); p = 0.51
Level of sedation during 72h # (total number of observations = 283)
Oversedation (COMFORT-B< 10) 79 (27.9 %)
Optimal sedation (COMFORT-B 10–00) 180 (63.6 %)
Undersedation (COMFORT-B > 20) 24 (8.5 %)
During clonidine infusion: patients with at least one episode of:
Oversedation (COMFORT-B< 10) 13 (56.5 %)
Optimal sedation (COMFORT-B 10–00) 19 (82.6 %)
Undersedation (COMFORT-B > 20) 6 (26.1 %)
bOLUS OF ANALGESICS, SEDATIVES AND NEUROMUSCULAR bLOCKERS
Total dose per patient for 72h, Median (Q1-Q3)
Morphine (mg/kg) 0.9 (0.6–6.4) 
Fentanyl (mcg/kg) 5.2 (0–02.8)
Clonidine (mcg/kg) 0.8 (0–0.4)
Vecuronium (mg/kg) 0.3 (0–0.7)
Bolus, number of patients exposed during 72h, n (%)
Morphine 23 (100 %)
Fentanyl 13 (56.5 %)
Clonidine 13 (56.5 %)
Vecuronium 17 (73.9 %)
CLONIDINE bOLUS AND INFUSION
bolus clonidine at infusion start
Number of patient exposed, n (%) 12 (52.2 %)
Delay between bolus and infusion, hours 3 (0–0)
Dose of bolus, mcg/kg 1.5 (1.0–0.2)
Clonidine infusion
Rate 0.5–5 mcg/kg/h
Start (h after surgery), Mean (SD) 18.2 (10.8)
Duration (hours), Median (Q1-Q3) 30 (12–24)
Maximal duration of infusion 290 hours
Number of patient with infusion > 72 hours, n (%) 3 (13.0 %)
Total dose (mcg/kg), Median (Q1-Q3) 21.5 (11–15.5)
# Data on level of sedation during 72 hours have been calculated on the total number of observations 
(n = 283).
Normally distributed data were analyzed by paired t-test and reported with mean (SD).
Non-normally distributed data are expressed by median (Q1-Q3).
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higher in 3 patients: 2 had morphine infusions 50–60 mcg/kg/h and 1 patient received 
3mcg/kg/h of clonidine. Mean COMFORT-B score did not change after clonidine infusion.
Hemodynamic tolerance
Figure 1 shows the trend of heart rate (HR), systolic and diastolic blood pressure (SBP and 
DBP) and the central venous pressure (CVP). HR was significantly lower than baseline 
from 12 to 48 hours after clonidine start. Maximal decrease in heart rate corresponded 
to a mean 12 % decrease from baseline (from 149 bpm (SD17) to 131 bpm (SD17) at 48 
hours (p  <  0.0001)). There were no significant changes in systolic blood pressure and 
CVP after clonidine start. Diastolic BP was slightly lower than baseline at 36 and 48 hours 
after clonidine start (maximal decrease from baseline mean 42.8mmHg (SD5.9) to mean 
37.1 mmHg (SD4.0) at 48 hours; p = 0.018). Figure 2 shows that urine output increased 
during clonidine infusion, while the amount of fluid bolus administration, left atrial pres-
sure and VIS did not change.
ScvO2 showed a favourable trend (from 53.7 (10.8) at baseline to 58.9 (6.1) in the 24 
hours following clonidine start, n = 12, p = 0.14) and lactate decreased (from median 
1.7 mmol/L (Q1-Q3: 1.2–2.1) at baseline (n = 23) to 1.2 mmol/L (Q1-Q3: 1–1.3) 12 hours 
following clonidine start (n = 17), p = 0.002).
Figure 1: Effect of clonidine infusion on Heart rate (beat per minute) and systolic, diastolic blood pressure 
and central venous pressure (mmHg) compared to baseline value (start of clonidine).
Mean values and significant p-values are indicated.
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Comparison of cardiovascular parameters in clonidine and midazolam groups
As shown in Figure 3, the clonidine and midazolam groups had similar heart rate on PICU 
admission but thereafter heart rate of the clonidine group decreased gradually. Systolic and 
diastolic blood pressures were higher in the clonidine group compared to the midazolam 
group. VIS score and the amount of fluid bolus received (Figure 4) were lower in the cloni-
dine group. The serum lactate level was not statistically different between the 2 groups.
Adverse events
There were no instances of accidental extubation, cardiac arrest, ECMO or death. One patient 
(7 weeks old, recovering from ventricular septal defect and aortic valve repair) had clonidine 
ceased because of sinus bradycardia. Clonidine was stopped on post-operative day 3 after 35 
hours of infusion (total clonidine dose: 39.5 mcg/kg, no bolus) when the heart rate fell to 100 
beats per minute. 24 hours later he was temporarily at his backup atrial pacing rate of 80 bpm 
and was discharged from the PICU. This patient had ongoing well-tolerated sinus bradycardia 
for 5 days after cessation of clonidine infusion. The pacemaker was removed at day 7 after sur-
gery when a Holter showed a sinus bradycardia with a minimal heart rate of 80 bpm. His renal 
and liver functions were similar to the other patient’s values (maximal creatinine: 52 mmol/L 
(normal values: 15–33) and alanine aminotransferase (ALT): 49 U/L (Normal values: 12–45)).
Figure 2: Effect of clonidine on fluid boluses, vasoactive inotropic score, urine output and Left Arterial Pres-
sure (LAP) compared to baseline value (start of clonidine).
Mean values and significant p-values are indicated.
LAP was measured in 11 patients
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Figure 3: Comparison of clonidine and midazolam groups: Heart rate (beat per minute) and systolic, dia-
stolic blood pressure (mmHg) and vasoactive inotropic score 
Mean values and p-values are indicated.
Figure 4: Comparison of clonidine and midazolam groups: lactate and fluid bolus
Mean values and p-values are indicated.
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DISCUSSION
This is the first study reporting the use of intravenous clonidine for analgosedation after 
neonatal cardiac surgery and the first to include unstable patients. A maximal decrease in 
heart rate of 12 % followed the start of clonidine. Cardiac output is directly proportional 
to heart rate. However, apart from the transient and limited decrease in diastolic blood 
pressure, no deterioration in markers of cardiac output was noted: systolic blood pres-
sure, vasoactive inotropic score, central and left atrial pressure and filling requirements 
remained stable while urine output increased. Laboratory markers were favourable: 
ScvO2 showed a trend toward improvement and serum lactate decreased. These data 
suggest that clonidine was well tolerated. However they do not distinguish between the 
hemodynamic effects of clonidine and the expected recovery following cardiac surgery.
The comparison with the midazolam group suggests that the gradual decrease in 
heart rate in the clonidine group was well tolerated: despite progressive bradycardia, 
blood pressure remained higher than in the midazolam group while inotrope score and 
the amount of administered fluid bolus remained lower. However, the different cardio-
vascular parameters of the midazolam group could also indicate more severe disease. 
Duffett et al. recently conducted a survey on factors influencing treatment choice in 
the PICU (23) and showed that published guidelines have less influence than severity of 
illness, physiologic rationale and potential for adverse effects. As the use of clonidine in 
this fragile population had not been previously reported, concerns about bradycardia 
and hypotension in unstable patients may have motivated protocol deviation. The same 
reason may explain why only half of the patients received a bolus of clonidine. Despite 
these limitations in interpretation of the data, our study suggests that clonidine is well 
tolerated after heart surgery in this high-risk population and should encourage study 
with a prospective design and a control group.
The mean COMFORT-B score did not change after starting the infusion. The mean 
COMFORT-B score of 11.3 pre and post-infusion suggest that rather deep sedation was 
targeted. Clonidine was probably needed to ensure adequate sedation after weaning 
from the remaining effect of high-dose opioid anesthesia.
Two previous studies report the use of clonidine for sedation after cardiac surgery (2, 
15). The change in hemodynamic variables described in our study contradicts the data 
from both studies that reported stable cardiovascular parameters.
Ambrose et al. documented hemodynamic tolerance in 10 stable patients during 6 
hours of clonidine infusion started 2 hours after cardiac surgery (2). Cardiac index, heart 
rate and blood pressure remained stable while in our cohort heart rate and diastolic 
blood pressure decreased. Our results may differ for several reasons. First, this earlier 
study used a fixed infusion rate of 1mcg/kg/h without bolus for 6 hours, whereas in 
our study clonidine was titrated up to 2mcg/kg/h for a median duration of 30 hours 
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and 52 % of patients received a bolus. Less than half of steady state concentration is 
expected from the limited duration of infusion (6 hours) relative to clonidine’s half-life 
(9 hours (19)). Second, age-related clonidine clearance may be different (18, 19, 24) but 
the age of the cardiac patients in the study by Ambrose et al. was not specified. Finally, 
only patients with stable or decreasing inotropic requirements were included while our 
study included all patients.
The second study by Arenas-Lopez et al. reported pharmacokinetics and cardiovascu-
lar stability in 16 infants aged one month to one year. No change in hemodynamics was 
noted after a single oral dose of clonidine (3mcg/kg) administered 2–6 hours after heart 
surgery. The difference in route of administration and dosing probably account for the 
absence of cardiovascular change. Taking the dosing and bioavailability into account 
(around 50 % oral bioavailability (25)), our patients received more than 10 times greater 
total doses. Moreover, each patient reached maximal serum clonidine concentration 
at different times due to the wide variability in absorption, thus making any effect on 
hemodynamics more difficult to detect. Finally, patients in that study were older, more 
stable and had undergone less complex surgeries; a population that is less likely to 
experience adverse cardiovascular effects.
Recently, three randomized, controlled trials of clonidine in the PICU have been 
published (14, 24, 26), all reporting hemodynamic tolerance as a secondary outcome. 
The first compared the opioid and sedative sparing effect of placebo versus clonidine 
(fixed dose of 1 mcg/kg/h; median duration: 168 hours) in ventilated medical and 
surgical patients (24). While children up to 2 years old were included, this trial demon-
strated decreased sedative and analgesic requirements only in neonates. A mild and 
well-tolerated decrease systolic and mean blood pressure was observed in the clonidine 
group compared to placebo but heart rate was similar between groups. The second trial 
(26) was a pilot study aiming to assess the feasibility of a multicentre trial comparing the 
opioid and benzodiazepine sparing effects of oral clonidine (5mcg/kg every 6 hours) 
to placebo. After inclusion of 50 ventilated patients (1 month to 18 years), the authors 
concluded that a large trial aiming to show major outcome differences (e.g duration 
of mechanical ventilation) was feasible. The incidence of significant hypotension and 
bradycardia was similar between groups. The third trial, the SLEEPS study, compared 
the efficacy of clonidine (0.75–3 μg/kg/hour) and midazolam (50–200 μg/kg/hour) for 
sedation in ventilated children (1 month-15 years)(14). Despite the recruitment of 129 
children instead of 1000 planned, it showed non-inferiority of clonidine to midazolam. In 
the clonidine group, one patient developed profound self-resoluting bradycardia with-
out hypotension. The incidence of hypotension was similar between groups. This trial 
included patients likely to require > 12 hours of mechanical ventilation among whom 
patients after cardiac surgery. But newborns, patients with delayed sternal closure and 
those needing of neuro-muscular blocking agents were excluded while they represent, 
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65 %, 22 % and 74 % of our population respectively. Therefore, our study reports sedation 
with clonidine in the youngest and most unstable population studied to this point.
The occurrence of significant sinus bradycardia in a patient who required temporary 
cardiac pacing warrants caution, as this is a known adverse event of clonidine. A causal-
ity link cannot be formally discarded but appears very unlikely. Five days after having 
stopped the clonidine, theoretically allowing complete clearance of the drug, Holter 
monitoring showed maximal decrease in HR to 80 bpm. No significant rhythm anomaly 
has been documented in studies reporting clonidine use in the PICU (2, 8, 15, 24, 26, 27).
The occurrence of a well-tolerated decrease in heart rate with clonidine following 
cardiac surgery is similar to the effect reported with dexmedetomidine under similar 
circumstances. Clonidine has a similar pharmacodynamic profile to dexmedetomidine 
(4) but is much cheaper (28), which drives the continued use of clonidine in many 
institutions. However dexmedetomidine is favoured over clonidine after heart surgery 
due to the paucity of data on clonidine in this setting and a potential concern about 
clonidine’s pharmacokinetic profile. The half-life of clonidine is much longer than that of 
dexmedetomidine (9 hours vs 2.4 hours, respectively in children (29)) and unlike dexme-
detomidine, its clearance is decreased in renal failure (30). Hence, potential dose-related 
adverse cardiovascular effects may linger longer than with dexmedetomidine which is 
excreted more rapidly. Whether these theoretical concerns really translate into different 
safety profile of these drugs remains to be determined.
The drop in heart rate reported with dexmedetomidine is more pronounced than with 
clonidine (maximal drop in the current study 12 % vs 13–18 % with dexmedethomidine 
(6, 11, 31)). The reported effect of dexmedetomidine on blood pressure and doses of 
inotropic and vasoactive drugs has been variable (6, 7, 11, 12, 31). Expect from brady-
cardia, no rhythm anomalies were reported in the clonidine group. Absence of rhythm 
disturbance with dexmedetomidine has been systematically studied: Chrysostomou 
et al. analysed changes in ECG interval patterns in 51 children on dexmedetomidine 
infusions and did not find any change apart from the expected decrease in HR (32). 
Moreover, dexmedetomidine after cardiac surgery decreased the incidence of ventricu-
lar and supraventricular tachyarrythmias compared to fentanyl (31). As clonidine has 
similar pharmacodynamics to dexmedetomidine, it may also decrease the incidence of 
arrhythmia but, to date, no study has investigated this effect.
Our study has several limitations. First, it has the inherent limitations of a retrospective 
study and involves a limited number of patients. The observations were recorded hourly 
on paper charts and therefore transient cardiovascular changes may have been missed. 
Moreover, the hemodynamic effect of clonidine boluses could not be differentiated from 
the overall hemodynamic course. In addition, the data suggest that some of the more 
unstable patients were treated with midazolam instead of clonidine. This precludes 
any robust conclusion about safety. The good cardiovascular tolerance inferred from 
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markers of cardiac output does not rule out a decrease in cardiac output. Our study is 
based on “bed-side” tools used by the clinician to get an approximation of adequacy of 
cardiac output, but more direct measurements are lacking. Half of the patients received 
clonidine within 12 hours after surgery. However, a significant proportion would not 
have achieved maximal concentration within the first 12 hours after surgery, when the 
decrease in cardiac output is most pronounced. Despite these limitations, this study 
reports clonidine use at relatively high doses in the most unstable population studied to 
date and known to have decreased drug clearance. Reporting a favourable cardiovascu-
lar profile in this vulnerable population provides useful information about the off-label 
use of clonidine.
CONCLUSION
Intravenous clonidine as a sedative added to morphine in selected patients appears 
hemodynamically safe. The observed decrease in heart rate and diastolic blood pressure 
seem of minimal clinical importance as all other hemodynamic parameters remained 
stable or improved. The safety of clonidine sedation early after infant pediatric cardiac 
surgery as an alternative to midazolam merits further investigation.
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Quand on parle d’un enfant, on n’exprime jamais l’objet lui-même; 
mais l’espoir que l’on fonde en lui.
Johann Wolfgang von Goethe
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AbSTRACT
Objective:
Clonidine is an antihypertensive drug used for analgo-sedation in the pediatric inten-
sive care unit. Lack of reliable data on its hemodynamic tolerance limits its use. This 
study explores the hemodynamic tolerance of intravenous clonidine infusion in a broad 
population of children with high severity of disease.
Design:
Retrospective analysis of prospectively collected data.
Setting:
A tertiary and quaternary referral PICU
Patients:
Critically ill children aged 0–18 years who received an IV clonidine infusion for analgo-
sedation of at least one hour.
Interventions:
None
Measurement and Main results:
The primary endpoints were incidence of bradycardia and hypotension. Secondary 
endpoints were changes in heart rate, blood pressure, vasoactive inotropic score, COM-
FORT-b score and body temperature during the infusion. The association of bradycardia 
with other hemodynamic parameters was explored, as well as potential risk factors for 
severe bradycardia.
186 children (median age 12.9 month (IQR: 3.5–60.6)) years and receiving a maximum 
median clonidine infusion of 0.7 mcg/kg/h (IQR: 0.3–1.5) were included. Severe brady-
cardia and systolic hypotension occurred in 72 patients (40.2 %) and 105 patients (58 %) 
respectively. Clonidine-associated bradycardia was hemodynamically well-tolerated, as 
it was not related with hypotension and the need for vasoactive drugs decreased in 
parallel with a sedation score guided clonidine infusion rate increase. Younger age was 
the only identified risk factor for clonidine-associated bradycardia.
Conclusion:
Although administration of clonidine is often associated with bradycardia and hypoten-
sion, these complications do not seem clinically significant in a mixed PICU population with 
a high degree of disease severity. Clonidine may have a vasoactive-inotropic sparing effect.
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INTRODUCTION
Clonidine is licensed as an antihypertensive drug but is increasingly used off-label 
as analgo-sedative in the pediatric intensive care unit (PICU) (1, 2). The benefits of 
clonidine are that it does neither induce respiratory depression nor neurotoxicity (3). 
Because critical illness influences oral absorption of drugs, intravenous administration 
is favoured when reliable sedation is crucial (4). Clonidine can induce hypotension and 
bradycardia mainly by inhibiting cardiac and vascular sympathetic activities (5). For this 
reason, many physicians are reluctant to use clonidine, especially in less stable patients 
(6). As around half of clonidine is renally excreted and the other half is metabolized by 
the liver, the frequently occurring renal and hepatic failure in critically ill patients may 
lead to higher blood levels and likely more adverse hemodynamic events (7, 8).
To our knowledge, three studies have reported hemodynamic tolerance to clonidine as 
a primary outcome in the PICU (1, 9, 10). All focused solely on neonates and infants after 
heart surgery and only one included hemodynamically unstable patients (1). Clonidine 
was hemodynamically well tolerated in spite of its possibly hypotensive effect. Three 
randomized controlled trials (RCTs) reported hemodynamic tolerance as a secondary 
outcome but included only hemodynamically stable patients (11) with low disease 
severity (6, 11) or on fixed and relatively low dose of clonidine (1mcg/kg/h without 
loading dose (2) or 5mcg/kg every 6 hours oral (11)). Good hemodynamic tolerance was 
generally reported but the only RCT reporting inotropic needs showed increased needs 
of inotropes with clonidine compared to midazolam in a population with low severity of 
disease (6). This observation suggests that clonidine may not be hemodynamically well 
tolerated in more unstable patients. Indeed, trial conditions differ greatly from the com-
mon clinical use of clonidine administered as a second or third line sedative in patients 
with high severity of disease and with titration to a maximal infusion rate of 2 mcg/kg/h.
Therefore, the aims of the present study were to determine the incidence and severity 
of bradycardia and hypotension during a clonidine infusion used as an adjunctive seda-
tive agent in a mixed population of PICU patients, to assess the risk factors of bradycardia 
and to identify the relation of clonidine-associated bradycardia with blood pressure and 
need for inotropes.
MATERIALS AND METHODS
Study design and setting
This is a retrospective cohort study used prospectively collected clinical data of patients 
admitted to the PICU of the Erasmus-MC Sophia Children’s Hospital in Rotterdam be-
tween January 2011 and July 2014. The institutional ethics review committee waived the 
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need for approval and informed consent, according to the Dutch law on Human Medical 
Research.
Patients
All patients who received an infusion of clonidine of at least one hour were eligible. 
Exclusion criteria were clonidine infusion received during ECMO, active cardiac pacing 
and palliative care.
Current clinical care
The analgesia and sedation protocol used in our unit is nurse-led. Nurses titrate analge-
sic and sedative infusions according to this protocol on the guidance of the COMFORT 
behavior scale (COMFORT-b) and the Nurse Interpretation of Sedation Score (NISS), 
which both have been validated for use in the PICU (12–15). COMFORT-b score ranges 
from 6 to 30 (adequate sedation: 11–22; oversedation: < 11; undersedation: > 22) (12). 
Inter-observer variability among nurses is satisfactory (Cohen’s κ > 0.65) (12). Midazolam 
is titrated first (up to 300 μg/kg/h); morphine is added in case of undersedation (up to 30 
μg/kg/h) and clonidine is added if adequate sedation is still not achieved. At the physi-
cian’s discretion, clonidine boluses (1–2 mcg/kg) are given at infusion start or when the 
infusion rate is increased due to breakthrough distress. Clonidine continuous infusion 
is started at 0.5–1 mcg/kg/h and uptitrated to 2 mcg/kg/h when needed. Other second 
line sedatives include esketamine, propofol and phenobarbital.
Primary outcomes
The primary outcomes were the incidences of bradycardia and hypotension during a 
clonidine infusion.
Bradycardia was defined as a time-weighted average heart rate (twa_HR) below the 
normal values for age (16) during three consecutive hours accompanied by a decrease 
in HR of at least 10 % compared to the pre-infusion value. The pre-infusion value was 
defined as twa_HR during 4 hours prior to the first clonidine administration (infusion or 
first bolus). Time-weighted average corresponds to an area under the curve and is there-
fore more precise than the unweighted average because it is adjusted for the variation 
in time interval between consecutively measured values. Bradycardia was categorized 
as severe when twa_HR was below the 1st percentile (P1) and as moderate when twa_HR 
was below the 10th percentile (P10) (16).
Similarly, hypotension was defined as a time weighted average value of systolic blood 
pressure (twa_SBP) (17) or mean blood pressure below P5 (twa_MBP) during one hour 
(18).
Occurrences of bradycardia and hypotension were studied during a maximum of 7 
days from start of the clonidine infusion.
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Secondary outcomes
Change in clinical parameters after clonidine start
The hemodynamic tolerance to a clonidine infusion was also determined by delineating 
the trend in the following parameters after infusion start:
•	 Blood	pressure	(BP)
•	 Vasoactive-inotropic	score	(VIS)
Moreover, the following parameters were determined:
•	 COMFORT-b	score
•	 Temperature
Pre-infusion values of these parameters were compared to values at six time points: 1, 
6, 12, 24, 72 and 168 hours after infusion start.
risk factors for severe bradycardia
The following risk factors were tested:
•	 Clonidine associated factors: maximal infusion rate and the use of a bolus dose at 
infusion start
•	 Patient-associated factors: age, PELOD 2 score (19), diagnosis and creatinine 
z-score (adjusted for sex and age-related changes in absolute creatinine concentra-
tions (20-22)).
relation of clonidine-associated severe bradycardia with blood pressure and need 
for inotropes and other clinical parameters.
Each patient’s first episode of severe bradycardia (HR<P1) was determined. This was 
considered to have started at the moment when the first hourly HR value was below P10 
and to have ended when the hourly HR value was higher than P10.
Values of BP, VIS, COMFORT-b and temperature at the start of this first episode were 
compared to values at four time points during severe bradycardia: 1, 6, 12, 24 hours. 
As bradycardic episodes lasted shorter than the duration of infusion, this outcome was 
studied until 24 hours or until the end of the first bradycardic episode.
Data collection
Data were retrieved from the patient data management system that prospectively stores 
real-time data of all parameters: HR, BP, temperature and COMFORT-B scores. All admin-
istered drugs – including vasoactive and inotropic drugs, analgesics and sedatives – are 
recorded with dosing and exact administration time. VIS was calculated from real-time 
infusion data as previously described: 1*(dopamine+dobutamine (mcg/kg/min)) + 
10*milrinone (mcg/kg/min) + 100*(epinephrine + norepinephrine (mcg/kg/min)) + 
10000*vasopressin (U/kg/min) (23). Every clonidine dose received before infusion start 
until one hour after was considered a bolus. Clonidine plasma levels were not measured.
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Statistics
Continuous variables are summarized as means ± SD for normally distributed variables 
and as medians and interquartile ranges (IQR) for non-normally distributed variables. 
Categorical variables are summarized as percentages.
To determine the hemodynamic consequences of the clonidine infusion, pre-infusion 
values of HR, BP, VIS, COMFORT-b score, temperature and clonidine infusion rate were 
compared to post-infusion values using linear mixed models. The dependent variables 
in these models were the combined pre-infusion and post-infusion values of these 
parameters; the independent variable was the time point (coded as a categorical vari-
able). A separate linear mixed model was estimated for each dependent variable, and 
a random intercept was included to account for the within-subject correlations. The 
results of the linear mixed models are summarized using the estimated marginal means, 
which are the predicted values of the dependent variable adjusted for the effect of the 
independent variable and missing observations in the dependent variable, as well as the 
associated 95 % confidence intervals (CIs).
Risk factors related to severe bradycardia were delineated in multivariable logistic 
regression analysis. The independent variables studied were maximal clonidine infusion 
rate, bolus of clonidine at infusion start, PELOD score, creatinine z-score, diagnosis (sur-
gical or medical) and age. Z-score of creatinine was determined for each value according 
to the age (20–22). When no creatinine value was available, a z-score of 0 was assumed. 
The p-value of the Hosmer and Lemeshow test was 0.275.
A similar analysis using linear mixed models was performed to study the trends of HR, 
BP, VIS COMFORT-b score, temperature and clonidine infusion rate during bradycardia. 
The association between occurrence of bradycardia and the presence of an arterial line 
was explored using a chi-square test. This test was also used to assess the association 
between the occurrence of bradycardia and hypotension.
All data management procedures were programmed in R (24), and all statistical meth-
ods were performed in SPSS. All statistical tests used a two-sided significance level of 
0.05.
RESULTS
Patients
As detailed in Figure 1, of 226 eligible patients, 40 were excluded, leaving a total of 186 
patients whose data were analyzed. Demographics and clonidine infusion details are 
described in table 1.
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Primary outcomes
Incidences of bradycardia and hypotension
For 8 patients no pre-infusion HR values were available. Of the remaining 179 patients, 
115 (64.3 %) experienced bradycardia (twa_HR P10), which was severe (twa_HR P1) in 
72 (40.2 %). Severe bradycardia started at a mean infusion rate of 0.6 mcg/kg/hour (95 % 
CI: 0.4–0.7). Of the 181 patients for whom hypotension information was available, 105 
(58 %) and 90 (49.7 %) had hypotension (twa_BP P10) based on SBP and MBP, respectively. 
The proportion of patients with an invasive BP measurement did not differ between 
bradycardic and non-bradycardic patients (Figure 1).
Secondary outcomes
Change in clinical parameters after clonidine start
HR, BP, VIS and COMFORT-b all significantly decreased while body temperature increased 
after clonidine infusion start (Figure 2). Table 2 details the maximum changes in each 
parameter presented in Figure  2 with their respective timings after infusion start. As 
soon as one hour after infusion start, COMFORT-b score had decreased from 17.1 (95 % 
CI: 15.8–18.5) to 13.7 (95 % CI: 12.2–15.1), p = 0.001.
Figure 1: Patient inclusion flow chart
Number of eligible patients and reasons for exclusion are described. The numbers of remaining patients 
at different time-points during clonidine infusion are detailed. Patients are then divided into two groups 
according to the presence/absence of severe bradycardia. Each group is then further divided according to 
the presence of an arterial line for continuous blood pressure monitoring.
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risk factors associated with severe bradycardia
Age was the only risk factor significantly associated with severe bradycardia (OR 0.74 
[95 % CI: 0.64–0.85]; p < 0.0001) (Table 3 Supplemental Material).
relation of clonidine-associated severe bradycardia with blood pressure, need for 
inotropes and other clinical parameters
In patients who at some point had severe bradycardia, SBP remained stable during the 
episode, despite a maximal decrease in HR of 17 %, while MBP and DBP had decreased 
only slightly and the VIS had decreased by 19.3 % at 6 hours (Figure 3). COMFORT-B score 
and temperature had decreased at one hour after bradycardia start but then increased 
again to stabilize at pre-bradycardia values. Table 2 details the maximal changes in each 
parameter with their respective timings.
Table 1 Patient’s characteristics and treatment (n = 186)
Patient’s characteristics and treatment Value
Age (month) 12.9 (3.5–50.6)
Weight (kg) 9.6 (4.7–78)
Sex, male; n (%) 99 (53.2 %)
Mortality rate; n (%) 15 (8 %)
Duration of PICU stay, days 10.5 (5–58).
PELOD II 5 (3–3)
PIM II predicted death rate 3.1 (1.3–3.2)
PRISM II 19 (11–16)
Diagnostic; n (%)
•	 Surgical 92 (51.7 %)
•	 Medical 86 (48.3 %)
Clonidine use
•	 Duration	of	PICU	stay	at	infusion	start,	days 2 (1–1)
•	 Duration	of	infusion,	hours 61.8 (24.7–754.8)
•	 Bolus	at	infusion	start,	n	(%) 124 (69.3 %)
•	 Maximal	infusion	rate 0.7 (0.3–3.5)
Laboratory values at infusion start
•	 Urea* 5.1 (3.2–2.6)
•	 Creatinine	(μmol/L)* 30 (20–01)
•	 ALT	(IU/L)** 23 (14–42)
•	 CRP	(n	=	135)# 41 (11–17)
Values are expressed as median and (Q1-Q3) unless specified otherwise
* n = 161; **=n = 114; # n = 135
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Figure 2:  HR, BP, VIS, level of sedation, temperature and clonidine infusion rate after 
start of clonidine infusion 
 
Estimated marginal means with their corresponding standard error based on the linear mixed 
model are reported. Time 0 corresponds to the beginning of the clonidine infusion (or loading 
dose whatever is first). 
Values were compared at six time-points after clonidine start: 1, 6, 12, 24, 72 and 168 hours. 
*= p-value: 0.05-0.01; **= p-value: 0.01-0.001; ***= p-value: <0.001 
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Figure 2: HR, BP, VIS, level of sedation, temperature and clonidine infusion rate after start of clonidine infusion
Estimated marginal means with their corresponding standard error based on the linear mixed model are 
reported. Time 0 corresponds to the beginning of the clonidine infusion (or loading dose whatever is first).
Values were compared at six time-points after clonidine start: 1, 6, 12, 24, 72 and 168 hours.
*= p-value: 0.05–5.01; **= p-value: 0.01–1.001; ***= p-value: < 0.001
Table 2 : Incidence of bradycardia and hypotension during an infusion of clonidine
Incidence of hemodynamic events : n %
- bRADYCARDIA (n = 179**)
Moderate bradycardia* 115 64.3
Severe bradycardia* 72 40.2
- HYPOTENSION (n = 181#)
Systolic Blood Pressure 105 58
Mean Blood Pressure 90 49.7
* A patient was considered bradycardic it his average hourly heart rate (HR) value for age was < P1 (severe 
bradycardia) or P10 (moderate bradycardia) during 3 consecutive hours (16) and that it had decreased by 
at least 10 % compared to preinfusion value.
** = 7 patients had missing pre-infusion HR value ; # = 5 patients had missing BP pre-infusion value 
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Figure 3:  Relation of clonidine-associated severe bradycardia with BP, VIS, level of 
sedation, temperature and clonidine infusion rate 
 
Estimated marginal means with their corresponding standard error based on the linear mixed 
model are reported. The first episode of severe bradycardia (HR<P1) was determined for each 
patient. Start of this episode (time 0) was defined as the first hourly HR value below P10; the 
end when the hourly HR value was higher than P10.  
0 6 12 18 24
80
90
100
110
120
130
HR
 (b
pm
)
***
*** ***
***
0 6 12 18 24
32
34
36
38
40
42
Duration of Bradycardia (hour)
Te
m
pe
ra
tu
re
 (°
C
)
*
0 6 12 18 24
0
5
10
15
20
CO
M
FO
R
T-
b 
sc
or
e
*
0 6 12 18 24
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Duration of Bradycardia (hour)
Cl
on
id
in
e 
in
fu
si
on
 ra
te
 (m
cg
/k
g/
h)
*
**
0 6 12 18 24
40
60
80
100
BP
 (m
m
Hg
) 
systolic
mean
diastolic
**
**
0 6 12 18 24
0
5
10
15
VI
S
*
Figure 3: Relation of clonidine-associated severe bradycardia with BP, VIS, level of sedation, temperature 
and clonidine infusion rat
Estimated marginal means with their corresponding standard error based on the linear mixed model are report-
ed. The first episode of severe bradycardia (HR<P1) was determined for each patient. Start of this episode (time 
0) was defined as the first hourly HR value below P10; the end when the hourly HR value was higher than P10.
Values were compared at four time-points during severe bradycardia: 1, 6, 12 and 24 hours.
*= p-value: 0.05–5.01; **= p-value: 0.01–1.001; ***= p-value: < 0.001
Table 3 : Risk factors associated to severe bradycardia : Logistic regression analysis
Variables* OR [95 %CI] p-value
Clonidine-related
Maximal infusion rate (mcg/kg/hour) 1,20 [0,72–2,01] 0,49
Bolus at infusion start (presence of absence) 0,78 [0,36–6,67] 0,52
Patient-related
Age (years) 0,74 [0,64–4,85] < 0.0001
Diagnosis (surgical or medical) 0,67 [0,34–4,35] 0,27
Creatinine (z-score) 0,94 [0,86–6,03] 0,16
PELOD 2 score 1,04 [0,91–1,19] 0,54
*= The Hosmer and Lemeshow test was used to assess the goodness of fit of the logistic regression (p-
value = 0.28)
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In addition, MBP and SBP hypotension were unrelated to the occurrence of severe 
bradycardia. MBP hypotension was found in 53.5 % of patients with severe bradycardia 
(p = 0.56); SBP hypotension in 63.4 % (p = 0.30).
DISCUSSION
This study is the first to document the incidences, clinical consequences and risk factors 
of bradycardia and hypotension in PICU patients with high disease severity (8 % mor-
tality rate) receiving a prolonged intravenous clonidine infusion for analgo-sedation. 
Severe bradycardia and systolic hypotension occurred in 40 % and more than 50 % of the 
patients, respectively. Younger age proved a risk factor for clonidine-associated brady-
cardia. Surprisingly, these complications do not appear to compromise hemodynamics 
as severe bradycardia was unrelated with hypotension, and the need for vasoactive 
drugs decreased with time in parallel with an increase in the clonidine infusion rate.
Good hemodynamic tolerance to clonidine has previously been shown in children 
under the age of 1 year after heart surgery in studies with sample sizes ranging from 
10 to 50 (9) (1) (10) , of which only one included unstable patients (1). The current study 
broadens this finding to a wide mixed PICU population with high severity of illness and 
adds useful information to the off-label use of clonidine.
Three RCTs (2, 11, 25, 26) have reported on the hemodynamic tolerance to clonidine 
as a secondary outcome in a mixed PICU population. One (2) compared the opioid and 
sedative-sparing properties of clonidine versus placebo in 201 ventilated infants and 
demonstrated decreased sedative and analgesic requirements. HR was similar between 
groups while SBP and MBP decreased slightly in the clonidine group. Yet, hemodynamic 
tolerance could not be inferred from this study as the infants received a fixed low dose of 
clonidine (1 μg/kg/h) without loading dose (> 24h to reach steady-state concentrations 
(27)) while common clinical dosing implies the use of a loading dose and titration to 
higher infusion rates.
A second RCT concerned a pilot study on opioid and benzodiazepine sparing effects 
of oral clonidine in 50 ventilated patients (1 month-18 years) (28). The frequencies of 
hypotension and bradycardia did not differ between the clonidine group and a placebo 
group. Again, this finding cannot be generalised to the general PICU population as 
patients on inotropes were excluded and relatively low doses were administered (5 μg/
kg every 6 hr orally, 50 % oral bioavailability, equals approximately 0.4 mcg/kg/h IV infu-
sion).
A third RCT, the SLEEPS study, compared the sedative properties of clonidine (0.75–3 
μg/kg/hr) to midazolam (50–200 μg/kg/hr) in ventilated children (1 month-15 years). As 
recruitment proved difficult the study was severely underpowered (129 subjects instead 
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of the 1000 planned). The incidences of hypotension and bradycardia were similar 
between groups. Of note, and in contrast to what we found, the patients on clonidine 
consumed more inotropes during the first 12 hours than did patients on midazolam. 
This discrepancy cannot be attributed to the severity of disease as our population had 
a 10 times higher mortality rate. It may be explained perhaps by the higher loading (3 
versus 2μg/kg in the current study) and starting infusion doses in the SLEEPS study (1.5 
versus 0.3 mcg/kg/h in the current study). These results suggest that starting at low dose 
and titrating according to hemodynamic tolerance may be safer in unstable patients.
Bradycardia is often a concern because cardiac output is directly proportional to HR. 
Still, the good hemodynamic tolerance reported in this study and others suggests that 
compensating mechanisms may play a role. Decreasing HR may increase stroke volume 
and improve force-frequency relation (29). Moreover, a clonidine-associated blood 
pressure decrease may favour cardiac output by reducing afterload. Clonidine has been 
shown to suppress sympathetic hyperactivity (30) and to decrease oxygen consumption 
(31, 32). These mechanisms may compensate for the potential detrimental effect of HR 
decrease on cardiac output.
Interestingly, in our study the VIS decreased after clonidine start, suggesting that 
lower doses of inotropic and vasopressors drugs were administered. Similarly, adults 
undergoing general anesthesia and premedicated with clonidine had a higher BP re-
sponse to vasopressors compared to a placebo group (33, 34). Recent animal studies 
(30) and case-reports have reported successful restoration of pressor responsiveness 
with clonidine in refractory septic shock (35). It was postulated that sepsis-associated 
sympathetic overactivation and consequent catecholamine increase downregulates 
α1-receptors leading to vascular hyporesponsiveness restored by the clonidine sympa-
tholytic effect that favours α1-receptor upregulation (35). These observations are in line 
with the decreased VIS following clonidine initiation in our mixed PICU population.
The rapid decrease in COMFORT-B score after clonidine start strongly suggests that 
clonidine is an effective sedative agent. Despite being underpowered, the SLEEPS study 
showed non-inferiority of clonidine vs midazolam from the proportion of patients ad-
equately sedated clonidine at least 80 % of the time (6). Similar studies are needed to 
confirm these interesting results.
During clonidine infusion, body temperature increased and reached significance 
at day 7 (mean 38.2 °C). The known pharmacological properties of clonidine include, 
however, a temperature decrease through central activation of postsynaptic alpha 2-ad-
renoceptors (36). Moreover, an RCT in an adult ICU showed a lower temperature and a 
lower relative risk of fever in patients receiving clonidine vs placebo (37). Our contradic-
tory finding may be explained perhaps by a greater likelihood of secondary infection 
and concomitant fever in the 47/179 patients still receiving clonidine infusion at day 7.
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This study is the first to specifically explore the hemodynamic effect of severe 
clonidine-associated bradycardia. This frequent complication was hemodynamically 
well-tolerated, which suggests that the fear of severe bradycardia may not be entirely 
justified. During severe bradycardia, SBP remained stable; MBP and DBP decreased 
minimally probably secondary to a prolonged diastole (giving more time for the physi-
ologic decrease in diastolic pressure) while VIS tended to decrease and the clonidine 
infusion rate was further increased. Nevertheless, some patients may still be prone 
to develop clinically significant bradycardia or hypotension. In the SLEEPS study, one 
patient developed profound bradycardia upon which, despite stable BP, the study drug 
was discontinued and intervention was not needed. This patient tolerated bradycardia 
well, however, and discontinuation may not have been warranted. Outside a research 
setting, down-titration of clonidine and follow-up might have been an acceptable treat-
ment option in this case.
In the present study younger children appeared to be more at risk for clonidine-
associated bradycardia. Body-weight corrected clonidine clearance is indeed lower the 
first year of life (27, 38, 39), with expected subsequent higher blood levels suggesting 
a concentration-related lowering effect on HR. The association of HR decrease and age 
was also found at a later age, suggesting other factors.
The major strength of this study is its large population, which also is the broadest PICU 
population exposed to clonidine to date. Moreover, the use of clonidine as a second line 
sedative agent led to a sample of sicker patients than in previous studies, as reflected 
by a mortality rate more than twice the usual PICU mortality rate in PICUs in the Nether-
lands (8 % vs 3.5 % (40)) and higher than in previous studies (0.8 % in the SLEEPS study (6) 
and 5.5 % in the study by Hünseler et al (2)). Moreover, the included patients were prone 
to hemodynamic compromise due to the effect of disease and the concomitant use of 
other sedatives. Our results can therefore likely be generalized to most PICU patients. A 
second strength is unparalleled accuracy of the vital sign analysis, which was performed 
using values recorded per minute and weighting them according to the time between 
measurements.
The main limitation of the study lies in its observational nature. Clonidine may have 
been avoided in the most unstable patients, implying a possible ‘bias by indication’ that 
may have influenced the results. However, this type of bias is unlikely to be resolved 
with a RCT. One of the reasons for the low recruitment rate in the SLEEPS study was 
the physicians’ reluctance to randomize the unstable patients for fear of hemodynamic 
adverse effects of clonidine (6). Nonetheless, taking into account that the choice of a 
sedative agent at the bedside is based on knowledge derived from population based 
studies, physiological knowledge and clinical judgement (41), these encouraging data 
should motivate the use of clonidine in the PICU. Furthermore, they should stimulate 
studies exploring the vasoactive-inotropic drug sparing effect of clonidine.
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CONCLUSION
Clonidine is an effective sedative when given as an adjunct to morphine and midazolam. 
The often-associated bradycardia and hypotension do not seem clinically significant in 
a mixed PICU population with a high degree of disease severity. Clonidine may have a 
vasoactive-inotropic sparing effect.
Acknowledgments: We thank Joke Dunk for her help in data collection. Ko Hagoort is 
thanked for editing the manuscript.
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PART V
REFLECTION
“If it is known exactly what is going to be done, why do it?
“Si on sait exactement ce que l’on va faire à quoi bon le faire?” 
Pablo Picasso
 Chapter 11
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PEDIATRIC PHARMACOLOGY
In medicine and in particular in pharmacology, children have long been considered “small 
adults”, but around 40 years ago it became clear that down scaling of adult doses could 
be detrimental to children because it did not respect the maturation processes unique 
to children (1). Likewise, the concept of dose-weight proportionality is not applicable 
during early life as renal and liver functions then are still maturing (2, 3). Unawareness of 
the immaturity of metabolic pathways has led to catastrophes like death from gray baby 
syndrome of neonates with immature glucuronidation pathway who had been given 
chloramphenicol (4, 5).
There is still a long way to go to a shift from empirical to evidence based and potentially 
individualized drug dosing in children (6). The ideal drug choice and dosing should take 
into account patient specific properties such as age, weight, disease severity, disease re-
lated treatment and genetics as well as drug specific properties such as ADME pathways 
and mechanism of action. Individualized drug dosing is highly challenging, however, 
especially in critically ill children whose properties keep changing during admission.
PICU PHARMACOLOGY
Critical illness impacts on each pharmacokinetic step (ADME) and pharmacodynamics. 
Absorption may be affected by the impact of disease on all factors involved, such as gas-
tric pH, gastric emptying, intestinal drug transport and metabolism. Therefore, the oral 
route of administration is usually avoided (7, 8). Volume of distribution can be affected 
by a change in plasma albumin and total protein, total body water (e.g. generalized 
oedema) or the application of extracorporeal techniques like extracorporeal membrane 
oxygenation (ECMO) and continuous venous-venous hemofiltration (CVVH) that add an 
extra volume to the body. The liver is the main organ involved in drug metabolism. In 
phase I reactions, a reactive group is attached to the drug (e.g. oxidation, reduction, 
hydrolysis) while in phase II reactions drugs are conjugated with charged groups (e.g. 
glucuronidation, sulfation, methylation). After conjuguation, lipophilic drugs become 
more hydrophilic and can be excreted by the kidneys. Thus, drug clearance may be 
compromised by liver or kidney failure, which conditions are often seen among PICU 
patients (9, 10). Inflammation also affects drug metabolism and drug transport by up- or 
downregulating the expressions of cytochrome P450 enzymes and membrane trans-
porters (11). For example, clearance of midazolam is only 30 % in case of severe inflam-
mation. This may lead to overdosing of metabolized drugs if doses are not decreased 
accordingly (12).
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In addition, acute illness often involves specific treatments that also affect PK and 
PD. For example hypothermia slows drug metabolism (13), which can increase drug 
exposure and lead to overdosing (14). During ECMO treatment the plastic tubing and 
ECMO oxygenator adsorb drugs so that even in a closed ex vivo circuit the concentration 
decreases with time (15, 16). Studying drug PK during ECMO is needed to rationalize 
drug treatment of children on ECMO.
The effect of critical illness on organ function implies also changes in pharmacody-
namics. Good knowledge of the interaction between a patient’s clinical condition and 
adverse drug effect profile is important to determine the most ideal drug and dosing for 
the patient. For example, children with severely decreased heart function are at risk of 
fatal collapse caused by the cardiodepressant effect of analgesics and sedatives when 
rapidly injected. Slow injection and titrated dosing of sedatives and analgesics with 
limited cardiodepressant effect are required in this situation.
The current level of evidence on “PICU pharmacology” does not allow a rational drug 
choice and dosing guidelines taking into account the diversity of situations in the inten-
sive care unit. In this regard, Duffett et al concluded that published guidelines have less 
influence on treatment choice than have severity of illness, physiologic rationale, and 
potential risk for adverse effects (17). Until results of dedicated studies become avail-
able, knowledge of pharmacology can help rationalizing drug choice and dosing in the 
critically ill and maximize the desired effect while minimizing adverse effects.
RESEARCH IN THE PICU
Children are considered vulnerable and therefore have long been excluded from clinical 
drug trials. Thus they are a kind of ‘therapeutic orphans’ in whom administering drugs in 
the absence of safety and efficacy data should be considered an experiment. Research 
on drugs in children is still trying to fill the gap where unfortunately the aim of protecting 
children led paradoxically to empirical and dangerous practices. But since new research 
methods have become available, research with a lesser burden can be undertaken.
Traditional drug study design implies administration of a non-therapeutic drug fol-
lowed by extensive blood sampling but this is not an ethical option in children. The PK 
data presented in this thesis were generated using alternative study designs. One of 
these is what is known as opportunistic design: the study of a drug given as per standard 
of care. Both PK studies presented in this thesis were based on this study design. Sparse 
sampling implies collecting blood samples as part of routine blood sampling without the 
need of extra vascular access. Population PK analysis makes use of randomly collected 
and a lower number of blood samples, thus lowering the number of samples per patient 
(18). A microtracer design, a new and very innovative technique, was used in Chapter 7 
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to determine paracetamol bioavailability with an accuracy that is unique to this study 
design. For the first time in paediatrics, an oral radiolabeled microtracer was given 
simultaneously to an intravenous dose and coupled to a population PK analysis. Despite 
being the same molecule, the therapeutic iv dose can be quantified independently from 
the oral microtracer. These innovative approaches allow generating evidence-based 
drug regimens in critically ill children while minimizing burden and risks (19, 20).
Another barrier to PICU research is informed consent. Children in the PICU are especially 
vulnerable as the consent-seeking process may be threatened by altered consciousness, 
for instance due to sedation and disease, or communication problems when intubated, 
in addition to age-related limits to informed consent in neonates and young children. 
The acuity and life-threatening nature of illness puts great pressure on the informed 
consent processes as parents may be too overwhelmed to also think about their child’s 
participation in a research study and attending medical staff may discourage the child’s 
participation in a trial for fear of any burdens and risks of the trial (21, 22). Alternative 
forms of consent have newly been developed taking into account parental stress and 
the unpredictable reality of the acute critical care environment: deferred consent and 
continuous consent (or two-step consent). Deferred consent implies enrolling patients 
before consent is obtained and obtain informed consent after enrolment for the use of 
already collected information and ongoing participation (23). In continuous consent, 
in the first step only the most relevant information is given to parents to seek consent, 
followed in the second step by a deeper informed consent conversation (23). Data sug-
gests that parents generally support both forms of consent, if adequately explained (24).
We suggest considering more systematically the use of alternative consent forms as 
these potentially can increase recruitment rates while preserving freedom of choice. 
Eventually this will help build solid knowledge on individual drugs in the PICU.
ANALGESICS AND SEDATIVES IN THE PICU
Neonates and children admitted to a PICU almost inevitably experience stress and pain 
(25). It is therefore not surprising that sedative and analgesic drugs are among the most 
common prescribed drugs in the PICU. Adequate sedation is defined as the level of seda-
tion at which a patient is asleep but easily arousable (26). Sedation should be assessed 
using an instrument validated for PICU patients, such as the COMFORT scale (27), the 
COMFORT behavior scale (28–30), and the State Behavioral Scale (SBS) (31, 32). Both 
under- and oversedation are undesirable. Undersedation may cause distress and lead 
to unintentional extubation or catheter displacement while oversedation may delay 
recovery (33, 34) and induce tolerance and withdrawal syndrome (35, 36). Despite this 
knowledge, a tendency toward oversedation in the PICU setting has been described 
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(37). In addition to conscious sedation, deeper sedation may sometimes be targeted to 
guarantee hemodynamic stability, e.g. post cardiac surgery or in pulmonary hyperten-
sion. Interestingly, the benefits of deep sedation for these outcomes have not received 
much attention in clinical trials.
Reaching this ideal level of sedation and optimal safety requires good knowledge of 
PD and PD of analgo-sedative agents in a variety of different situations. Analgosedatives 
are the most studied drugs in the PICU (38) but most studies were conducted without 
prior pharmacokinetic data and therefore patients may not have reached comparable 
plasma levels, obscuring the pharmacodynamic effect (39). It is therefore of paramount 
importance to obtain pharmacokinetic data before conducting clinical research and 
include dosing in any prospective drug study.
Sedatives and analgesics can be titrated clinically but PK data are required to titrate 
rationally (40, 41), decide the most optimal route of administration (8, 42), choose the 
best agent for an individual patient in a specific situation (43), individualize dosing to 
the patient’s individual characteristics (12, 44), optimize the effect of every sedative and 
analgesic used concomitantly and avoid accumulation and toxicities (45, 46). Rational 
use of analgosedatives in the PICU implies that every agent has to be studied in a variety 
of clinical conditions. First of all disease-related PK changes including inflammation and 
organ failure need to be determined. Second, PK data in common care situations need to 
be obtained to guide dosing, such as after cardio-pulmonary bypass (implying induced 
PK changes, hemodynamic instability and inflammation) or sepsis. Lastly, the effect of 
treatment related PK changes during interventions such as ECMO, CVVH or hypothermia 
has to be delineated.
We chose to study two specific situations related to PK of drugs in critically ill children, 
ECMO and oral absorption. In addition, we focused on the hemodynamic impact of dif-
ferent sedation regimens and more specifically that of clonidine for continuous sedation.
PK OF ANALGESICS AND SEDATIVES IN THE PICU
ECMO
This thesis presents the first estimations of PK parameters of intravenous clonidine in 
children on ECMO and CVVH (Chapter 5) using population PK. We found that on the 
particular ECMO system studied, clonidine PK is influenced by age, ECMO and adminis-
tration of diuretics. The maturation of clearance was quicker in patients on ECMO: they 
reached 70 % of adult clearance at 1.5 weeks on ECMO compared to 1 month (47) and 9 
months (48) in patients not on ECMO. Clonidine clearance was two-fold that measured 
in patients not on ECMO and decreased by 30 % with the use of diuretics. Volume of 
distribution increased by 55 % during ECMO support. It proposes new individualized 
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dosing guidelines on this particular ECMO system with higher infusion rates and higher 
bolus dose to reach therapeutic levels. Besides the reported results, this study illustrates 
the difficulty to isolate the aetiology of PK changes. The quicker maturation of clearance 
than reported in patients not on ECMO illustrates that this parameter is driven by other 
mechanisms that could not be isolated because of co-linearity (as age parallels time on 
ECMO and clinical improvement during extracorporeal support). Moreover, the evolu-
tion in technology implies regular changes in ECMO systems. Newer systems are made 
from material with less adsorptive capacities (polymethylpentene hollow fibre), with 
lower priming volume and driving less inflammatory response at ECMO initiation (49). 
This implies that ECMO-PK studies will need to be regularly re-conducted. As this may 
be not feasible for financial and practical reasons, mechanistic models that take into 
account specific technical changes in the ECMO systems may be an interesting alterna-
tive. Physiologically based PK models taking into account in vitro ECMO data (coupled 
to CVVH or not) according to drug physicochemical properties models may simplify the 
difficult task of isolating the effect of ECMO from the patient’s characteristics.
Oral bioavailability
The oral bioavailability of commonly used sedatives and analgesics (e.g. lorazepam, 
paracetamol) has not been determined in children in general and in the critically ill 
child in particular. Nevertheless, a high proportion of drugs are administered orally to 
critically ill children: 15 % in ventilated children and 27 % in non-ventilated (50), possibly 
without good efficacy or safety. Clinicians often base their decision about the route of 
administration according to the patient’s clinical condition, availability of intravenous 
access, enteral food tolerance and availability or price of the oral versus the iv formu-
lation. For life-saving drugs, the iv formulation is invariably preferred. Intravenous 
administration is usually preferred when a defined level of sedation must be maintained 
for conditions such as sepsis and traumatic brain injury) or their related management 
(ventilation, ECMO) because this is more reliable with quicker onset of effect. Chapter 
7 of this thesis describes the first determination of oral bioavailability of paracetamol 
in children and in critically ill children in particular. For the first time in pediatrics we 
used an innovative microtracer study design coupled to population pharmacokinetics 
to obtain the oral bioavailability measure of paracetamol in children. The average oral 
bioavailability was 70 %, which we found somewhat surprising as critical illness is often 
thought to severely reduce oral absorption. While this percentage was lower than in a 
study in healthy adults showing almost complete absorption (51), it was similar to that 
reported in other adult studies (52, 53). Hence, oral administration of drugs may result in 
adequate systemic exposures even in critically ill children. Caution is needed, however, 
as we have observed a wide interindividual variability in bioavailability (10–90 %) in our 
patients. The systemic exposure may be unpredictable therefore, with risk of underdos-
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ing in patients with low bioavailability and overdosing in patients with nearly complete 
bioavailability (when higher oral than intravenous dose are used). Importantly, none 
of the patient characteristics in our study has proved a predictor of bioavailability and 
feeding status as a surrogate marker of preserved gut function was not a significant 
covariate. The results of this study indicate that oral paracetamol likely not results in a 
consistent response and that intravenous administration is preferred if vascular access is 
in place. These data should motivate health regulatory agencies worldwide to license iv 
paracetamol for the broad pediatric age range. This study furthermore made clear that 
determining interindividual variability in bioavailability is of paramount importance. 
Based on mean population bioavailability the advocated oral dosing is often higher 
than the iv dosing, which may lead to overdosing in a patient with high bioavailability. 
Bioavailability studies are the only way to accurately disentangle bioavailability and 
clearance and their related interindividual variabilities that are otherwise confounded. 
In summary, obtaining more insight in children’s individual bioavailability of much used 
drugs in the PICU may help improving drug dosing and its related safety.
CONCLUSIONS AND RECOMMENDATIONS:
•	 The	interplay	of	ECMO	coupled	to	CVVH	and	postnatal	age	significantly	influences	
clonidine PK in critically ill neonates and young infants. As ECMO systems technically 
change rapidly, mechanistic models need to be developed to estimate exposure in 
these children.
•	 Oral	 bioavailability	 of	 paracetamol	 is	 70	%	 with	 a	 wide	 interindividual	 variability,	
which implies that plasma concentrations after oral dosing may widely vary with risk 
of under- and overdosing.
•	 Oral	dosing	guidelines	based	on	mean	population	bioavailability	may	lead	to	inad-
equate drug efficacy and when a drug’s bioavailability variability is high.
HEMODYNAMIC EFFECTS OF ANALGOSEDATION IN THE PICU
Hemodynamic stability after heart surgery, should we worry?
After cardiac surgery, oversedation is usually aimed for as it decreases oxygen consump-
tion and promotes aerobic metabolism. Unfortunately, all sedatives have potential 
adverse hemodynamic effects, such as myocardial depression or vasodilation, which 
may counteract the expected decrease in oxygen consumption (54–56). This widely 
used clinical practice of oversedation during profound hemodynamic instability is 
empirical and not supported by objective data. Traditionally, infants undergoing heart 
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surgery were pre-emptively sedated during the first 12 to 24 hours postoperatively (57) 
to decrease oxygen consumption and prevent low cardiac output. But after the adverse 
effects of oversedation had been recognized, practice shifted from pre-emptive to 
targeted sedation based on hemodynamic stability). Nevertheless, numerous PICUs still 
favour pre-emptive sedation after heart surgery.
Chapter 8 retrospectively compares hemodynamic stability with two sedation 
practices after major heart surgery in young infants: pre-emptive (routine sedation 
with midazolam) and targeted sedation (aimed to reach a predefined level of sedation 
according to cardiovascular stability). We found that hemodynamic parameters and 
surrogate markers of cardiac output adequacy in the pre-emptively sedated group were 
comparable to those of the targeted sedation group. This questions the use of deep 
sedation to prevent low cardiac output as it might unnecessarily expose the children to 
sedatives that may cause neurotoxicity (58) and withdrawal (36).
The effect of sedatives on neurodevelopment is increasingly being debated (58–60). 
Neurotoxic effects of analgosedatives have been demonstrated in animal studies (16, 17) 
and in human studies, but these were confounded with the effect of disease. A recent 
large RCT showed similar neurodevelopment outcome at 2 years after awake-regional 
and general anaesthesia for inguinal hernioraphy in infancy (59). Other reassuring data 
have come from wide retrospective studies (58, 61, 62) but no study to date has addressed 
the long-term neurodevelopment outcome after prolonged use of analgosedatives in 
the PICU. Given the very active neurodevelopment in neonates and young infants, it 
would seem advisable to decrease the use of analgosedatives in this age group, at least 
until more evidence on the effects of their prolonged use becomes available. The FDA 
has incorporated this advice in the official label of most analgosedatives (63).
Hemodynamic stability with clonidine in the PICU
Clonidine is among the few analgosedatives that do not cause neurotoxicity in animals 
(64) and is therefore not included in the list of general analgosedatives affected by the 
FDA label change. These reassuring data on neurodevelopment along with the absence 
of respiratory depression (65) motivated its recent use in the PICU. But as clonidine 
was first licensed as an antihypertensive drug, physicians are often reluctant to use 
it for fear of its known bradycardic and hypotensive effect. A population that may be 
particularly prone to these adverse effects are neonates after heart surgery because 
their myocardial function decreases in the early postoperative period (57). Furthermore, 
small infants have limited ability to preserve cardiac output by increasing preload and 
may therefore be particularly prone to hemodynamic compromise in case of clonidine-
associated bradycardia. These theoretical concerns may not be entirely justified as the 
study presented in Chapter 8 shows that clonidine infusion was hemodynamically well 
tolerated in 23 neonates after heart surgery. Heart rate decreased maximally 12 % fol-
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lowed the start of clonidine administration. Apart from a transient and limited decrease 
in diastolic blood pressure, no deterioration in markers of cardiac output was noted. 
These data suggest that clonidine was well tolerated. However, a subset of children with 
the highest degree of disease severity had been treated “off-protocol” with midazolam 
instead of clonidine, suggesting that clinicians may have been reluctant to administer 
clonidine in case of acute instability. Nonetheless, this is the first study on hemodynamic 
tolerance including unstable, post-cardiac surgery patients. These encouraging results 
motivated the next study, presented in Chapter 9, which describes the broadest mixed 
clonidine-exposed PICU population studied to date. This population was expected to 
be particularly vulnerable to the adverse hemodynamic effects of clonidine due to a 
high severity of illness score and the concomitant use of additional sedatives. However, 
clonidine was well tolerated. Our data are line with secondary outcomes reported in 
pediatric clonidine trials (66, 67). This study is also the first to specifically explore the 
hemodynamic effect of severe clonidine-associated bradycardia and shows that this 
complication is hemodynamically well tolerated. As clonidine is among the few seda-
tives not associated with neurotoxicity (58, 64, 68), the results of our study should favour 
its use in the PICU and motivate further studies in unstable patients.
CONCLUSIONS AND RECOMMENDATIONS:
•	 Tailored	 sedation	early	 after	heart	 surgery	 is	 hemodynamically	well	 tolerated	and	
pre-emptive sedation to prevent low cardiac output syndrome may not be neces-
sary.
•	 Sedation	as	a	way	to	decrease	oxygen	consumption	(and	balance	oxygen	consump-
tion and delivery) should be questioned and systematically assessed.
•	 Despite	 its	 bradycardic	 and	hypotensive	 effects,	 clonidine	 infusion	used	 for	 seda-
tion is well tolerated in patients at risk of hemodynamic adverse effects, including 
neonates after heart surgery and a broad mixed PICU population with high disease 
severity.
•	 Data	on	the	pharmacodynamics	(efficacy	and	safety)	of	commonly	used	sedatives	is	
still missing. To ensure their applicability, these data should ideally be obtained in a 
population with clinical characteristics and severity of illness representative of the 
general PICU population.
•	 PD	studies	are	needed	to	challenge	the	choice	of	a	particular	sedative	or	analgesic	
agent solely based on theoretical concerns taking into account physiological knowl-
edge and potential interaction with the patient’s disease.
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In conclusion, the studies described in this thesis present interesting new data that sup-
port tailoring of drug therapy in critically ill children, taking into account critical illness, 
maturation, and intensive care therapies. The data also challenge general beliefs on the 
efficacy and safety of pharmacotherapy in the critically ill, concerning drug absorption, 
the need for deep sedation after cardiac surgery, and the risk of hemodynamic instabil-
ity with clonidine.
So we may ask ourselves, are we really doing the right thing? Could our practices be 
detrimental to our patients’ health? Until bedside therapeutic drug monitoring becomes 
widely available and non-invasive markers of cardiac output become reliable enough to 
avoid hemodynamic deterioration due to drug-disease interaction, we need to question 
the current practices. Every day, drugs are administered to critically ill children in the 
absence of reliable bioavailability data. Do we realize that a dosing regimen adapted 
to population oral bioavailability could be harmful on account of wide interindividual 
variability in bioavailability? That this could lead to under- but also overdosing? Seda-
tion to decrease oxygen consumption is an attractive theoretical idea – but is it really 
justified? Is a lower level of sedation justifiable or should sedatives that potentially do 
not cause neurotoxicity be preferred? If we do follow the strategy suggested above, will 
we find out in 30 years that we have prevented neurotoxicity and have improved cogni-
tive outcomes? Sedation and analgesia provision is certainly “more than sleep alone”.
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“On ne va jamais aussi loin que lorsqu’on ne sait pas où on va” 
Christophe Colomb
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Pediatric dosing regimens have long been derived from adult dosing regimens. Although 
important progress has been made in pediatric clinical pharmacology, there is still a 
long way to go to shift from empirical to rational and individualized drug dosing. To get 
the desired effect while avoiding toxicities, pediatric dosing has to take into account the 
ontogeny of metabolizing and elimination processes that are unique to children.
The ideal drug choice and dosing should take into account patient-specific properties 
such as age, weight, disease severity, disease-related treatment and genetics as well as 
drug-specific properties such as ADME pathways and mechanism of action. Moreover, 
for critical ill children admitted to a PICU, matters are complicated by the effect of critical 
illness, the use of multiple drugs in the acutely ill child, and increased vulnerability to 
adverse effects.
Results of studies determining the pharmacokinetics (PK) and pharmacodynam-
ics (PD) and their interactions with patient’s characteristics and clinical condition are 
needed to design evidence-based drug regimens.
The aim of this thesis is:
1.) Review existing knowledge on PK, PD and ethical challenges in critically ill children, 
with a focus on analgosedatives.
2.) To study complex PICU pharmacokinetics using as examples:
a.)  the pharmacokinetics of clonidine in ECMO-treated patients
b.) the oral bioavailability of paracetamol in critically ill patients
3.) To study hemodynamic efficacy and safety outcomes of analgosedatives, addressing 
the following questions:
a.)  Is hemodynamic stability similar in tailored sedation versus pre-emptive sedation 
after heart surgery in young infants?
b.)  What is the impact of clonidine on hemodynamic stability in neonates after heart 
surgery and in a general mixed PICU population?
Part I The impact of critical illness on pharmacokinetics (PK) and 
pharmacodynamics (PD) and challenges to improve knowledge on drugs in the 
pediatric intensive care unit
Chapter 2 delineates general principles governing PK-PD in the critically ill child to re-
duce the risk of improper dosing. Drug dosing in the critically ill child is a real challenge 
because in addition to the age-related variation in PK, the effect of acute illness and its 
treatment modalities impacts on every step of PK-PD. Our current knowledge does not 
allow for setting dosing guidelines accounting for the diversity of situations found in 
the PICU. PK-PD models taking into account patient characteristics, consequences of 
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critical illness and its treatment modalities are needed to facilitate individualized dosing. 
Conducting drug research in the vulnerable PICU population is hampered by practical, 
ethical, and scientific challenges, as reviewed in Chapters 3 and 4. Chapter 3 address the 
main ethical and practical issues specific to drug research in critically ill children and 
proposes to tailor the informed consent process to the reality of the acute care setting 
with the use of approaches known as ’deferred consent’ and ’combined consent’. New 
methods to gain knowledge on drugs while limiting burden and risk are encouraged, 
such as opportunistic studies that derive PK of the drugs given per standard of care 
or sparse blood sampling methods that take advantage of sample leftovers or routine 
blood analysis. These randomly collected and limited blood samples per patient can 
be analyzed with population PK. Highly innovative microdosing studies are introduced 
as new techniques to gain insight into PK without exposing patients to therapeutic or 
adverse effects. Chapter 4 proposes the use of alternative forms of consent in a study on 
inotropic drugs in the acute care setting. Chapter 5 describes the current knowledge on 
PK and PD of analgosedatives in the critically ill, on sedation management, and on the 
specific PK-PD aspects of sedative drugs in the critically ill child and the consequences 
for dosing. Knowledge gaps still remain.
PART II Pharmacokinetics of analgosedation in the PICU
Chapters 6 and 7 provide new evidence on PK of analgesics and sedatives in critically ill 
children using the study design with minimized burden and risks described in Chapter 
3. Chapter 6 illustrates how clonidine PK during extracorporeal membrane oxygenation 
(ECMO) and continuous veno-venous hemofiltration (CVVH) is influenced by age, dis-
ease and concomitant drugs and proposes new individualized dosing guidelines on this 
particular ECMO system. In children on ECMO, 70 % of adult clearance was reached at 
1.5 weeks, while previous studies have reported that this was reached after 1 month 
and 9 months, respectively, in patients not on ECMO. Clonidine clearance was two-fold 
that measured in patients not on ECMO and CVVH and decreased by 30 % with the use 
of diuretics. Volume of distribution increased by 55 % during ECMO support. In patients 
on ECMO, higher infusion rates and higher bolus doses are needed to reach therapeutic 
levels compared to patients not on ECMO. The study described in Chapter 7 was the first 
in paediatrics that used the innovative microtracer study design coupled to population 
pharmacokinetics to estimate paracetamol oral bioavailability in stable patients in the 
PICU up to the age of 6 years. The bioavailability was on average 70 %, which is lower 
than generally assumed, with large interindividual variability (10–90 %). Thus, oral ad-
ministration of paracetamol may result in a low and unpredictable systemic exposure 
with higher probability of therapeutic failure. These PK data suggest that with regard to 
paracetamol for the treatment of acute pain in children the intravenous route is to be 
preferred over the oral route.
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PART III Pharmacodynamics of sedatives and analgesics in the PICU
Chapter 8 retrospectively compares hemodynamic stability with two sedation prac-
tices after major heart surgery in young infants: pre-emptive (routine sedation with 
midazolam) and targeted sedation (discretionary use to predefined level of sedation). 
It appeared that pre-emptive sedation after high risk cardiac surgery cannot always 
prevent low cardiac output. To avoid exposing children unnecessarily to sedatives this 
strategy must be re-evaluated. Chapters 9 and 10 describe hemodynamic tolerance 
to sedation with a clonidine infusion in the PICU. The study presented in Chapter 9 
included 23 neonates after high-risk heart surgery and good hemodynamic tolerance 
of IV clonidine as sedative added to morphine in selected patients. The study presented 
in Chapter 10 included a mixed PICU population with high disease severity, and who 
showed hemodynamic tolerance of a clonidine infusion used as a second line sedative. 
Young patients are at increased risk of clonidine associated bradycardia. This study is 
the first to specifically explore the hemodynamic effect of severe clonidine-associated 
bradycardia and shows that this complication is hemodynamically well tolerated. These 
findings should motivate the use of clonidine, which is among the few analgosedatives 
not associated with neurotoxicity in animals.
In Chapter 10, the results of our studies are discussed and recommendations for future 
research are given. We conclude that PK data are needed to tailor treatment to widely 
encountered interventions in the PICU, such as ECMO and CVVH. Also we suggest that 
clinicians’ common beliefs need to be challenged by research. By showing that after 
high-risk cardiac surgery, targeted sedation (discretionary use to predefined level of 
sedation) compared to pre-emptive sedation (routine sedation with midazolam) does 
not result in any hemodynamic change, we encourage questioning the use of profound 
sedation to decrease oxygen consumption. Moreover, our findings about paracetamol 
bioavailability should encourage further bioavailability studies in the PICU where drugs 
are commonly given orally without data to justify this practice. We believe that long-
term neurodevelopmental outcome should be taken into account when choosing seda-
tion strategies. Animal data on neurotoxicity of commonly used sedatives led recently to 
an FDA warning and therefore, the hemodynamic tolerance shown with clonidine use is 
encouraging with regard to this drug, which is not associated with neurotoxicity.
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De dosering van geneesmiddelen voor kinderen is lang gebaseerd geweest op doserin-
gen voor volwassenen. Inmiddels is er grote vooruitgang geboekt op het gebied van de 
pediatrische klinische farmacologie, maar er is nog een lange weg te gaan om tot een 
verschuiving te komen van een empirische tot een rationale en geïndividualiseerde do-
sering. Om bij kinderen het gewenste effect te krijgen zonder toxiciteit moet rekening 
worden gehouden met de ontwikkelingsfysiologie van de specifieke metabolisatie- en 
eliminatieprocessen. 
Idealiter wordt bij de keuze van een medicijn en de dosering rekening gehouden met de 
leeftijd van de patiënt, het gewicht, de ernst van de ziekte, de behandeling van de ziekte 
maar ook met genetische en medicijn-specifieke eigenschappen zoals ADME-pathways 
en het werkingsmechanisme. Voor ernstig zieke kinderen in de intensive care setting 
moet bovendien rekening worden gehouden met het effect van de ziekte, het gebruik 
van meerdere medicijnen tegelijk, en een grotere kans op nadelige bijwerkingen.
Een evidence-based medicamenteuze behandeling kan worden gerealiseerd aan de 
hand van de resultaten van studies naar de farmacokinetiek (PK) en farmacodynamiek 
(PD) van een medicijn en de interacties met de kenmerken en klinische conditie van de 
patiënt.
Mijn promotieonderzoek had als doel:
1.) De huidige kennis te inventariseren op het gebied van PK/PD en ethische aspecten 
bij ernstig zieke kinderen, met een focus op analgetica en sedativa. 
2.) Inzicht te krijgen in de complexe farmacokinetiek in de kinder-intensive care setting, 
met als voorbeelden:
a.)  de farmacokinetiek van clonidine bij kinderen tijdens extracorporale membraan-
oxygenatie (ECMO) 
b.) de biologische beschikbaarheid van orale paracetamol bij ernstig zieke kinderen
3.) Het bestuderen van de hemodynamische werkzaamheid en veiligheid van analgose-
dativa, waarvoor de volgende onderzoeksvragen werden geformuleerd: 
a.) Is na een hartoperatie bij jonge kinderen de hemodynamische stabiliteit verge-
lijkbaar tussen sedatie-op-maat en preventieve sedatie?
b.) Wat is de impact van clonidine op de hemodynamische stabiliteit bij neonaten 
na een hartoperatie en bij een algemene gemengde populatie in de kinder-
intensive care setting? 
Deel I De impact van een kritieke ziekte op de farmacokinetiek en 
farmocodynamiek en de uitdagingen voor kennisverwerving over medicijnen 
in de kinder-intensive care setting
hoofdstuk 2 schetst de algemene PK/PD principes die bij het kritiek zieke kind in 
het geding zijn; kennis hiervan kan het risico op onjuiste dosering verminderen. Het 
doseren van medicijnen bij deze kinderen vormt een echte uitdaging omdat naast de 
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leeftijdsgerelateerde variatie in PK, ook het effect van acute ziekte en de behandeling 
daarvan invloed heeft op iedere PK-PD stap. De huidige kennis is niet toereikend om 
doseringsrichtlijnen op te stellen voor de vele diverse situaties die zich kunnen voor-
doen in de kinder-intensive care setting. Om te komen tot geïndividualiseerde dosering 
zijn PK/PD modellen nodig die rekening houden met kenmerken van de patiënt, de 
gevolgen van kritieke ziekte en de behandeling daarvan. Medicijnonderzoek bij de 
kwetsbare populatie in de kinder-intensive care setting wordt bemoeilijkt door prak-
tische, ethische, en wetenschappelijke belemmeringen volgens de literatuur beschre-
ven in de hoofdstukken 3 en 4. Hoofdstuk 3 gaat in op de belangrijkste ethische en 
praktische zaken, met een pleidooi om het proces van informed consent aan te passen 
aan de realiteit in de acute care setting met benaderingen zoals ’uitgesteld consent’ 
en ’gecombineerd consent’. Minder belastende en minder risicovolle methoden zijn 
bijvoorbeeld opportunistic studies naar de PK van medicijnen als standaardzorg of 
sparse blood sampling, met gebruikmaking van overgebleven bloed of het bloed dat 
routinematig wordt geanalyseerd. Deze bloedmonsters, willekeurig verzameld en een 
beperkt aantal per patiënt, kunnen worden geanalyseerd met populatie-PK. Ten slotte 
wordt aandacht geschonken aan zeer innovatieve microdosing studies die informatie 
kunnen opleveren over PK zonder patiënt bloot te stellen aan therapeutische of nade-
lige effecten. Hoofdstuk 4 geeft een voorstel voor het gebruik van alternatieve vormen 
van consent in een studie betreffende inotrope medicijnen in de acute zorg. Hoofdstuk 
5 beschrijft de huidige kennis op het gebied van PK en PD van analgetica en sedativa bij 
kritieke ziekte, sedatiemanagement, en de specifieke PK-PD aspecten van sedativa bij 
het kritiek zieke kind en de consequenties daarvan voor de dosering. Er zijn nog steeds 
hiaten in de kennis. 
DEEL II Farmacokinetiek of analgosedatie in de kinder-intensive care setting
Hoofdstukken 6 en 7 brengen nieuwe informatie over de PK van analgetica en sedativa bij 
kritiek zieke kinderen door toepassing van het onderzoeksdesign met een lage belasting 
en risico dat beschreven is in hoofdstuk 3. Hoofdstuk 6 geeft aan hoe de farmacokine-
tiek van clonidine tijdens ECMO-behandeling en continue veno-veneuze hemofiltratie 
(CVVH) wordt beïnvloed door leeftijd, ziekte en gebruik van andere medicijnen en geeft 
nieuwe geïndividualiseerde doseringsrichtlijnen tijdens behandeling met dit ECMO-
systeem. Bij de onderzochte kinderen werd 70% van de klaring bij volwassenen bereikt 
na 1,5 week, terwijl in voorgaande studies bij patiënten zonder ECMO-ondersteuning 
kregen dit percentage pas werd bereikt na respectievelijk 1 maand en 9 maanden. De 
clonidineklaring was het dubbele van dat in patiënten zonder ECMO-ondersteuning en 
CVVH en werd 30% lager bij gebruik van plaspillen. Het distributievolume steeg met 
55% tijdens ECMO-ondersteuning. Tijdens ECMO-behandeling zijn hogere infusiesnel-
heden en hogere bolusdoses nodig om de therapeutische concentraties te bereiken van 
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patiënten zonder ECMO-ondersteuning. Het onderzoek dat is beschreven in hoofdstuk 
7 is het eerste bij kinderen dat gebruik maakte van het innovatieve microtracer design 
gekoppeld met populatiefarmacokinetiek. Het ging hierbij om het bepalen van de 
biologische beschikbaarheid van orale paracetamol bij stabiele kinderen tot de leeftijd 
van 6 jaar. De biologische beschikbaarheid was gemiddeld 70%, een lager percentage 
dan algemeen  aangenomen, met een hoge interindividuele variabiliteit (10-90%). Dit 
impliceert dat orale toediening van paracetamol kan resulteren in een lage en niet te 
voorspellen systemische blootstelling met een grotere kans op therapiefalen. Deze far-
macokinetische data geven aan dat wat betreft paracetamol voor de behandeling van 
acute pijn bij kinderen de intraveneuze route de voorkeur verdient boven de orale route. 
DEEL III Pharmacodynamiek van sedativa en analgesica in de kinder-intensive 
care setting 
Hoofdstuk 8 betreft een retrospectief onderzoek waarin de hemodynamische stabiliteit 
bij jonge kinderen na een grote hartoperatie wordt vergeleken voor twee verschil-
lende sedatiemethoden: preventief (routinematig met midazolam) en doelgericht 
(naar believen tot een van tevoren bepaald niveau). Het bleek dat preventieve sedatie 
na een risicovolle hartoperatie niet altijd een lage cardiale output kan voorkomen. Met 
het oog op onnodige blootstelling aan sedativa dient deze strategie nader te worden 
bestudeerd. De hoofdstukken 9 en 10 gaan over hemodynamische tolerantie bij sedatie 
met een clonidine infusie. Het onderzoek in hoofdstuk 9 betrof 23 neonaten die een 
risicovolle hartoperatie hadden ondergaan; bij bepaalde geselecteerde patiënten was 
er een goede hemodynamische tolerantie van IV clonidine als een sedativum gegeven 
in aanvulling op morfine. Het onderzoek in hoofdstuk 10 betrof een gemengde popu-
latie met zeer ernstige ziekte, en deze lieten hemodynamische tolerantie zien van een 
clonidine-infusie als tweedelijns-sedativum. Jonge kinderen hebben een groter risico 
op clonidine-geassocieerde bradycardia. Dit onderzoek is het eerste dat specifiek was 
gericht op het hemodynamische effect van ernstige clonidine-geassocieerde brady-
cardia en het laat zien dat deze complicatie hemodynamisch goed wordt getolereerd. 
Deze bevindingen breken een lans voor het gebruik van clonidine, een van de weinige 
analgosedativa die niet zijn geassocieerd met neurotoxiciteit bij dieren.
De bevindingen van alle studies worden besproken in hoofdstuk 10, met aanbeve-
lingen voor nader onderzoek. We concluderen dat meer PK data nodig zijn om de be-
handeling toe te spitsen op veelvoorkomende interventies in de kinder-intensive care, 
zoals ECMO en CVVH. Ook wordt gesteld dat stellige overtuigingen van clinici moeten 
worden onderbouwd door onderzoeksresultaten. Omdat we hebben aangetoond dat 
doelgerichte sedatie na een grote hartoperatie vergeleken met preventieve sedatie 
geen hemodynamische veranderingen met zich meebrengt, zetten we vraagtekens bij 
de praktijk van diepe sedatie om de zuurstofconsumptie te verlagen. Verder wijzen onze 
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bevindingen over de biologische beschikbaarheid van paracetamol op de noodzaak 
van meer studies op dit gebied in de kinder-intensive care setting, waar medicineren 
meestal oraal worden toegediend zonder dat hier bewijs voor is. We vinden dat bij de 
keuze van de sedatiestrategie moet worden gedacht aan de neurologische ontwikke-
ling op de lange termijn. De Amerikaanse Food and Drug Administration (FDA) heeft 
recentelijk een waarschuwing doen uitgaan naar aanleiding van data uit dierstudies 
over de neurotoxiciteit van veel gebruikte sedativa; wat dat betreft is het bemoedigend 
dat clonidine – een medicijn dat niet is geassocieerd met neurotoxiciteit – een goede 
hemodynamische tolerantie liet zien.
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AS Adequate sedation 
AV Atrio-ventricular
BP Blood pressure
CAP-D Cornwell Assessment Pediatric Delirium tool 
Cl Clearance 
CO cardiac output
COMFORT-b COMFORT behavior scale 
CPB Cardio-pulmonary bypass 
CrCl  Creatinine clearance 
CRRT Continuous renal replacement therapy 
Css Steady-state concentration
CVP Central venous pressure 
CVVH Continuous veno-venous hemofiltration 
ECMO  Extracorporeal membrane oxygenation
FDA Food and Drug Administration 
FOCE First-order conditional estimation 
GA Gestational age 
GABA  Gamma-amino butyric acid 
GFR Glomerular filtration rate
HR Heart rate 
ICC Intraclass correlation coefficient
IQR Interquartile range
IRB  Institutional Review Board 
IV Intravenous
LCOS  Low cardiac output syndrome 
M3G  Morphine-3-glucuronide 
M6G Morphine-6-glucuronide
NISS Nurse interpretation sedation score 
NONMEM Non-linear mixed effect modeling 
NPDEs  Normalized prediction distribution errors 
NRS Numeric rating scale
OFV Objective function value 
OS Oversedation 
pCAM-ICU  pediatric Confusion Assessment Method for ICU
PD Pharmacodynamic
PICU  Pediatric intensive care unit 
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PES  Preemptive sedation 
PK Pharmacokinetic 
PMA  Post-menstrual age 
PNA Post-natal age 
PRIS Propofol infusion syndrome 
Q1-Q3 1st and 3rd quartile 
RASS  Richmond Agitation Sedation Scale 
RCT Randomized controlled trials 
SA  Sinus Node 
SBS State Behavior Scale
Sc Sieving coefficient 
SD Standard deviation
SE Standard error of the estimate 
ScvO2 Central venous oxygen saturation 
SOS Sophia Observation Withdrawal Symptoms-scale 
SVR Systemic vascular resistance 
TARG Targeted sedation Group 
TDM  Therapeutic drug monitoring 
US Undersedation;
V  Volume of distribution 
VAS Visual analogue scale
VD  Volume of distribution 
VIS Vasoactive inotropic score 
WAT-1 Withdrawal Assessment Tool version-1 
WT Bodyweight
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